GIPC Clinical Trials - Medical Students doing research in lab
Jul 21, 2020 - 12:00pm

Discover & Deliver: All-of-Nation Effort to Find Safe and Effective Solutions to Eradicate the Global Pandemic

Right now, our nation’s brightest scientific minds, most innovative companies, and leading universities are moving at unprecedented speed to deliver the pandemic-ending treatments, vaccines, diagnostics, and cures we need.

The interactive map will not load properly in this browser. Please visit this page with a modern browser.

StateDistrictStudy TitleEnrollmentFacilitiesSponsorsIntervention
DelawareDE-00Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Alfred I. DuPont Hospital for Children,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
DelawareDE-00NCI COVID-19 in Cancer Patients, NCCAPS Study2000Beebe South Coastal Health Campus, Beebe Medical Center, Delaware Clinical and Laboratory Physicians PA, Helen F Graham Cancer Center, Medical Oncology Hematology Consultants PA, Christiana Care Health System-Christiana Hospital, Beebe Health Campus, Nanticoke Memorial Hospital, Christiana Care Health System-Wilmington Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
District of ColumbiaDC-00Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Children s National Hospital,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
District of ColumbiaDC-00Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
District of ColumbiaDC-00Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0George Washington University Hospital,Gilead SciencesDrug: Remdesivir
District of ColumbiaDC-00Convalescent Plasma to Stem Coronavirus (CSSC-001)500Medstar Georgetown University Hospital,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
District of ColumbiaDC-00Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site, Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
District of ColumbiaDC-00Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384Georgetown University Hospital, GW Medical Faculty Associates,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
District of ColumbiaDC-00Awake Prone Position for Early Hypoxemia in COVID-19560Medstar Georgetown University Hospital,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
District of ColumbiaDC-00Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen120Georgetown University Medical Center,Biohaven Pharmaceuticals, Inc.Drug: Zavegepant (BHV-3500), Drug: Placebo
District of ColumbiaDC-00Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 190George Washington University,Spectral Diagnostics (US) Inc.Device: Toraymyxin PMX-20R (PMX Cartridge)
District of ColumbiaDC-00WGS Analysis of COVID-19 Positive Patients5000Vanda Pharmaceuticals,Vanda Pharmaceuticals 
District of ColumbiaDC-00Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920Whitman-Walker Health CRS,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
District of ColumbiaDC-00Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000MedStar Washington Hospital Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
District of ColumbiaDC-00Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection180Medstar Washington Medical Center,National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC) 
District of ColumbiaDC-00A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Medstar Georgetown University Hospital,Hoffmann-La RocheDrug: Tociliuzumab
District of ColumbiaDC-00Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270MedStar Georgetown University Hospital,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
District of ColumbiaDC-00Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury46MedStar Washington Hospital Center, GW Medical Faculty Associates,AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company)Drug: Ibrutinib, Drug: Placebo
District of ColumbiaDC-00COVID-19: Human Epidemiology and Response to SARS-CoV-25605Children's National Medical Center,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
District of ColumbiaDC-00Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Georgetown University Medical Center,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
District of ColumbiaDC-00Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
District of ColumbiaDC-00Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52MedStar Health Research Institute,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
District of ColumbiaDC-00Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
District of ColumbiaDC-00NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Capitol Hill Medical Center, Sibley Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
District of ColumbiaDC-00An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic0MedStar Washington Hosp Center,Genentech, Inc.Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
District of ColumbiaDC-00Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
District of ColumbiaDC-00Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
District of ColumbiaDC-00COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)175Medstar Georgetown University Hospital, Washington Hospital Center,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
District of ColumbiaDC-00Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons180MedStar Washington Hospital Center,National Institutes of Health Clinical Center (CC) 
District of ColumbiaDC-00Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Georgetown University Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
District of ColumbiaDC-00Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727George Washington University CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
District of ColumbiaDC-00A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Medstar Georgetown University Hospital,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
FloridaFL-10Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-10Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363AdventHealth,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
FloridaFL-10Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
FloridaFL-11Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Florida Health Central Florida,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
FloridaFL-12Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-13COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial38Johns Hopkins All Children's Hospital,Neil Goldenberg, Johns Hopkins All Children's HospitalDrug: Enoxaparin Prefilled Syringe [Lovenox]
FloridaFL-13Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000DMI Research,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
FloridaFL-13A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Bay Pines VA Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
FloridaFL-13Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Theia Clinical Research LLC,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
FloridaFL-14Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-14Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
FloridaFL-14Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of South Florida,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
FloridaFL-14Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
FloridaFL-14Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390James A. Haley Veterans' Hospital,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
FloridaFL-14A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device300Tampa General Hospital, University of South Florida, AdventHealth Tampa,Kaligia Biosciences, LLC, University of South FloridaDiagnostic Test: RBA-2
FloridaFL-14Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Tampa General Hospital,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
FloridaFL-14Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Tampa General Hospital, University of South Florida,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
FloridaFL-14Immunophenotyping Assessment in a COVID-19 Cohort2000University of South Florida Health Tampa,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
FloridaFL-14Compassionate Use of Hyperbaric Oxygen Therapy100Innovative Healing Systems,SerenaGroup, Inc., SerenaGroup Research Foundation 
FloridaFL-14NCI COVID-19 in Cancer Patients, NCCAPS Study2000Moffitt Cancer Center-International Plaza, Moffitt Cancer Center, Moffitt Cancer Center - McKinley Campus,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
FloridaFL-14Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite0Participating Research Facility,Hope PharmaceuticalsDrug: Sodium Nitrite, Drug: Normal Saline
FloridaFL-15Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
FloridaFL-15Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Meris Clinical Research,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
FloridaFL-15Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Teradan Clinical Trials,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
FloridaFL-16Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-16Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Sarasota Memorial Hospital,Gilead SciencesDrug: Remdesivir
FloridaFL-16NCI COVID-19 in Cancer Patients, NCCAPS Study2000Florida Cancer Specialists - Bradenton, Florida Cancer Specialists - Sarasota, Florida Cancer Specialists - Sarasota Downtown, Sarasota Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
FloridaFL-16Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Nova Clinical Research LLC,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
FloridaFL-17NCI COVID-19 in Cancer Patients, NCCAPS Study2000Florida Cancer Specialists - Venice Island, Florida Cancer Specialists - Venice Healthpark,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
FloridaFL-18Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Lawnwood Regional Medical Center,Gilead SciencesDrug: Remdesivir
FloridaFL-18Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
FloridaFL-18Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Jupiter Medical Center,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
FloridaFL-18Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury46Midway Immunology and Research,AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company)Drug: Ibrutinib, Drug: Placebo
FloridaFL-18Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
FloridaFL-18Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure524Wellington Regional Medical Center,ChimerixDrug: Dociparastat sodium, Drug: Placebo
FloridaFL-19Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-19Convalescent Plasma to Stem Coronavirus (CSSC-001)500Lee Memorial Health System,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
FloridaFL-20Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection60St. Mary's Medical Center,Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical CenterDrug: Alteplase 50 MG [Activase]
FloridaFL-20Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury46Triple O Research Institute,AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company)Drug: Ibrutinib, Drug: Placebo
FloridaFL-22Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services, OMNI Medical Services, OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-22The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection100Invesclinic US LLC,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
FloridaFL-22The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200Invesclinic US LLC,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
FloridaFL-22Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Invesclinica US LLC,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
FloridaFL-22Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
FloridaFL-22Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
FloridaFL-22A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Holy Cross Hospital,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
FloridaFL-22NCI COVID-19 in Cancer Patients, NCCAPS Study2000Broward Health North, Holy Cross Hospital, Broward Health Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
FloridaFL-22LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)60Broward Health Medical Center,Arch Biopartners Inc.Drug: LSALT peptide, Drug: Placebo
FloridaFL-22A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Holy Cross Hospital Inc,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
FloridaFL-22Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944Holy Cross Hospital,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
FloridaFL-23The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection100DBC Research Corp.,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
FloridaFL-23Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Aventura Hospital and Medical Center,Gilead SciencesDrug: Remdesivir
FloridaFL-23Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation520Cleveland Clinic,The Cleveland ClinicDietary Supplement: Ascorbic Acid, Dietary Supplement: Zinc Gluconate, Dietary Supplement: Ascorbic Acid and Zinc Gluconate, Other: Standard of Care
FloridaFL-23Canakinumab in Covid-19 Cardiac Injury (The Three C Study)45Cleveland Clinic Florida,The Cleveland Clinic, NovartisDrug: Canakinumab Injection 600mg, Drug: Canakinumab Injection 300mg, Drug: Placebos
FloridaFL-23Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Research Centers of America,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
FloridaFL-23NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mount Sinai Comprehensive Cancer Center at Aventura,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
FloridaFL-23Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation30Cleveland Clinic Florida,The Cleveland Clinic, Kiniksa Pharmaceuticals, Ltd.Drug: Mavrilimumab, Drug: Placebos
FloridaFL-24Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Joe DiMaggio Childrens Hospital,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
FloridaFL-24Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-24Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure165University of Miami Medical Center,NeuroRx, Inc., Lavin Consulting, LLCDrug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care
FloridaFL-24Acute Encephalopathy in Critically Ill Patients With COVID-19250University of Miami Miller School of Medicine,Ictal GroupOther: Follow up
FloridaFL-24A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450University of Miami Miller School of Medicine,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
FloridaFL-24Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Memorial Regional Hospital,Gilead SciencesDrug: Remdesivir
FloridaFL-24Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of Miami Clinical Translational Research Site,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
FloridaFL-24Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Miami Florida,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
FloridaFL-24Effects of DPP4 Inhibition on COVID-1920University of Miami,University of MiamiDrug: Linagliptin, Drug: Insulin regimen
FloridaFL-24Collection of Anti-SARS-CoV-2 Immune Plasma1500University of Miami Infectious Diseases Research Unit,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
FloridaFL-24Use of UC-MSCs for COVID-19 Patients24University of Miami Infectious Diseases Research Unit,Camillo Ricordi, University of MiamiBiological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Other: Vehicle + Heparin along with best supportive care
FloridaFL-24Convalescent Plasma in Outpatients With COVID-19600Jackson Memorial Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
FloridaFL-24Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection60University of Miami Hospital,Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical CenterDrug: Alteplase 50 MG [Activase]
FloridaFL-24Study of the Use of Favipiravir in Hospitalized Subjects With COVID-1950University of Miami Miller School of Medicine,Fujifilm Pharmaceuticals U.S.A., Inc.Drug: Favipiravir + Standard of Care, Drug: Standard of Care
FloridaFL-24CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients300University of Miami Hospital and Clinics,NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of MiamiBiological: Convalescent Plasma, Other: Saline solution
FloridaFL-24Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Acevedo Clinical Research Associates,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
FloridaFL-24A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Miami Veterans Administration Healthcare System, University of Miami Pulmonary,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
FloridaFL-24Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of Miami Clinical Translational Research Site,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
FloridaFL-24Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury46University of Miami,AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company)Drug: Ibrutinib, Drug: Placebo
FloridaFL-24Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198Miami VA Healthcare System,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
FloridaFL-24iNOPulse for COVID-190University of Miami Hospitals & Clinics,Roger Alvarez, Bellerophon Therapeutics, University of MiamiDrug: Inhaled nitric oxide (iNO), Drug: Nitrogen gas, Drug: Oxygen gas
FloridaFL-24Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Miami Miller School of Medicine,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
FloridaFL-24A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500University of Miami Miller School of Medicine,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
FloridaFL-25Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000South Florida Research Organization,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
FloridaFL-25Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Indago Research & Health Center,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
FloridaFL-25Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Alternative Research Associates,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
FloridaFL-25A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Larkin Community Hospital Palm Springs Campus,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
FloridaFL-25Zofin (Organicell Flow) for Patients With COVID-1920Larkin Community Hospital,Organicell Regenerative MedicineBiological: Zofin, Other: Placebo
FloridaFL-25A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Larkin Community Hospital,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
FloridaFL-25A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204Indago Research and Health Center,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
FloridaFL-25A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Larkin Community Hospital Palm Springs Campus,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
FloridaFL-26Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000New Horizon Research Center,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
FloridaFL-27The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection100Clinical Research of South Florida Alliance for Multispecialty Research,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
FloridaFL-27The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200Clinical Research of South Florida Alliance for Multispecialty Research,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
FloridaFL-27Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Miami Center for Advanced Cardiology,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
FloridaFL-27Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Mount Sinai Medical Center,Gilead SciencesDrug: Remdesivir
FloridaFL-27Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of Miami,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
FloridaFL-27Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Miami Cancer Institute at Baptist Health,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
FloridaFL-27A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Miami Cancer Institute,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
FloridaFL-27Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Alliance for Multispecialty Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
FloridaFL-27A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Larkin Community Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
FloridaFL-27Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of Miami,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
FloridaFL-27Mindfulness Training for Seniors53University of Miami,University of MiamiBehavioral: Mindfulness training (MT) Connect
FloridaFL-27Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease682Westchester Research Center,Algernon Pharmaceuticals, Novotech (Australia)Drug: NP-120 (Ifenprodil)
FloridaFL-27Zofin (Organicell Flow) for Patients With COVID-1920Larkin Community Hospital,Organicell Regenerative MedicineBiological: Zofin, Other: Placebo
FloridaFL-27A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Larkin Community Hospital,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
FloridaFL-27NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mount Sinai Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
FloridaFL-27A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Westchester General Hospital,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
FloridaFL-27A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Larkin Community Hospital,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
FloridaFL-09Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy12123Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute,Tabula Rasa HealthCareOther: Simulation of Repurposed Drugs for COVID-19
FloridaFL-09Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)800Chappel Group Research,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
FloridaFL-09Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Chappel Group Research,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
FloridaFL-09Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations100Tabula Rasa HealthCare Precision Pharmacotherapy Research,Tabula Rasa HealthCare, Cambia Health Solutions 
FloridaFL-04CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243Baptist Health Research Institute,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
FloridaFL-04Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Mayo Clinic - Jacksonville,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
FloridaFL-04Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Mayo Clinic in Florida,Gilead SciencesDrug: Remdesivir
FloridaFL-04Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry50000Mayo Clinic in Florida,Mayo Clinic, Society of Critical Care Medicine, Boston UniversityOther: observational
FloridaFL-04Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-190Mayo Clinic in Florida,Mayo ClinicBiological: COVID-19 convalescent plasma
FloridaFL-04Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases120Mayo Clinic Florida,Mayo ClinicDiagnostic Test: Collection of breath sample
FloridaFL-04Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300Baptist Medical Center, Mayo Clinic,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
FloridaFL-04Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Naval Hospital Jacksonville,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
FloridaFL-04A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Mayo Clinic,Hoffmann-La RocheDrug: Tociliuzumab
FloridaFL-04Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Jacksonville Center for Clinical Research, Clinical Neuroscience Solutions,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
FloridaFL-04Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Mayo Clinic Florida,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
FloridaFL-04Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
FloridaFL-04Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers300Mayo Clinic,Mayo ClinicOther: Serologic testing
FloridaFL-04Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140Baptist Health Medical Center,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
FloridaFL-04A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Baptist Medical Center Beaches,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
FloridaFL-04PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Ascension St. Vincent's Riverside Hospital,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
FloridaFL-04Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944Mayo Clinic in Florida,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
FloridaFL-01Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-01Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Eglin Air Force Base,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
FloridaFL-05Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Florida Jacksonville Shands Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
FloridaFL-05Losartan for Patients With COVID-19 Requiring Hospitalization200University of Florida Health,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
FloridaFL-05Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Florida Jacksonville,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
FloridaFL-05A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100University of Florida Health Services Center,Hoffmann-La RocheDrug: Tociliuzumab
FloridaFL-05Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270University of Florida,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
FloridaFL-05Immunophenotyping Assessment in a COVID-19 Cohort2000University of Florida Health Jacksonville,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
FloridaFL-05Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
FloridaFL-08Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-06A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)252Renibus Therapeutics,Renibus Therapeutics, Inc.Drug: RBT-9 (90 mg), Drug: 0.9% sodium chloride (normal saline)
FloridaFL-06Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998DeLand Clinical Research Unit,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
FloridaFL-03Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100University of Florida College of Medicine,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
FloridaFL-03Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
FloridaFL-03Losartan for Patients With COVID-19 Requiring Hospitalization200University of Florida Health,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
FloridaFL-03Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
FloridaFL-03Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479University of Florida,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
FloridaFL-03Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Florida,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
FloridaFL-03A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227University of Florida,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
FloridaFL-03Convalescent Plasma in Outpatients With COVID-19600UF Health Shands Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
FloridaFL-03Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Fleming Island Center for Clinical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
FloridaFL-03Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
FloridaFL-03Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500University of Florida,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
FloridaFL-03Immunophenotyping Assessment in a COVID-19 Cohort2000University of Florida at Gainesville,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
FloridaFL-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Florida Health Science Center – Gainesville,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
FloridaFL-03Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Florida Health,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
FloridaFL-07Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
FloridaFL-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0AdventHealth Orlando,Gilead SciencesDrug: Remdesivir
FloridaFL-07A COVID-19 Symptom, Exposure and Immune Response Registry10000ObvioHealth,ObvioHealth 
FloridaFL-07Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300AdventHealth Orlando,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
FloridaFL-07Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Clinical Neuroscience Solutions Inc.,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
FloridaFL-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Clinical Neuroscience Solutions Inc,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
FloridaFL-07SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)0AdventHealth Orlando,AdventHealthBiological: SARSCoV2 Convalescent Plasma
FloridaFL-02Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
GeorgiaGA-11Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
GeorgiaGA-11Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)800Clinical Trial Specialists Inc.,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
GeorgiaGA-11A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410WellStar Research Institute,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
GeorgiaGA-12Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Eisenhower Army Medical Center,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
GeorgiaGA-12Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Augusta University,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
GeorgiaGA-12NCI COVID-19 in Cancer Patients, NCCAPS Study2000Augusta Oncology Associates PC-Wheeler, Augusta University Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
GeorgiaGA-12Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140Medical College of Georgia at Augusta University,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
GeorgiaGA-13The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200Clinical Research Atlanta,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
GeorgiaGA-13Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Piedmont Fayette Hospital,Gilead SciencesDrug: Remdesivir
GeorgiaGA-13Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Clinical Research Atlanta,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
GeorgiaGA-08Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0John D. Archbold Memorial Hospital,Gilead SciencesDrug: Remdesivir
GeorgiaGA-08Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52John D. Archbold Memorial Hospital,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
GeorgiaGA-02Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Piedmont Columbus Regional,Gilead SciencesDrug: Remdesivir
GeorgiaGA-02Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Martin Army Community Hospital,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
GeorgiaGA-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998IACT Health,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
GeorgiaGA-02A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Corporation of Mercer University,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
GeorgiaGA-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Phoebe Putney Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
GeorgiaGA-02Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140Sarah Cannon Research Institute, LLC,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
GeorgiaGA-01Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Memorial Health University Medical Center,Gilead SciencesDrug: Remdesivir
GeorgiaGA-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Meridian Clinical Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
GeorgiaGA-01Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant1419Meridian Clinical Research,Novavax, Coalition for Epidemic Preparedness Innovations (CEPI)Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2
GeorgiaGA-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Memorial Health University Medical Center, Lewis Cancer and Research Pavilion at Saint Joseph's/Candler,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
GeorgiaGA-01Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Meridian Clinical Research,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
GeorgiaGA-05Losartan for Patients With COVID-19 Requiring Hospitalization200Grady Memorial Hospital,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
GeorgiaGA-05Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
GeorgiaGA-05Acute Encephalopathy in Critically Ill Patients With COVID-19250Wellstar Atlanta Medical Center,Ictal GroupOther: Follow up
GeorgiaGA-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Piedmont Atlanta Hospital, Wellstar Atlanta Medical Center,Gilead SciencesDrug: Remdesivir
GeorgiaGA-05Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-192Emory University Hospital,Emory UniversityDevice: GO2 PEEP MOUTHPIECE
GeorgiaGA-05Awake Prone Position for Early Hypoxemia in COVID-19560Piedmont Atlanta,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
GeorgiaGA-05Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Emory University,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
GeorgiaGA-05Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300Emory University,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
GeorgiaGA-05A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Piedmont Healthcare, Emory University School of Medicine,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
GeorgiaGA-05Convalescent Plasma in Outpatients With COVID-19600Grady Memorial Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
GeorgiaGA-05Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)0Emory University Hospital,Emory University, National Cancer Institute (NCI)Other: Best Practice, Biological: Tocilizumab
GeorgiaGA-05Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
GeorgiaGA-05Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-1910Emory University Hospital Midtown,Emory UniversityRadiation: Low Dose Radiation Therapy
GeorgiaGA-05Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Atlanta Center for Medical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
GeorgiaGA-05Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-1924Emory University Hospital,Emory University, Georgia Tech Research Foundation, Georgia Clinical & Translational Science AllianceDevice: V/Q Vest
GeorgiaGA-05MSCs in COVID-19 ARDS223Emory University,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
GeorgiaGA-05Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000Emory University Hospital Midtown,University of Manitoba, University Health Network, TorontoDrug: Heparin
GeorgiaGA-05Immunophenotyping Assessment in a COVID-19 Cohort2000Emory University School of Medicine,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
GeorgiaGA-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Atlanta VA Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
GeorgiaGA-05Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
GeorgiaGA-05Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Atlanta VA Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
GeorgiaGA-05Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Ponce de Leon Center CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
GeorgiaGA-05PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Grady Memorial Hospital,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
GeorgiaGA-05A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924Emory University,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
GeorgiaGA-09Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986Center for Advanced Research & Education,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
GeorgiaGA-09Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Center for Advanced Research & Education,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
GeorgiaGA-09NCI COVID-19 in Cancer Patients, NCCAPS Study2000University Cancer and Blood Center LLC, Northeast Georgia Medical Center Braselton, Northeast Georgia Medical Center-Gainesville,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
GeorgiaGA-06Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Childrens Healthcare of Atlanta,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
GeorgiaGA-06Treating COVID-19 With a Bidirectional Oxygenation Valve30Emory Saint Joseph's Hospital,TMC HealthCare, PEEP Medical, LLCDevice: bidirectional oxygenation mouthpiece
GeorgiaGA-06Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-192Emory Saint Joseph's Hospital,Emory UniversityDevice: GO2 PEEP MOUTHPIECE
GeorgiaGA-06Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-1910Emory Saint Joseph's Hosptial,Emory UniversityRadiation: Low Dose Radiation Therapy
GeorgiaGA-06A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Northside Hospital,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
GeorgiaGA-06Use of Convalescent Plasma for COVID-19700Northside Hospital,Northside Hospital, Inc.Biological: Convalescent Plasma
GeorgiaGA-04Adaptive COVID-19 Treatment Trial (ACTT)1062Emory Vaccine Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
GeorgiaGA-04Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)120Emory Vaccine Center,National Institute of Allergy and Infectious Diseases (NIAID)Biological: mRNA-1273
GeorgiaGA-04Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Grady Memorial Hospital,Gilead SciencesDrug: Remdesivir
GeorgiaGA-04Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Emory Vaccine Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
GeorgiaGA-04Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Hope Clinic of the Emory Vaccine Center CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
HawaiiHI-01Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Kapiolani Womens and Childrens Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
HawaiiHI-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Hawaii Moanalua Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
HawaiiHI-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Hawaii Moanalua Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
HawaiiHI-01A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients17Queen's Medical Centre,Queen's Medical CentreDrug: Hydroxychloroquine
HawaiiHI-01Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Tripler Army Medical Center,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
HawaiiHI-01Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients40University of Hawaii - Manoa,University of HawaiiDrug: Telmisartan 40mg, Drug: Placebo
HawaiiHI-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998East-West Medical Research Institute,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
HawaiiHI-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente Moanalua Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
HawaiiHI-01Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
IdahoID-02Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
IdahoID-02Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
IdahoID-02A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379St. Lukes Boise Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
IdahoID-02Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
IdahoID-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Alphonsus Cancer Care Center-Boise, Saint Luke's Mountain States Tumor Institute, Saint Luke's Mountain States Tumor Institute-Twin Falls,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IdahoID-02A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500St Luke's Health System,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
IdahoID-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Solaris Clinical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
IdahoID-01Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant1419Advanced Clinical Research,Novavax, Coalition for Epidemic Preparedness Innovations (CEPI)Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2
IdahoID-01Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial120Kootenai Health,Kootenai Health, Washington State UniversityDrug: Hydroxychloroquine
IdahoID-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Alphonsus Cancer Care Center-Caldwell, Kootenai Medical Center, Walter Knox Memorial Hospital, Saint Luke's Mountain States Tumor Institute – Fruitland, Idaho Urologic Institute-Meridian, Saint Luke's Mountain States Tumor Institute – Meridian, Saint Alphonsus Medical Center-Nampa, Saint Luke's Mountain States Tumor Institute – Nampa, Kootenai Cancer Center, Kootenai Cancer Clinic,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-10Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Northwestern Lake Forest Hospital,Gilead SciencesDrug: Remdesivir
IllinoisIL-10COVID-19 Patient Positioning Pragmatic Trial503NorthShore University HealthSystem,Vanderbilt University Medical CenterOther: Prone, Other: Usual Care
IllinoisIL-10Leflunomide in Mild COVID-19 Patients20University of Chicago,University of ChicagoDrug: Leflunomide
IllinoisIL-11NCI COVID-19 in Cancer Patients, NCCAPS Study2000Rush - Copley Medical Center, UC Comprehensive Cancer Center at Silver Cross,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-12A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection152BJC,Washington University School of MedicineDrug: Fluvoxamine, Drug: Placebo
IllinoisIL-12NCI COVID-19 in Cancer Patients, NCCAPS Study2000Memorial Hospital of Carbondale, SIH Cancer Institute, Good Samaritan Regional Health Center, Cancer Care Center of O'Fallon, Southwest Illinois Health Services LLP,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-13NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cancer Care Specialists of Illinois – Decatur, Decatur Memorial Hospital, Southern Illinois University School of Medicine, Springfield Clinic, Memorial Medical Center, Carle Cancer Center, The Carle Foundation Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-14NCI COVID-19 in Cancer Patients, NCCAPS Study2000Rush-Copley Healthcare Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-15NCI COVID-19 in Cancer Patients, NCCAPS Study2000Centralia Oncology Clinic, Carle on Vermilion, Carle Physician Group-Effingham, Crossroads Cancer Center, Carle Physician Group-Mattoon/Charleston,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-16NCI COVID-19 in Cancer Patients, NCCAPS Study2000Illinois CancerCare-Dixon, Illinois CancerCare-Ottawa Clinic, Illinois CancerCare-Peru, Valley Radiation Oncology, Illinois CancerCare-Princeton,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-17Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384OSF Healthcare Saint Francis Medical Center,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
IllinoisIL-17Observational Study of COVID-19 Treatment Efficacy1000OSF HealthCare St Francis Medical Center,OSF Healthcare SystemOther: No intervention
IllinoisIL-17A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270University of Illinois College of Medicine,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
IllinoisIL-17NCI COVID-19 in Cancer Patients, NCCAPS Study2000Illinois CancerCare-Canton, Illinois CancerCare-Galesburg, Western Illinois Cancer Treatment Center, Illinois CancerCare-Kewanee Clinic, Illinois CancerCare-Pekin, Methodist Medical Center of Illinois, Saint Jude Midwest Affiliate,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-18Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
IllinoisIL-18Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Optimal Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
IllinoisIL-18Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
IllinoisIL-18Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52SIU School of Medicine,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
IllinoisIL-18NCI COVID-19 in Cancer Patients, NCCAPS Study2000Illinois CancerCare-Bloomington, Illinois CancerCare-Carthage, Illinois CancerCare-Eureka, Illinois CancerCare-Macomb, Illinois CancerCare-Peoria,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-09Convalescent Plasma to Stem Coronavirus (CSSC-001)500NorthShore University HealthSystem,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
IllinoisIL-09A Study of LY3127804 in Participants With COVID-1995NorthShore University HealthSystem,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
IllinoisIL-09Dapagliflozin in Respiratory Failure in Patients With COVID-19900NorthShore University HealthSystem,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
IllinoisIL-09A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227NorthShore University HealthSystem,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
IllinoisIL-09A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Advocate Christ Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
IllinoisIL-09Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344NorthShore University HealthSystem,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
IllinoisIL-09A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Great Lakes Clinical Trials,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
IllinoisIL-09NCI COVID-19 in Cancer Patients, NCCAPS Study2000Advocate Lutheran General Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-09Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19160NorthShore University HealthSystem,University of MichiganDrug: Dipyridamole 100 Milligram(mg), Drug: Placebo oral tablet
IllinoisIL-09The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Advocate Christ Medical Center,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
IllinoisIL-07Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Ann and Robert H Lurie Childrens Hospital of Chicago,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
IllinoisIL-07Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Ann & Robert H. Lurie Children's Hospital of Chicago, Loyola University Medical Center,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
IllinoisIL-07Adaptive COVID-19 Treatment Trial (ACTT)1062Northwestern Hospital, University of Illinois at Chicago College of Medicine,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
IllinoisIL-07Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Cook County General Hospital, Rush University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
IllinoisIL-07Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891John H. Stroger Hospital of Cook County, Rush University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
IllinoisIL-07Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
IllinoisIL-07A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Rush University Medical Center,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
IllinoisIL-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Mercy Hospital & Medical Center, Loyola University Medical Center,Gilead SciencesDrug: Remdesivir
IllinoisIL-07Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS346Rush University Medical Center,Rush University Medical CenterDevice: high flow nasal cannula (HFNC), Procedure: Prone positioning (PP)
IllinoisIL-07Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Northwestern Medicine, Rush University,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
IllinoisIL-07Non-contact ECG Sensor System for COVID19100Northwestern Medicine,Northwestern MedicineDevice: Non-contact ECG
IllinoisIL-07Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia30Loyola University Medical Center,University of CincinnatiDrug: Sirolimus, Drug: Placebo
IllinoisIL-07Dapagliflozin in Respiratory Failure in Patients With COVID-19900Loyola University,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
IllinoisIL-07Treatment for COVID-19 in High-Risk Adult Outpatients300Ruth M. Rothstein CORE Center,University of Washington, Bill and Melinda Gates FoundationDrug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
IllinoisIL-07Convalescent Plasma in Outpatients With COVID-19600Rush University Medical Center, University of Illinois Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
IllinoisIL-07COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being500Clinical Nutrition Research Center,Clinical Nutrition Research Center, Illinois Institute of Technology 
IllinoisIL-07Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920Northwestern University CRS, Rush University CRS,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
IllinoisIL-07Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease20Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: HCQ, Drug: HCQ+AZT, Drug: Placebo
IllinoisIL-07Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Chicago Clinical Research Institute, Chicago Clinical Research Institute,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
IllinoisIL-07Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Loyola University Medical Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
IllinoisIL-07Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
IllinoisIL-07Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Rush University Medical Center,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
IllinoisIL-07COVID-19: Human Epidemiology and Response to SARS-CoV-25605Ann & Robert H. Lurie Children's Hospital of Chicago,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
IllinoisIL-07Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Northshore University Health System, Loyola University Medical Center,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
IllinoisIL-07A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Loyola University Medical Center,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
IllinoisIL-07Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Loyola University Medical Center,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
IllinoisIL-07Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease682Affinity Health - Loretto Hospital,Algernon Pharmaceuticals, Novotech (Australia)Drug: NP-120 (Ifenprodil)
IllinoisIL-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Lurie Children's Hospital-Chicago, Northwestern University, University of Illinois, Edward Hines Jr VA Hospital, West Suburban Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-07Predictors of Severe COVID-19 Outcomes1500University of Illinois at Chicago, Rush University Medical Center,Verily Life Sciences LLC 
IllinoisIL-07Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms100Shirley Ryan AbilityLab,Shirley Ryan AbilityLabDevice: ADAM Sensor
IllinoisIL-07Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site, Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
IllinoisIL-07Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Northwestern Hospital, University of Illinois at Chicago College of Medicine,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
IllinoisIL-07A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Northwestern University, Feinberg School of Medicine, Loyola University Medical Center,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
IllinoisIL-07Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Adolescent & Young Adult Research at The CORE Center,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
IllinoisIL-07The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Cook County Hospital,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
IllinoisIL-06Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Northwestern Medicine Central Hospital,Gilead SciencesDrug: Remdesivir
IllinoisIL-06Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
IllinoisIL-02Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Chicago Clinical Research LLC,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
IllinoisIL-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Ingalls Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-08Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry50000Society of Critical Care Medicine,Mayo Clinic, Society of Critical Care Medicine, Boston UniversityOther: observational
IllinoisIL-03Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Advocate Christ Medical Center,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
IllinoisIL-03A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Advocate Christ Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
IllinoisIL-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Chicago Medicine-Orland Park,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-03The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Advocate Christ Medical Center,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
IllinoisIL-03A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Advocate Christ Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
IllinoisIL-01Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100University of Chicago Hospital,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
IllinoisIL-01Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of Chicago,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
IllinoisIL-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113University of Chicago,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
IllinoisIL-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891University of Chicago,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
IllinoisIL-01A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450University of Chicago,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
IllinoisIL-01Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis32University of Chicago Medicine,University of ChicagoDrug: Tocilizumab
IllinoisIL-01Beat COVID-19 - Observational Trial100000Beat COVID LLC,Beat COVID LLC 
IllinoisIL-01COVID-19 Convalescent Plasma10University of Chicago Medicine,University of ChicagoBiological: anti-SARS-CoV-2 convalescent plasma
IllinoisIL-01High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-1920University of Chicago,University of ChicagoDrug: Hydroxychloroquine
IllinoisIL-01Convalescent Plasma in Outpatients With COVID-19600University of Chicago Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
IllinoisIL-01Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Quad Clinical Research,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
IllinoisIL-01Long Term Outcomes of Patients With COVID-19500University of Chicago Medicine,University of ChicagoOther: Quality of Life, Other: Impact Event Score, Other: Hospital anxiety and depression scale
IllinoisIL-01Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Chicago,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
IllinoisIL-01Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000University of Chicago,University of Manitoba, University Health Network, TorontoDrug: Heparin
IllinoisIL-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Chicago Comprehensive Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IllinoisIL-01Registry of CytoSorb Therapy in COVID-19 ICU Patients500University of Chicago Medicine,CytoSorbents, IncDevice: CytoSorb 300 mL device
IllinoisIL-05Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Ann and Robert H. Lurie Childrens Hospital of Chicago,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
IllinoisIL-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Swedish Hospital,Gilead SciencesDrug: Remdesivir
IllinoisIL-05Home Pulse Oximeter Use in Patients With COVID-19209Swedish Hospital,Swedish HospitalDevice: Home Pulse Oximetry Monitoring
IndianaIN-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113IU Health Methodist Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
IndianaIN-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891IU Health Methodist Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
IndianaIN-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St. Vincent Hospital and Health Care Center, Riverview Health,Gilead SciencesDrug: Remdesivir
IndianaIN-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000IU Health North Hospital, Saint Vincent Hospital and Health Care Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IndianaIN-05PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364St. Vincent Medical Group inc.,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
IndianaIN-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Goshen Center for Cancer Care, Memorial Hospital of South Bend,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IndianaIN-03A Study of LY3127804 in Participants With COVID-1995Parkview Research Center,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
IndianaIN-03MSCs in COVID-19 ARDS223Lutheran Hospital,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
IndianaIN-03Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
IndianaIN-03A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Lutheran Health Physicians,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
IndianaIN-06Compassionate Use of Hyperbaric Oxygen Therapy100Decatur Memorial Hospital,SerenaGroup, Inc., SerenaGroup Research Foundation 
IndianaIN-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Reid Health,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IndianaIN-07Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Riley Hospital for Children at Indiana University,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
IndianaIN-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Richard L Roudebush Indianapolis VA,Gilead SciencesDrug: Remdesivir
IndianaIN-07Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384Indiana University Health,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
IndianaIN-07A Study of LY3127804 in Participants With COVID-1995Franciscan St. Francis Health,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
IndianaIN-07Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Indiana University Simon Cancer Center, Indiana University Health Central Indiana Cancer Centers,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
IndianaIN-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Indiana University/Melvin and Bren Simon Cancer Center, IU Health Methodist Hospital, Richard L. Roudebush Veterans Affairs Medical Center, Sidney and Lois Eskenazi Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IndianaIN-07Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Indiana University School of Medicine,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
IowaIA-02Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Iowa Stead Family Children's Hospital,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
IowaIA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113University of Iowa Hospitals & Clinics,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
IowaIA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891University of Iowa Hospitals & Clinics,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
IowaIA-02Acceptance and Commitment Therapy Delivered by Automated Software Messaging90University of Iowa Hospitals and Clinics,University of IowaBehavioral: Software Messaging
IowaIA-02Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Iowa,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
IowaIA-02Awake Prone Position for Early Hypoxemia in COVID-19560University of Iowa Hospitals and Clinics,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
IowaIA-02Convalescent Plasma in Outpatients With COVID-19600University of Iowa Hospitals & Clinics,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
IowaIA-02Covid-19 Associated Coagulopathy170University of Iowa,University of IowaDrug: Intermediate dose thromboprophylaxis, Drug: Standard of Care thromboprophylaxis
IowaIA-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998University of Iowa Hospitals & Clinics,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
IowaIA-02Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52University of Iowa,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
IowaIA-02A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410University Of Iowa Hospitals And Clinics,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
IowaIA-02Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
IowaIA-02A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966University of Iowa Hospitals and Clinics,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
IowaIA-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Physicians' Clinic of Iowa PC, Mercy Hospital, Oncology Associates at Mercy Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IowaIA-01Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Northeast Iowa Medical Education Foundation,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
IowaIA-04Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
IowaIA-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Trinity Regional Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
IowaIA-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Medical Oncology and Hematology Associates-West Des Moines, Mercy Cancer Center-West Lakes, Alegent Health Mercy Hospital, Greater Regional Medical Center, Blank Children's Hospital, Iowa Methodist Medical Center, Medical Oncology and Hematology Associates-Des Moines, Broadlawns Medical Center, Medical Oncology and Hematology Associates-Laurel, Mercy Medical Center - Des Moines, Iowa Lutheran Hospital, Mercy Medical Center-West Lakes, Methodist West Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
KansasKS-04Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Wesley Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
KansasKS-04Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Alliance for Multispecialty Research LLC, Alliance for Multispecialty Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
KansasKS-04Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant1419Alliance for Multispecialty Research, Alliance for Multispecialty Research,Novavax, Coalition for Epidemic Preparedness Innovations (CEPI)Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2
KansasKS-04Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Heartland Research Associates,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
KansasKS-03Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of Kansas Medical Center,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
KansasKS-03Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Kansas Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
KansasKS-03Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Kansas Medical Center,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
KansasKS-03Study of Open Label Losartan in COVID-1934University of Kansas Medical Center,University of Kansas Medical CenterDrug: Losartan
KansasKS-03Awake Prone Position for Early Hypoxemia in COVID-19560University of Kansas Medical Center,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
KansasKS-03Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202University of Kansas Medical Center,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
KansasKS-03Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Kansas Medical Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
KansasKS-03Compassionate Use of Hyperbaric Oxygen Therapy100Providence Medical Wound Care Center,SerenaGroup, Inc., SerenaGroup Research Foundation 
KansasKS-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Kansas Clinical Research Center, University of Kansas Cancer Center, Olathe Health Cancer Center, University of Kansas Cancer Center-Overland Park, University of Kansas Hospital-Indian Creek Campus, University of Kansas Hospital-Westwood Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
KansasKS-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Lawrence Memorial Hospital, Ascension Via Christi – Pittsburg, University of Kansas Health System Saint Francis Campus,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
KansasKS-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000HaysMed University of Kansas Health System, Salina Regional Health Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
KentuckyKY-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Kentucky Pediatric/ Adult Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
KentuckyKY-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Flaget Memorial Hospital, Jewish Hospital Medical Center South,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
KentuckyKY-03Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Louisville Norton Childrens Hospital,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
KentuckyKY-03Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure165University of Louisville,NeuroRx, Inc., Lavin Consulting, LLCDrug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care
KentuckyKY-03Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
KentuckyKY-03Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Norton Healthcare,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
KentuckyKY-03Convalescent Plasma in Outpatients With COVID-19600University of Louisville Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
KentuckyKY-03Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Norton Healthcare,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
KentuckyKY-03INB03 for the Treatment of Pulmonary Complications From COVID-19366Jewish Hospital,Inmune Bio, Inc.Drug: INB03, Drug: Placebo
KentuckyKY-03Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
KentuckyKY-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000James Graham Brown Cancer Center at University of Louisville, Jewish Hospital, Saints Mary and Elizabeth Hospital, Jewish Hospital Medical Center Northeast,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
KentuckyKY-03A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Norton Women's and Children's Hospital, Audobon Hospital,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
KentuckyKY-06Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479University of Kentucky,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
KentuckyKY-06Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
KentuckyKY-06Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers120Central Kentucky Research Associates,Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations (CEPI)Drug: INO-4800, Device: CELLECTRA® 2000
KentuckyKY-06COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients300University of Kentucky,Alexandra Kejner, University of KentuckyDrug: Povidone-Iodine Nasal Spray and Gargle
KentuckyKY-06Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant1419Central Kentucky Research Associates Inc,Novavax, Coalition for Epidemic Preparedness Innovations (CEPI)Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2
KentuckyKY-06Novel Agents for Treatment of High-risk COVID-19 Positive Patients240University of Kentucky,Susanne Arnold, University of KentuckyDrug: Ivermectin, Drug: Camostat Mesilate, Dietary Supplement: Artemesia annua, Drug: Artesunate
KentuckyKY-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Joseph Radiation Oncology Resource Center, Saint Joseph Hospital East,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
KentuckyKY-06Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections30University of Kentucky,SeaStar MedicalDevice: SCD
KentuckyKY-04The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection100St. Elizabeth Healthcare,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
KentuckyKY-04Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300St. Elizabeth Healthcare,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
KentuckyKY-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Commonwealth Cancer Center-Corbin, Saint Joseph London,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
LouisianaLA-05Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
LouisianaLA-05Compassionate Use of Hyperbaric Oxygen Therapy100Wound Treatment Center,SerenaGroup, Inc., SerenaGroup Research Foundation 
LouisianaLA-05A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410DM Clinical Research,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
LouisianaLA-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Ochsner LSU Health Monroe Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
LouisianaLA-05A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Cambridge Medical Trials,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
LouisianaLA-06A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Ochsner Clinic Foundation,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
LouisianaLA-06Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Our Lady of the Lakes Regional Medical Center,Gilead SciencesDrug: Remdesivir
LouisianaLA-06A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Baton Rouge General,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
LouisianaLA-06Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease20Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: HCQ, Drug: HCQ+AZT, Drug: Placebo
LouisianaLA-06Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Our Lady of the Lake Regional Medical Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
LouisianaLA-06SQuISH-COVID: A Pilot Study300Our Lady of the Lake Regional Medical Center,Cytovale, Inc., Biomedical Advanced Research and Development Authority 
LouisianaLA-06Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
LouisianaLA-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Louisiana Hematology Oncology Associates LLC, Mary Bird Perkins Cancer Center, Our Lady of the Lake Physicians Group - Medical Oncology, Medical Center of Baton Rouge, Woman's Hospital, Ochsner High Grove,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
LouisianaLA-06Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure524Our Lady of the Lake,ChimerixDrug: Dociparastat sodium, Drug: Placebo
LouisianaLA-06GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel225Sinus and Nasal Specialists of Louisiana,GeneOne Life Science, Inc.Drug: GLS-1200, Drug: Placebo
LouisianaLA-01Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Ochsner Clinic Foundation, Slidell Memorial Hospital,Gilead SciencesDrug: Remdesivir
LouisianaLA-01Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)829Tulane University,University of Washington, Bill and Melinda Gates FoundationDrug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid
LouisianaLA-01Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Ochsner Clinic Foundation,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
LouisianaLA-01Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384MedPharmics, Ochsner Medical Center,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
LouisianaLA-01A Study of LY3127804 in Participants With COVID-1995Ochsner Clinic Foundation,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
LouisianaLA-01Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection48Ochsner Health System,Ochsner Health SystemDevice: Hyperbaric Oxygen Therapy
LouisianaLA-01Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-1980Covidcraz 19 LLC, Covidcraz 19 LLC,Perseverance Research Center, LLC, Athena Medical GroupDrug: Hydroxychloroquine, Drug: Indomethacin, Drug: Zithromax Oral Product
LouisianaLA-01A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227East Jefferson General Hospital,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
LouisianaLA-01Treatment for COVID-19 in High-Risk Adult Outpatients300Tulane University,University of Washington, Bill and Melinda Gates FoundationDrug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
LouisianaLA-01A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100MedPharmics,Hoffmann-La RocheDrug: Tociliuzumab
LouisianaLA-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Benchmark Research, Ochsner Clinici Foundation,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
LouisianaLA-01MSCs in COVID-19 ARDS223Ochsner Clinic,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
LouisianaLA-01A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Ochsner Clinic,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
LouisianaLA-01Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000Ochsner Clinic,University of Manitoba, University Health Network, TorontoDrug: Heparin
LouisianaLA-01Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500East Jefferson General Hospital,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
LouisianaLA-01A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410MedPharmics,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
LouisianaLA-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mary Bird Perkins Cancer Center – Covington, Northshore Oncology Associates-Covington, Ochsner Hematology Oncology North Shore - Covington, Women's Cancer Care-Covington, Mary Bird Perkins Cancer Center – Houma, Terrebonne General Medical Center, Ochsner Medical Clinic, East Jefferson General Hospital, LSU Healthcare Network / Metairie Multi-Specialty Clinic, Ochsner Medical Center Jefferson,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
LouisianaLA-01Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes80Ochsner Clinic Foundation,TScan Therapeutics, Inc. 
LouisianaLA-01Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
LouisianaLA-01Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Ochsner Medical Clinic,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
LouisianaLA-01A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Ochsner Clinic Foundation,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
LouisianaLA-02Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Tulane University Health Science Center, Ochsner Baptist Clinical Trials Unit,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
LouisianaLA-02Adaptive COVID-19 Treatment Trial (ACTT)1062Southeast Louisiana Veterans Health Care System,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
LouisianaLA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Tulane University,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
LouisianaLA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Tulane University,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
LouisianaLA-02Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
LouisianaLA-02Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Touro Infirmary,Gilead SciencesDrug: Remdesivir
LouisianaLA-02Convalescent Plasma to Stem Coronavirus (CSSC-001)500Tulane University,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
LouisianaLA-02Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479University Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
LouisianaLA-02Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University Medical Center New Orleans,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
LouisianaLA-02Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease600University Medical Center New Orleans,LCMC HealthDrug: Hydroxychloroquine, Drug: Azithromycin
LouisianaLA-02Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-190Tulane Medical Center,Nakhle Saba, MD, Tulane UniversityBiological: Biological: COVID-19 convalescent plasma
LouisianaLA-02Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Tulane University,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
LouisianaLA-02A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Louisiana State University Health Sciences Center,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
LouisianaLA-02Compassionate Use of Hyperbaric Oxygen Therapy100West Jefferson Medical Center,SerenaGroup, Inc., SerenaGroup Research Foundation 
LouisianaLA-02A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Southeast Louisiana Veterans Health Care System,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
LouisianaLA-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000LSU Health Baton Rouge-North Clinic, Louisiana State University Health Science Center, Tulane University Health Sciences Center, University Medical Center New Orleans,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
LouisianaLA-02Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure524Tulane University, University Medical Center,ChimerixDrug: Dociparastat sodium, Drug: Placebo
LouisianaLA-02Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Southeast Louisiana Veterans Health Care System,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
LouisianaLA-02Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727New Orleans Adolescent Trials Unit CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
LouisianaLA-02A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204NOLA Research,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
LouisianaLA-03Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)800Centex Studies Inc.,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
LouisianaLA-03Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Centex Studies Inc,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
LouisianaLA-03Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)1700Lafayette General Medical Center, University Hospital and Clinics,Louisiana State University Health Sciences Center in New Orleans, Lafayette General Health, University of Louisiana at LafayetteDrug: Hydroxychloroquine, Drug: Placebo
LouisianaLA-03Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
LouisianaLA-04Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Louisiana State University,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
LouisianaLA-04Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-1970Louisiana State Health Shreveport,Massachusetts General Hospital, University of Alabama at BirminghamDrug: Nitric Oxide
LouisianaLA-04Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19200Louisiana State Health Shreveport,Massachusetts General Hospital, Xijing Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda HospitalDrug: Nitric Oxide Gas
LouisianaLA-04The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200Willis-Knighton Physcian Network,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
LouisianaLA-04Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998LSUHSC-Shreveport Clinical Trials Office, LSUHSC-Shreveport,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
LouisianaLA-04Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Overton Brooks VA Medical Center,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
LouisianaLA-04Compassionate Use of Hyperbaric Oxygen Therapy100Christus Shreveport Bossier Hyperbaric,SerenaGroup, Inc., SerenaGroup Research Foundation 
LouisianaLA-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000LSU Health Sciences Center at Shreveport,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
LouisianaLA-04LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)60LSU Health Shreveport,Arch Biopartners Inc.Drug: LSALT peptide, Drug: Placebo
LouisianaLA-04A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Louisiana State University Health Sciences Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
MaineME-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Maine Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MaineME-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Maine Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MaineME-01Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Maine Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
MaineME-01A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Maine Medical Center,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
MaineME-01Convalescent Plasma in Outpatients With COVID-19600Maine Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MaineME-01Sarilumab for Patients With Moderate COVID-19 Disease120VA Maine Healthcare System,Westyn Branch-Elliman, VA Boston Healthcare SystemBiological: SARILUMAB
MaineME-01MSCs in COVID-19 ARDS223Maine Medical Center,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
MaineME-01Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000Maine Medical Center,University of Manitoba, University Health Network, TorontoDrug: Heparin
MaineME-01Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
MaineME-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Harold Alfond Center for Cancer Care, Waldo County General Hospital, MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Southern Maine Health Center/Biddeford Medical Center, Maine Medical Center-Bramhall Campus, Penobscot Bay Medical Center, MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Maine Medical Center- Scarborough Campus, Maine Medical Partners - South Portland,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MaineME-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Eastern Maine Medical Center, Lafayette Family Cancer Center-EMMC,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MarylandMD-06CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243Shady Grove Medical Center,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
MarylandMD-06Tocilizumab for Patients With Cancer and COVID-19 Disease217National Cancer Institute,National Cancer Institute (NCI)Biological: Tocilizumab
MarylandMD-06A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Holy Cross Germantown Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
MarylandMD-06Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
MarylandMD-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000FMH James M Stockman Cancer Institute,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MarylandMD-06Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury50Frederick Health Hospital,Frederick HealthDrug: Heparin, Drug: 0.9% Sodium-chloride
MarylandMD-04Adaptive COVID-19 Treatment Trial (ACTT)1062University of Maryland School of Medicine,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
MarylandMD-04Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344MedStar Washington Hospital Center,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
MarylandMD-07Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS20University of Maryland Medical Center,University of Maryland, BaltimoreDevice: Hypothermia, Drug: Neuromuscular Blocking Agents, Device: Standard of Care
MarylandMD-07Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)200Johns Hopkins,Vanderbilt University Medical Center, United States Department of Defense 
MarylandMD-07Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of Maryland, Johns Hopkins Hospital,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
MarylandMD-07Adaptive COVID-19 Treatment Trial (ACTT)1062Johns Hopkins Hospital,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
MarylandMD-07CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243Institute of Human Virology,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
MarylandMD-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0University of Maryland Medical Center, Mercy Medical Center,Gilead SciencesDrug: Remdesivir
MarylandMD-07Convalescent Plasma to Stem Coronavirus (CSSC-001)500Johns Hopkins University,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
MarylandMD-07Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)829University of Maryland Medical Center,University of Washington, Bill and Melinda Gates FoundationDrug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid
MarylandMD-07Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Johns Hopkins University,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
MarylandMD-07Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
MarylandMD-07Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384University of Maryland Medical Center,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
MarylandMD-07Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation70Johns Hopkins Hospital,Johns Hopkins UniversityOther: Postural Positioning
MarylandMD-07Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection164Johns Hopkins Hospital,Johns Hopkins University, Eiger BioPharmaceuticalsDrug: Peginterferon lambda alfa-1a subcutaneous injection, Other: Saline
MarylandMD-07Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure60Johns Hopkins University,Noah Merin, Johns Hopkins University, Cedars-Sinai Medical CenterBiological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
MarylandMD-07Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease20Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: HCQ, Drug: HCQ+AZT, Drug: Placebo
MarylandMD-07Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Maryland Medical Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
MarylandMD-07Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
MarylandMD-07Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection30Johns Hopkins Hospital,Johns Hopkins UniversityDrug: Clazakizumab, Drug: Placebo
MarylandMD-07A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100University of Maryland Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
MarylandMD-07Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)220Johns Hopkins Hospital,Johns Hopkins University, Fast GrantsDrug: Prazosin, Other: Standard of care
MarylandMD-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Pharmaron CPC, University of Maryland - Center for Vaccine Development,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
MarylandMD-07Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Baltimore VA Medical Center,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
MarylandMD-07MSCs in COVID-19 ARDS223University of Maryland Medical Center,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
MarylandMD-07Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Johns Hopkins University,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
MarylandMD-07Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic50Wilmer Eye Institute,Johns Hopkins University 
MarylandMD-07Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
MarylandMD-07Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)30Johns Hopkins Hospital,Johns Hopkins UniversityBiological: Anti-SARS-CoV-2 Human Convalescent Plasma
MarylandMD-07Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
MarylandMD-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Maryland/Greenebaum Cancer Center, Mercy Medical Center, Sinai Hospital of Baltimore, Kaiser Permanente-Woodlawn Medical Center, Johns Hopkins University/Sidney Kimmel Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MarylandMD-07Trial of Imatinib for Hospitalized Adults With COVID-19204University of Maryland Medical Center,University of Maryland, BaltimoreDrug: Imatinib, Drug: Placebo oral tablet
MarylandMD-07Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)120Johns Hopkins Hospital,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
MarylandMD-07An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic0University of Maryland School of Medicine,Genentech, Inc.Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
MarylandMD-07Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Maryland School of Medicine, Johns Hopkins Hospital,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
MarylandMD-07Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Johns Hopkins University CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
MarylandMD-07The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Johns Hopkins Hospital, Howard County General Hospital,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
MarylandMD-07A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500University of Maryland School of Medicine,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
MarylandMD-08Viral Infections in Healthy and Immunocompromised Hosts1000National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
MarylandMD-08Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologics20Medicine Invention Design Incorporation,Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair, PPD, Medicine Invention Design, IncBiological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
MarylandMD-08Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP)20Medicine Invention Design Incorporation,Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair, Medicine Invention Design, IncBiological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
MarylandMD-08Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine300National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC)Biological: Flucelvax, Biological: Fluvirin, Biological: Fluzone High Dose
MarylandMD-08Adaptive COVID-19 Treatment Trial (ACTT)1062Walter Reed National Medical Center, National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
MarylandMD-08Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)120National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID)Biological: mRNA-1273
MarylandMD-08Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Holy Cross Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MarylandMD-08Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Holy Cross Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MarylandMD-08SARS-COV2 Pandemic Serosurvey and Blood Sampling15000National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
MarylandMD-08Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers10000National Institute of Mental Health,National Institute of Mental Health (NIMH), National Institutes of Health Clinical Center (CC) 
MarylandMD-08Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions90National Institutes of Health Clinical Center,National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health Clinical Center (CC) 
MarylandMD-08Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-191500National Institutes of Health Clinical Center,National Institutes of Health Clinical Center (CC) 
MarylandMD-08Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection180National Institutes of Health Clinical Center,National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC) 
MarylandMD-08Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant1419Meridian Clinical Research,Novavax, Coalition for Epidemic Preparedness Innovations (CEPI)Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2
MarylandMD-08Genetics of COVID-19 Susceptibility and Manifestations2500National Institutes of Health Clinical Center,National Human Genome Research Institute (NHGRI), National Institutes of Health Clinical Center (CC) 
MarylandMD-08A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Holy Cross Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
MarylandMD-08Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
MarylandMD-08Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses5000National Institute of Mental Health,National Institute of Mental Health (NIMH), National Institutes of Health Clinical Center (CC)Behavioral: Computer task questionnaires
MarylandMD-08Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site, Research Site, Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
MarylandMD-08Surveillance of Individuals Following SARS-CoV-2 Infection1050National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
MarylandMD-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente - Kensington Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MarylandMD-08COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study700NIAAA Section on Human Psychopharmacology,National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health Clinical Center (CC) 
MarylandMD-08Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)120Walter Reed National Medical Center, National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
MarylandMD-08COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)175National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
MarylandMD-08Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons180National Institutes of Health Clinical Center,National Institutes of Health Clinical Center (CC) 
MarylandMD-08Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Walter Reed National Medical Center, National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
MarylandMD-08The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Suburban Hospital,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
MarylandMD-08A Longitudinal Study of COVID-19 Sequelae and Immunity900National Institutes of Health Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
MarylandMD-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0CalvertHealth Medical Center,Gilead SciencesDrug: Remdesivir
MarylandMD-03CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243Anne Arundel Medical Center, White Oak Medical Center,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
MarylandMD-03Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0University of Maryland St. Joseph Medical,Gilead SciencesDrug: Remdesivir
MarylandMD-03Convalescent Plasma to Stem Coronavirus (CSSC-001)500Anne Arundel Medical Center,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
MarylandMD-03Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation70Johns Hopkins Bayview Medical Center,Johns Hopkins UniversityOther: Postural Positioning
MarylandMD-03Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection180Medstar Montgomery Medical Center,National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC) 
MarylandMD-03Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Center for Immunization Research Inpatient Unit,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
MarylandMD-03Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Anne Arundel Medical Center,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
MarylandMD-03Trial to Promote Recovery From COVID-19 With Endocrine Therapy60Johns Hopkins Hospital,Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDrug: Bicalutamide 150 Mg Oral Tablet
MarylandMD-03Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Johns Hopkins University,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
MarylandMD-03Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
MarylandMD-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Greater Baltimore Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MarylandMD-03PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364St. Agnes Healthcare,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
MarylandMD-03The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Johns Hopkins Bayview Medical Center,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
MarylandMD-01Study of Sargramostim in Patients With COVID-19120TidalHealth Peninsula Regional, Inc,Partner Therapeutics, Inc.Drug: Sargramostim, Drug: Standard of care
MarylandMD-02Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection180Medstar Franklin Square Medical Center,National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC) 
MassachusettsMA-04Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Charlton Memorial Hospital,Gilead SciencesDrug: Remdesivir
MassachusettsMA-04SOLIRIS® (Eculizumab) Treatment of Participants With COVID-190Newton-Wellesley Hospital,Alexion PharmaceuticalsBiological: eculizumab
MassachusettsMA-04Convalescent Plasma in Outpatients With COVID-19600Newton-Wellesley Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MassachusettsMA-04Efficacy of Tocilizumab on Patients With COVID-19243Newton-Wellesley Hospital,Massachusetts General Hospital, Genentech, Inc.Drug: Tocilizumab, Drug: Placebos
MassachusettsMA-04Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Newton-Wellelsey Hospital,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
MassachusettsMA-04Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial750Brigham and Women's Hospital,The TIMI Study GroupDrug: Unfractionated Heparin IV, Drug: Enoxaparin 1 mg/kg, Drug: Clopidogrel, Drug: Unfractionated heparin SC, Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution
MassachusettsMA-08A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)242Massachusetts General Hospital,Millennium Pharmaceuticals, Inc., TakedaDrug: TAK-981, Drug: Standard of care
MassachusettsMA-08Adaptive COVID-19 Treatment Trial (ACTT)1062Massachusetts General Hospital,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
MassachusettsMA-08Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-1970Massachusetts General Hospital,Massachusetts General Hospital, University of Alabama at BirminghamDrug: Nitric Oxide
MassachusettsMA-08Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19200Massachusetts General Hospital,Massachusetts General Hospital, Xijing Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda HospitalDrug: Nitric Oxide Gas
MassachusettsMA-08NO Prevention of COVID-19 for Healthcare Providers470Massachusetts General Hospital,Massachusetts General HospitalDrug: Inhaled nitric oxide gas
MassachusettsMA-08Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
MassachusettsMA-08Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0South Shore Hospital,Gilead SciencesDrug: Remdesivir
MassachusettsMA-08COVID-19 Symptom Tracker10000000Massachusetts General Hospital,King's College London, Zoe Global Limited, Massachusetts General Hospital, Harvard School of Public Health, Stanford UniversityOther: No Intervention
MassachusettsMA-08Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Massachusetts General Hospital,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
MassachusettsMA-08Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED260Massachusetts General Hospital,Massachusetts General Hospital, Department of Anesthesia, MGHDrug: Nitric Oxide Gas, Other: Inhaled Supplemental Oxygen
MassachusettsMA-08Pegylated Interferon Lambda Treatment for COVID-1920Massachusetts General Hospital,Raymond Chung, Eiger BioPharmaceuticals, Massachusetts General HospitalDrug: Pegylated interferon lambda
MassachusettsMA-08Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection500Massachusetts General Hospital,Massachusetts General HospitalDevice: AirGo Respiratory Monitor
MassachusettsMA-08Efficacy of Tocilizumab on Patients With COVID-19243Massachusetts General Hospital,Massachusetts General Hospital, Genentech, Inc.Drug: Tocilizumab, Drug: Placebos
MassachusettsMA-08Sarilumab for Patients With Moderate COVID-19 Disease120VA Boston Healthcare System,Westyn Branch-Elliman, VA Boston Healthcare SystemBiological: SARILUMAB
MassachusettsMA-08Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Massachusetts General Hospital,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
MassachusettsMA-08COVID-19: Human Epidemiology and Response to SARS-CoV-25605Massachusetts General Hospital,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
MassachusettsMA-08Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Massachusetts General Hospital,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
MassachusettsMA-08Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Massachusetts General Hospital,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
MassachusettsMA-08COVID-19 and Mental Health2000Northeastern University,Northeastern UniversityOther: Exposure to the SARS-CoV-2
MassachusettsMA-08A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924Massachusetts General Hospital,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
MassachusettsMA-01A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Baystate Health System,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
MassachusettsMA-01Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Baystate Health System,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
MassachusettsMA-01Convalescent Plasma in Outpatients With COVID-19600Baystate Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MassachusettsMA-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mercy Medical Center, Baystate Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MassachusettsMA-01A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Baystate Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
MassachusettsMA-03Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Lawrence General Hospital, Lowell General Hospital,Gilead SciencesDrug: Remdesivir
MassachusettsMA-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Lowell General Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MassachusettsMA-03Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease10Lowell General Hospital,Lowell General HospitalDevice: MLS Laser, Other: Regular Inpatient Medical Care
MassachusettsMA-05Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Massachusetts General Hospital,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
MassachusettsMA-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Cambridge Health Alliance,Gilead SciencesDrug: Remdesivir
MassachusettsMA-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Winchester Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MassachusettsMA-07Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Childrens Hospital Boston,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
MassachusettsMA-07Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)200Beth Israel Deaconess Medical Center,Vanderbilt University Medical Center, United States Department of Defense 
MassachusettsMA-07Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Brigham and Women's Hospital, Beth Israel Deaconess Medical Center,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
MassachusettsMA-07Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects3350Harvard University,Harvard University, Stanford University, Massachusetts Institute of TechnologyBehavioral: Video about safety and effectiveness of adult seasonal flu vaccination, Behavioral: Message directing subjects to information on COVID-19 vaccine safety and efficacy
MassachusettsMA-07Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Boston Children's Hospital,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
MassachusettsMA-07Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Tufts Medical Center, Brigham & Women's Hospital, Beth Israel Deaconess Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MassachusettsMA-07Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Tufts Medical Center, Brigham & Women's Hospital, Beth Israel Deaconess Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MassachusettsMA-07Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19200Beth Israel Deaconess Medical Center,Massachusetts General Hospital, Xijing Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda HospitalDrug: Nitric Oxide Gas
MassachusettsMA-07Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
MassachusettsMA-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Steward St. Elizabeth's Medical Center,Gilead SciencesDrug: Remdesivir
MassachusettsMA-07Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)829Boston University,University of Washington, Bill and Melinda Gates FoundationDrug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid
MassachusettsMA-07Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Beth Israel Deaconess Medical Center, Brigham and Women's Hospital,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
MassachusettsMA-07Hydroxychloroquine in Outpatient Adults With COVID-198Investigational Site Number 8400001,SanofiDrug: Hydroxychloroquine SAR321068, Drug: Placebo
MassachusettsMA-07COVID-19 Risk Stratification1326Brigham and Women's Hospital,Brigham and Women's Hospital 
MassachusettsMA-07Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384Brigham and Women's Hospital,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
MassachusettsMA-07Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986Beth Israel Deaconess Medical Center,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
MassachusettsMA-07Study of the Treatment and Outcomes in Critically Ill Patients With COVID-195220Brigham and Women's Hospital,Brigham and Women's Hospital, Icahn School of Medicine at Mount Sinai, Montefiore Medical Center, Baylor College of Medicine, Baylor Health Care System, Beth Israel Deaconess Medical Center, University of Colorado, Denver, Cook County Hospital, The Cooper Health System, Duke University, Georgetown University, Hackensack mountainside hospital, Hackensack Meridian Health, Indiana University Health Methodist Hospital, Johns Hopkins University, Loma Linda University, Mayo Clinic, Medical College of Wisconsin, Northwestern, Weill Medical College of Cornell University, NYU Langone Health, Ochsner Health System, Oregon Health and Science University, Renown Health, Rush University Medical Center, New Jersey Medical School, Rutgers Robert Wood Johnson Medical School, Stanford University, Temple University, Tufts Medical Center, Tulane University, University of California, Davis, University of California, Los Angeles, University of California, San Diego, University of California, San Francisco, University of North Carolina, Chapel Hill, University Hospitals Cleveland Medical Center, University Medical Center of Southern Nevada, University of Alabama at Birmingham, University of Chicago, University of Florida, University of Illinois at Chicago, University of Kentucky, University of Miami, University of Michigan, University of Oklahoma, University of Pennsylvania, University of Pittsburgh Medical Center, University of Tennessee Health Science Center, University of Washington, University of Texas, Southwestern Medical Center at Dallas, Yale UniversityOther: No intervention
MassachusettsMA-07Awake Prone Position for Early Hypoxemia in COVID-19560Boston Medical Center,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
MassachusettsMA-07A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Brigham and Women's Hospital,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
MassachusettsMA-07Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Beth Israel Deaconess Medical Center,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
MassachusettsMA-07Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Boston Medical Center,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
MassachusettsMA-07A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Brigham & Women's Hospital,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
MassachusettsMA-07Treatment for COVID-19 in High-Risk Adult Outpatients300Boston University,University of Washington, Bill and Melinda Gates FoundationDrug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
MassachusettsMA-07SOLIRIS® (Eculizumab) Treatment of Participants With COVID-190Boston Medical Center,Alexion PharmaceuticalsBiological: eculizumab
MassachusettsMA-07Convalescent Plasma in Outpatients With COVID-19600Tufts Medical Center, Beth Israel Deaconess Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MassachusettsMA-07Etoposide in Patients With COVID-19 Infection64Boston Medical Center,Boston Medical CenterDrug: Etoposide
MassachusettsMA-07Efficacy of Tocilizumab on Patients With COVID-19243Brigham and Women's Hospital,Massachusetts General Hospital, Genentech, Inc.Drug: Tocilizumab, Drug: Placebos
MassachusettsMA-07Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection60Beth Israel Deaconess Medical Center,Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical CenterDrug: Alteplase 50 MG [Activase]
MassachusettsMA-07Study of the Use of Favipiravir in Hospitalized Subjects With COVID-1950Brigham and Women's Hospital, Boston Medical Center, Massachusetts General Hospital,Fujifilm Pharmaceuticals U.S.A., Inc.Drug: Favipiravir + Standard of Care, Drug: Standard of Care
MassachusettsMA-07Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy220Brigham and Women's Hospital,Brigham and Women's HospitalBiological: High-Titer COVID-19 Convalescent Plasma (HT-CCP), Biological: Standard Plasma (FFP)
MassachusettsMA-07Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Beth Israel Deaconess Medical Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
MassachusettsMA-07Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site, Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
MassachusettsMA-07COVID-19 Active Research Experience (CARE)100000IQVIA,Iqvia Pty Ltd 
MassachusettsMA-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Boston Medical Center,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
MassachusettsMA-07Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Brigham and Women's Hospital, Boston Medical Center,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
MassachusettsMA-07MSCs in COVID-19 ARDS223Brigham and Women's Hospital,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
MassachusettsMA-07COVID-19 Health Messaging to Underserved Communities15475JPAL North America,National Bureau of Economic Research, Inc., Massachusetts General Hospital, Stanford University, Yale University, Massachusetts Institute of Technology, Harvard UniversityBehavioral: Messaging
MassachusettsMA-07Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19600Beth Israel Deaconess Medical Center,Vanderbilt University Medical Center, AbbVieDrug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo
MassachusettsMA-07Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury46Brigham and Women's Hospital, Beth Israel Deaconess Medical Center,AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company)Drug: Ibrutinib, Drug: Placebo
MassachusettsMA-07COVID-19: Human Epidemiology and Response to SARS-CoV-25605Boston Children's Hospital, Boston Medical Center,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
MassachusettsMA-07Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Boston Medical Center,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
MassachusettsMA-07Immunophenotyping Assessment in a COVID-19 Cohort2000Brigham and Women's Hospital,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
MassachusettsMA-07Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Brigham and Women's Hospital,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
MassachusettsMA-07Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site, Novartis Investigative Site, Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
MassachusettsMA-07Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)400Beth Israel Deaconess Medical Center, Inc.,University Hospital, Clermont-Ferrand, Hospital Clínico Universitario de Valencia, University Hospital Schleswig-Holstein, Groupe Hospitalier Pitie-SalpetriereDrug: Intravenous sedation, Drug: Inhaled sedation
MassachusettsMA-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Tufts Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MassachusettsMA-07Inhaled Nitric Oxide for Preventing Progression in COVID-1942Tufts Medical Center,Tufts Medical Center, BellerophonDrug: Nitric Oxide
MassachusettsMA-07The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-1930Brigham and Women's Hospital,Windtree TherapeuticsDrug: Lucinactant
MassachusettsMA-07Lung Irradiation for COVID-19 Pneumonia48Brigham and Women's Hospital,Brigham and Women's HospitalRadiation: Phase 1, Radiation: Phase 2
MassachusettsMA-07An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic0Dana Farber Cancer Institute,Genentech, Inc.Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
MassachusettsMA-07Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
MassachusettsMA-07Niclosamide for Mild to Moderate COVID-19100Tufts Medical Center,Tufts Medical CenterDrug: Niclosamide, Drug: Placebo, Other: Telehealth monitoring
MassachusettsMA-07Pulmozyme to Improve COVID-19 ARDS Outcomes60Brigham and Women's Hospital,Boston Children's Hospital, Brigham and Women's HospitalDrug: Pulmozyme, Drug: Placebo
MassachusettsMA-07Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Brigham and Women's Hospital CRS, Fenway Health Clinical Research Site CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
MassachusettsMA-07PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Brigham and Women's Hospital,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
MassachusettsMA-07A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Boston Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
MassachusettsMA-06A Study of LY3127804 in Participants With COVID-1995Lahey Hospital and Medical Center,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
MassachusettsMA-06Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Lahey Clinic Inc,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
MassachusettsMA-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Beverly Hospital, Lahey Hospital and Medical Center, Addison Gilbert Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MassachusettsMA-06Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Lahey Hospital and Medical Center,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
MassachusettsMA-02Adaptive COVID-19 Treatment Trial (ACTT)1062University of Massachusetts Medical School,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
MassachusettsMA-02Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0UMass Memorial Medical Center,Gilead SciencesDrug: Remdesivir
MassachusettsMA-02Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of Massachusetts Worcester,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
MassachusettsMA-02Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479St. Vincent's Hospital,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
MassachusettsMA-02Study of the Use of Favipiravir in Hospitalized Subjects With COVID-1950UMass Memorial Health Care,Fujifilm Pharmaceuticals U.S.A., Inc.Drug: Favipiravir + Standard of Care, Drug: Standard of Care
MassachusettsMA-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998UMass Memorial Medical Center,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
MassachusettsMA-02Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of Massachusetts Worcester,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
MassachusettsMA-02Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500UMass MMC - University Campus,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
MassachusettsMA-02Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Massachusetts Medical School,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
MassachusettsMA-02A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924University of Massachusetts Medical Center,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
MichiganMI-10NCI COVID-19 in Cancer Patients, NCCAPS Study2000Caro Cancer Center, Great Lakes Cancer Management Specialists-Doctors Park, Great Lakes Cancer Management Specialists-Macomb Medical Campus, Michigan Breast Specialists-Macomb Township, Saint Mary's Oncology/Hematology Associates of Marlette, McLaren-Port Huron, Henry Ford Macomb Health Center - Shelby Township,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-11Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Huron Valley-Sinai Hospital,Gilead SciencesDrug: Remdesivir
MichiganMI-11Convalescent Plasma in Outpatients With COVID-19600William Beaumont Hospital-Troy,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MichiganMI-11NCI COVID-19 in Cancer Patients, NCCAPS Study2000IHA Hematology Oncology Consultants-Canton, Saint Joseph Mercy Canton, Hope Cancer Clinic, Saint Mary Mercy Hospital, Ascension Providence Hospitals – Novi, Henry Ford Medical Center-Columbus, William Beaumont Hospital – Troy,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-11Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD90Ascension Providence Hospital Novi Campus,Ascension South East MichiganDrug: SARS-CoV-2 plasma
MichiganMI-12Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of Michigan,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
MichiganMI-12Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113University of Michigan Hospitals and Health Systems,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MichiganMI-12Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891University of Michigan Hospitals and Health Systems,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MichiganMI-12Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
MichiganMI-12Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St. Joseph Mercy Hospital,Gilead SciencesDrug: Remdesivir
MichiganMI-12Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479University of Michigan Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
MichiganMI-12Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Michigan,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
MichiganMI-12The Role of Resistant Starch in COVID-19 Infection1500University of Michigan,Yale University, University of Michigan, University of MinnesotaDrug: Dietary Supplement containing resistant starch, Dietary Supplement: Placebo Starch
MichiganMI-12Awake Prone Position for Early Hypoxemia in COVID-19560University of Michigan,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
MichiganMI-12Convalescent Plasma in Outpatients With COVID-19600University of Michigan,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MichiganMI-12Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Vida Clinical Studies,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
MichiganMI-12Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
MichiganMI-12MSCs in COVID-19 ARDS223University of Michigan,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
MichiganMI-12Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000Henry Ford University,University of Manitoba, University Health Network, TorontoDrug: Heparin
MichiganMI-12NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Joseph Mercy Hospital, University of Michigan Comprehensive Cancer Center, Henry Ford Cancer Institute-Downriver, Beaumont Hospital – Dearborn, Henry Ford Medical Center-Fairlane, Huron Gastroenterology PC, IHA Hematology Oncology Consultants-Ann Arbor,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-12Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19160University of Michigan,University of MichiganDrug: Dipyridamole 100 Milligram(mg), Drug: Placebo oral tablet
MichiganMI-12Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections30University of Michigan,SeaStar MedicalDevice: SCD
MichiganMI-12PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364University of Michigan,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
MichiganMI-12A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924University of Michigan,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
MichiganMI-13Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Henry Ford Health System,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MichiganMI-13Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Henry Ford Health System,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MichiganMI-13Losartan for Patients With COVID-19 Requiring Hospitalization200Henry Ford Hospital,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
MichiganMI-13CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243Henry Ford Health System,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
MichiganMI-13Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Wayne State University/ Detroit Hospital, Henry Ford Health System,Gilead SciencesDrug: Remdesivir
MichiganMI-13Convalescent Plasma to Stem Coronavirus (CSSC-001)500Wayne State University,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
MichiganMI-13Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
MichiganMI-13Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384Henry Ford Health System,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
MichiganMI-13Will Hydroxychloroquine Impede or Prevent COVID-19624Henry Ford Hospital,Henry Ford Health SystemDrug: Hydroxychloroquine - Daily Dosing, Drug: Hydroxychloroquine - Weekly Dosing, Other: Placebo oral tablet, Diagnostic Test: Monitoring Visit - Baseline, Diagnostic Test: Monitoring Visit - Week 4, Diagnostic Test: Monitoring Visit - Week 8, Other: Weekly Assessment
MichiganMI-13A Study of LY3127804 in Participants With COVID-1995Henry Ford Hospital,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
MichiganMI-13A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Detroit Receiving Hospital, Harper Hospital, Henry Ford Hospital,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
MichiganMI-13Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Karmanos,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
MichiganMI-13Convalescent Plasma in Outpatients With COVID-19600Detroit Receiving Hospital, Harper University Hospital, Henry Ford Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MichiganMI-13Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Henry Ford Hospital,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
MichiganMI-13A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Henry Ford Health System,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
MichiganMI-13Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Wayne State University,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
MichiganMI-13Early Short Course Corticosteroids in COVID-19250Henry Ford Health System,Henry Ford Health SystemDrug: Methylprednisolone
MichiganMI-13COVID-19: Human Epidemiology and Response to SARS-CoV-25605Henry Ford Health System,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
MichiganMI-13Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic8500Wayne State University,Żelazna Medical Centre, LLC, University of Medicine, Tirana, Royal Prince Alfred Hospital, Sydney, Australia, Charles University, Czech Republic, Hôpital Necker-Enfants Malades, Charite University, Berlin, Germany, Chinese University of Hong Kong, Meir Medical Center, Università degli Studi di Brescia, American University of Beirut Medical Center, Karolinska Institutet, Pomeranian Medical University Szczecin, Nicolaus Copernicus University, Centre of Postgraduate Medical Education, Polish Academy of Sciences, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland, Fundación Para la Investigación y el Desarrollode la Medicina Materno-Fetal y Neonatal "iMaterna", Madrid, Taiji Clinic, Taipei, Wayne State University, Chang Gung University, University of TromsoOther: Pandemic control measures
MichiganMI-13A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Henry Ford Hospital,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
MichiganMI-13Convalescent Plasma for Patients With COVID-1930Henry Ford Hospital,Henry Ford Health SystemBiological: Convalescent plasma
MichiganMI-13A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Henry Ford Health System,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
MichiganMI-13NCI COVID-19 in Cancer Patients, NCCAPS Study2000Wayne State University/Karmanos Cancer Institute, Henry Ford Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-13A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Henry Ford Hospital,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
MichiganMI-14Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
MichiganMI-14Will Hydroxychloroquine Impede or Prevent COVID-19624Detroit Department of Transportation, Detroit Fire Department & Detroit EMS, Detroit Police Department,Henry Ford Health SystemDrug: Hydroxychloroquine - Daily Dosing, Drug: Hydroxychloroquine - Weekly Dosing, Other: Placebo oral tablet, Diagnostic Test: Monitoring Visit - Baseline, Diagnostic Test: Monitoring Visit - Week 4, Diagnostic Test: Monitoring Visit - Week 8, Other: Weekly Assessment
MichiganMI-14A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Sinai Grace,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
MichiganMI-14Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Michigan Center of Medical Research,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
MichiganMI-14Convalescent Plasma in Outpatients With COVID-19600Sinai-Grace Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MichiganMI-14Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Michigan Center for Medical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
MichiganMI-14A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Sinai Grace Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
MichiganMI-14Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000Beaumont Hospital,University of Manitoba, University Health Network, TorontoDrug: Heparin
MichiganMI-14NCI COVID-19 in Cancer Patients, NCCAPS Study2000Ascension St. John Hospital, Weisberg Cancer Treatment Center, Beaumont Hospital - Farmington Hills, Academic Hematology Oncology Specialists, Great Lakes Cancer Management Specialists-Van Elslander, Michigan Breast Specialists-Grosse Pointe Woods, 21st Century Oncology-Pontiac, Hope Cancer Center, Newland Medical Associates-Pontiac, Saint Joseph Mercy Oakland, Ascension Providence Hospitals – Southfield, Henry Ford West Bloomfield Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-14A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Ascension Providence Hospital,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
MichiganMI-14Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19100Ascension St. John Hospital,Ascension South East MichiganDiagnostic Test: ID NOW vs. Accula
MichiganMI-14PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Ascension St. John Hospital, Ascension Providence Hospital- Novi Campus, Providence Cancer Institute,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
MichiganMI-14Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD90Ascension Providence Hospital Southfield Campus,Ascension South East MichiganDrug: SARS-CoV-2 plasma
MichiganMI-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000IHA Hematology Oncology Consultants-Chelsea, Saint Joseph Mercy Chelsea, Allegiance Health,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-06Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Bronson Methodist Hospital,Gilead SciencesDrug: Remdesivir
MichiganMI-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Bronson Methodist Hospital, West Michigan Cancer Center, Borgess Medical Center, Lakeland Hospital Niles, Lakeland Medical Center Saint Joseph, Marie Yeager Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0McLaren Health Care Corporation,Gilead SciencesDrug: Remdesivir
MichiganMI-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000McLaren Cancer Institute-Bay City, Genesee Cancer and Blood Disease Treatment Center, Genesee Hematology Oncology PC, Genesys Hurley Cancer Institute, Hurley Medical Center, McLaren Cancer Institute-Flint, Singh and Arora Hematology Oncology PC, Ascension Saint Mary's Hospital, Oncology Hematology Associates of Saginaw Valley PC, Ascension Saint Joseph Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-09A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)242Barbara Ann Karmanos Cancer Institute,Millennium Pharmaceuticals, Inc., TakedaDrug: TAK-981, Drug: Standard of care
MichiganMI-09Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 225Beaumont Health System,William Beaumont HospitalsDevice: CT-V
MichiganMI-09Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Henry Ford Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
MichiganMI-09Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Michigan Center of Medical Research,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
MichiganMI-09Beaumont Health Large-scale Automated Serologic Testing for COVID-1956000Beaumont Health System,William Beaumont HospitalsDiagnostic Test: EUROIMMUN assay
MichiganMI-09A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Beaumont Health System,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
MichiganMI-09Convalescent Plasma in Outpatients With COVID-19600William Beaumont Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MichiganMI-09Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19500William Beaumont Hospital,William Beaumont HospitalsDrug: Naltrexone, Drug: Ketamine, Other: Placebo
MichiganMI-09A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Beaumont Health Systems,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
MichiganMI-09NCI COVID-19 in Cancer Patients, NCCAPS Study2000Henry Ford Macomb Hospital-Clinton Township, McLaren Cancer Institute-Macomb, William Beaumont Hospital-Royal Oak, Bhadresh Nayak MD PC-Sterling Heights, Advanced Breast Care Center PLLC, Great Lakes Cancer Management Specialists-Macomb, Macomb Hematology Oncology PC, Michigan Breast Specialists-Warren, Saint John Macomb-Oakland Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-09Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure524William Beaumont Hospital,ChimerixDrug: Dociparastat sodium, Drug: Placebo
MichiganMI-09Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD90Ascension Providence Hospital Warren Campus,Ascension South East MichiganDrug: SARS-CoV-2 plasma
MichiganMI-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mid-Michigan Medical Center - Midland, McLaren Cancer Institute-Central Michigan, Spectrum Health Reed City Hospital, Saint Mary's Oncology/Hematology Associates of West Branch,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-04Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
MichiganMI-02Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Mercy Health Muskegon,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
MichiganMI-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mercy Health Mercy Campus, Cancer and Hematology Centers of Western Michigan - Norton Shores, Metro Health Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000McLaren Cancer Institute-Northern Michigan, Munson Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-03Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations225Spectrum Health,University of Illinois at Chicago, National Institute of Nursing Research (NINR)Behavioral: Motivational social support from nurse, Behavioral: Motivational social support from nurse with additional support from significant other, Behavioral: Attention control
MichiganMI-03Convalescent Plasma in Outpatients With COVID-19600Spectrum Health Hospitals Butterworth Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MichiganMI-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Bronson Battle Creek, Helen DeVos Children's Hospital at Spectrum Health, Mercy Health Saint Mary's, Spectrum Health at Butterworth Campus,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MichiganMI-08Compassionate Use of Hyperbaric Oxygen Therapy100Ascension Providence Rochester Hospital,SerenaGroup, Inc., SerenaGroup Research Foundation 
MichiganMI-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000IHA Hematology Oncology Consultants-Brighton, Saint Joseph Mercy Brighton, Hematology Oncology Consultants-Clarkston, McLaren Cancer Institute-Clarkston, Newland Medical Associates-Clarkston, Michigan State University Clinical Center, McLaren-Greater Lansing, Mid-Michigan Physicians-Lansing, Sparrow Hospital, Great Lakes Cancer Management Specialists-Rochester Hills,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MinnesotaMN-05Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Minnesota,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
MinnesotaMN-05Adaptive COVID-19 Treatment Trial (ACTT)1062University of Minnesota Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
MinnesotaMN-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Hennepin Healthcare,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MinnesotaMN-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Hennepin Healthcare,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MinnesotaMN-05Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-21309University of Minnesota,University of Minnesota, McGill University Health Centre/Research Institute of the McGill University Health Centre, University of Manitoba, University of AlbertaDrug: Hydroxychloroquine, Other: Placebo
MinnesotaMN-05Losartan for Patients With COVID-19 Not Requiring Hospitalization580Hennepin County Medical Center, M Health Fairview University of Minnesota, University of Minnesota, Mayo Clinic Health System,University of Minnesota, The Minnesota FoundationDrug: Losartan, Other: Placebo
MinnesotaMN-05Losartan for Patients With COVID-19 Requiring Hospitalization200Hennepin County Medical Center, M Health Fairview University of Minnesota, University of Minnesota, North Memorial Health Hospital,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
MinnesotaMN-05Pre-exposure Prophylaxis for SARS-Coronavirus-21500University of Minnesota,University of MinnesotaDrug: Hydroxychloroquine, Other: Placebo
MinnesotaMN-05Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Allina Health,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
MinnesotaMN-05Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)500University of Minnesota Medical Center,University of MinnesotaDiagnostic Test: Point-of-Care Ultrasonography (POCUS)
MinnesotaMN-05A Study of LY3127804 in Participants With COVID-1995Alina Hospital Network,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
MinnesotaMN-05A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Methodist Hospital,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
MinnesotaMN-05Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300Hennepin County Medical Center,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
MinnesotaMN-05Convalescent Plasma in Outpatients With COVID-19600HealthPartners Methodist Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MinnesotaMN-05Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Minnesota,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
MinnesotaMN-05Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia12University of Minnesota,Masonic Cancer Center, University of MinnesotaDrug: FT516
MinnesotaMN-05Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
MinnesotaMN-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Unity Hospital, Abbott-Northwestern Hospital, Hennepin County Medical Center, Health Partners Inc, University of Minnesota / Masonic Cancer Center, North Memorial Medical Health Center, Park Nicollet Clinic - Saint Louis Park,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MinnesotaMN-05COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-11140Methodist Hospital,Veru Inc.Drug: Veru-111
MinnesotaMN-05The Professional Peer Resilience Initiative1200University of Minnesota,University of MinnesotaBehavioral: MinnRAP Peer Support Program
MinnesotaMN-05Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Minnesota Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
MinnesotaMN-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Monticello Cancer Center, Fairview Northland Medical Center, Coborn Cancer Center at Saint Cloud Hospital, Ridgeview Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MinnesotaMN-02Losartan for Patients With COVID-19 Requiring Hospitalization200M Health Fairview Ridges Hospital,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
MinnesotaMN-02Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-190Mayo Clinic Health System in Cannon Falls, Mayo Clinic Health System in Lake City, Mayo Clinic Health System in Red Wing,Mayo ClinicBiological: COVID-19 convalescent plasma
MinnesotaMN-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Fairview Ridges Hospital, Minnesota Oncology - Burnsville, Saint Francis Regional Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MinnesotaMN-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Sanford Joe Lueken Cancer Center, Rice Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MinnesotaMN-04A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)242HealthPartners Cancer Care Center - Regions Hospital,Millennium Pharmaceuticals, Inc., TakedaDrug: TAK-981, Drug: Standard of care
MinnesotaMN-04Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.16Regions Hospital,Swedish Orphan BiovitrumBiological: Emapalumab, Biological: Anakinra
MinnesotaMN-04Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)500M Health Fairview Bethesda Hospital,University of MinnesotaDiagnostic Test: Point-of-Care Ultrasonography (POCUS)
MinnesotaMN-04A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Regions Hospital,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
MinnesotaMN-04Convalescent Plasma in Outpatients With COVID-19600Regions Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
MinnesotaMN-04Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
MinnesotaMN-04Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Healthpartners Cancer Care Center - Regions Hospital,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
MinnesotaMN-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Minnesota Oncology Hematology PA-Maplewood, Saint John's Hospital – Healtheast, Regions Hospital, United Hospital, Lakeview Hospital, Minnesota Oncology Hematology PA-Woodbury,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MinnesotaMN-04COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-11140Regions Hospital,Veru Inc.Drug: Veru-111
MinnesotaMN-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cambridge Medical Center, Fairview Lakes Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MinnesotaMN-01Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia90Mayo Clinic,Mayo ClinicDrug: Methylprednisolone, Other: Usual Care
MinnesotaMN-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Mayo Clinic,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MinnesotaMN-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Mayo Clinic,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MinnesotaMN-01Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
MinnesotaMN-01A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Mayo Clinic,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
MinnesotaMN-01Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Mayo Clinic - Rochester,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
MinnesotaMN-01Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry50000Mayo Clinic,Mayo Clinic, Society of Critical Care Medicine, Boston UniversityOther: observational
MinnesotaMN-01Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Mayo Clinic Hospital,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
MinnesotaMN-01Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-190Mayo Clinic Health System in Albert Lea, Mayo Clinic Health System in Austin, Mayo Clinic Health System in Mankato, Mayo Clinic Health System in Owatonna, Mayo Clinic Health System in Rochester,Mayo ClinicBiological: COVID-19 convalescent plasma
MinnesotaMN-01Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300Mayo Clinic,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
MinnesotaMN-01SOLIRIS® (Eculizumab) Treatment of Participants With COVID-190Mayo Clinic,Alexion PharmaceuticalsBiological: eculizumab
MinnesotaMN-01Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Mayo Clinic Health System, Mayo Clinic,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
MinnesotaMN-01Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000Mayo Clinic,University of Manitoba, University Health Network, TorontoDrug: Heparin
MinnesotaMN-01Risks of COVID19 in the Pregnant Population100Mayo Clinic,Mayo ClinicOther: Biospecimen collection
MinnesotaMN-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mayo Clinic Health Systems-Mankato, New Ulm Medical Center, Mayo Clinic in Rochester,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MinnesotaMN-01Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944Mayo Clinic,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
MinnesotaMN-03Losartan for Patients With COVID-19 Requiring Hospitalization200M Health Fairview Southdale Hospital,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
MinnesotaMN-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mercy Hospital, Fairview Southdale Hospital, Fairview Clinics and Surgery Center Maple Grove,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MississippiMS-03Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Mississippi Medical Center, Mississippi Center for Advanced Medicine,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
MississippiMS-03Losartan for Patients With COVID-19 Requiring Hospitalization200University of Mississippi Medical Center,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
MississippiMS-03Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0University of Mississippi Medical Center,Gilead SciencesDrug: Remdesivir
MississippiMS-03Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479University of Mississippi Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
MississippiMS-03Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384University of Mississippi Medical Center,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
MississippiMS-03Dapagliflozin in Respiratory Failure in Patients With COVID-19900University of Mississippi Medical Center,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
MississippiMS-03Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Mississippi Medical Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
MississippiMS-03Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19600University of Mississippi Medical Center,Vanderbilt University Medical Center, AbbVieDrug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo
MississippiMS-03Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
MississippiMS-03Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140University of Mississippi Medical Center,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
MississippiMS-03Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124University of Mississippi Medical Center,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
MississippiMS-01Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000North Mississippi Medical Clinics,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
MississippiMS-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Baptist Memorial Hospital and Cancer Center-Golden Triangle, Baptist Memorial Hospital and Cancer Center-Union County, Baptist Memorial Hospital and Cancer Center-Oxford, Baptist Memorial Hospital and Cancer Center-Desoto,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MississippiMS-01Registry of CytoSorb Therapy in COVID-19 ICU Patients500Baptist Memorial Hospital,CytoSorbents, IncDevice: CytoSorb 300 mL device
MississippiMS-04Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Keesler Medical Center,,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
MississippiMS-04Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998MedPharmics LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
MississippiMS-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Gulfport Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MississippiMS-02INB03 for the Treatment of Pulmonary Complications From COVID-19366Mississippi Baptist,Inmune Bio, Inc.Drug: INB03, Drug: Placebo
MississippiMS-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Baptist Cancer Center-Grenada, Mississippi Baptist Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MissouriMO-06Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease682Heartland Regional Medical Center,Algernon Pharmaceuticals, Novotech (Australia)Drug: NP-120 (Ifenprodil)
MissouriMO-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Kansas Cancer Center – North, University of Kansas Cancer Center - Lee's Summit, Heartland Regional Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MissouriMO-05Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Childrens Mercy Hospital, Childrens Mercy Hospital,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
MissouriMO-05Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers120Center for Pharmaceutical Research,Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations (CEPI)Drug: INO-4800, Device: CELLECTRA® 2000
MissouriMO-05Dapagliflozin in Respiratory Failure in Patients With COVID-19900Saint Luke's Mid America Heart Institute,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
MissouriMO-05The COVID-19 ICU PRAYER Study1000Research Medical Center,Kansas City Heart Rhythm InstituteBehavioral: prayer
MissouriMO-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Truman Medical Centers, University of Kansas Cancer Center at North Kansas City Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MissouriMO-05Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Heartland Research Associates,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
MissouriMO-07Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Mercy Research,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
MissouriMO-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cox Cancer Center Branson, Freeman Health System, Mercy Hospital Joplin, Mercy Hospital Springfield, CoxHealth South Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MissouriMO-04COVID-19 in Patients With HIV500University of Missouri-Columbia,University of Missouri-ColumbiaOther: No intervention
MissouriMO-04Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Missouri-Columbia,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
MissouriMO-04Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth72Missouri Orthopedic Institute,University of Missouri-ColumbiaBehavioral: Therapy Intervention
MissouriMO-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Missouri,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MissouriMO-04Dornase Alfa for ARDS in Patients With SARS-CoV-220University of Missouri Hospital and Clinics,University of Missouri-ColumbiaDrug: Dornase Alfa Inhalation Solution
MissouriMO-04Study of Sargramostim in Patients With COVID-19120University of Missouri Health Care,Partner Therapeutics, Inc.Drug: Sargramostim, Drug: Standard of care
MissouriMO-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Francis Medical Center, Southeast Cancer Center, Parkland Health Center – Farmington, Delbert Day Cancer Institute at PCRMC, Mercy Clinic-Rolla-Cancer and Hematology, Sainte Genevieve County Memorial Hospital, Missouri Baptist Sullivan Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MissouriMO-01Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Washington University,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
MissouriMO-01Adaptive COVID-19 Treatment Trial (ACTT)1062Saint Louis University,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
MissouriMO-01Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Washington University School of Medicine,Gilead SciencesDrug: Remdesivir
MissouriMO-01CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION30000Washington University School of Medicine,Washington University School of Medicine, COVID -19 Therapeutics AcceleratorDrug: MR or M-M-R II ® vaccine, Drug: Placebo
MissouriMO-01Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection500Washington University School of Medicine,Washington University School of MedicineDrug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Chloroquine Sulfate
MissouriMO-01A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection152Washington University School of Medicine,Washington University School of MedicineDrug: Fluvoxamine, Drug: Placebo
MissouriMO-01Dapagliflozin in Respiratory Failure in Patients With COVID-19900Washington University School of Medicine,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
MissouriMO-01Evaluation of Antibody Tests for COVID-19461Washington University School of Medicine,Washington University School of MedicineDiagnostic Test: Diagnostic test
MissouriMO-01Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Washington University School of Medicine,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
MissouriMO-01Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000St. Louis University School of Medicine/St. Louis VA Medical Center,University of Manitoba, University Health Network, TorontoDrug: Heparin
MissouriMO-01Duvelisib to Combat COVID-1928Washington University School of Medicine,Washington University School of Medicine, Verastem, Inc.Drug: Duvelisib, Procedure: Peripheral blood draw, Drug: Placebo
MissouriMO-01COVID-19: Human Epidemiology and Response to SARS-CoV-25605St. Louis Children's Hospital,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
MissouriMO-01A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Washington University School of Medicine,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
MissouriMO-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cardinal Glennon Children's Medical Center, Saint Louis Cancer and Breast Institute-South City,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MissouriMO-01Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Saint Louis University,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
MissouriMO-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Capital Region Southwest Campus, Mercy Hospital Washington,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MissouriMO-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Clinical Research Professionals, Sundance Clinical Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
MissouriMO-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Louis Cancer and Breast Institute-Ballwin, Mercy Hospital South, Missouri Baptist Medical Center, Mercy Hospital Saint Louis, Missouri Baptist Outpatient Center-Sunset Hills,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MontanaMT-00Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Providence St Patrick Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MontanaMT-00Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Providence St Patrick Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
MontanaMT-00Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection10Robert W. Alexander MD,Black Tie Medical, Inc., Robert W. Alexander, MDProcedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Device: Centricyte 1000, Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Drug: Liberase Enzyme (Roche), Drug: Sterile Normal Saline for Intravenous Use
MontanaMT-00Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Bozeman Health Deaconess Hospital,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
MontanaMT-00A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Mercury Street Medical Group PLLC,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
MontanaMT-00NCI COVID-19 in Cancer Patients, NCCAPS Study2000Community Hospital of Anaconda, Billings Clinic Cancer Center, Saint Vincent Healthcare, Saint Vincent Frontier Cancer Center, Bozeman Deaconess Hospital, Saint James Community Hospital and Cancer Treatment Center, Benefis Healthcare- Sletten Cancer Institute, Great Falls Clinic, Kalispell Regional Medical Center, Saint Patrick Hospital - Community Hospital, Community Medical Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
MontanaMT-00Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
NebraskaNE-02Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of Nebraska Medical Center,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
NebraskaNE-02Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Nebraska Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
NebraskaNE-02Adaptive COVID-19 Treatment Trial (ACTT)1062University of Nebraska Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
NebraskaNE-02Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Nebraska Medical Center,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
NebraskaNE-02Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
NebraskaNE-02Awake Prone Position for Early Hypoxemia in COVID-19560Creighton University,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
NebraskaNE-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Quality Clinical Research Inc, Meridian Clinical Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
NebraskaNE-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Nebraska Methodist Hospital, Nebraska Medicine-Village Pointe, Alegent Health Immanuel Medical Center, Alegent Health Bergan Mercy Medical Center, Alegent Health Lakeside Hospital, Creighton University Medical Center, University of Nebraska Medical Center, Midlands Community Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
NebraskaNE-02Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Nebraska Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
NebraskaNE-02Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Meridian Clinical Research,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
NebraskaNE-02A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924Quality Clinical Research Inc.,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
NebraskaNE-01Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Beacom Family Health Connection,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
NebraskaNE-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Methodist Physicians Clinic, Meridian Clinical Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
NebraskaNE-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Nebraska Medicine-Bellevue, Saint Elizabeth Regional Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
NebraskaNE-01Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Meridian Clinical Research LLC,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
NebraskaNE-01A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Saint Elizabeth Regional Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
NebraskaNE-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000CHI Health Saint Francis, CHI Health Good Samaritan,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
NebraskaNE-03Study of Sargramostim in Patients With COVID-19120Great Plains Health,Partner Therapeutics, Inc.Drug: Sargramostim, Drug: Standard of care
NevadaNV-02A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Renown Institute for Heath & Vascular Health,Hoffmann-La RocheDrug: Tociliuzumab
NevadaNV-02Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
NevadaNV-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Carson Tahoe Regional Medical Center, Renown Regional Medical Center, Saint Mary's Regional Medical Center, Radiation Oncology Associates, Cancer Care Specialists - Reno,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
NevadaNV-03Tocilizumab for Patients With Cancer and COVID-19 Disease217Summerlin Hospital Medical Center,National Cancer Institute (NCI)Biological: Tocilizumab
NevadaNV-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cancer and Blood Specialists-Henderson, Comprehensive Cancer Centers of Nevada - Henderson, Comprehensive Cancer Centers of Nevada-Horizon Ridge, Las Vegas Cancer Center-Henderson, OptumCare Cancer Care at Seven Hills, 21st Century Oncology-Henderson, Comprehensive Cancer Centers of Nevada-Southeast Henderson, Las Vegas Urology-Green Valley, Las Vegas Urology-Pebble, Urology Specialists of Nevada - Green Valley, Las Vegas Urology - Pecos, HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas Prostate Cancer Center, Las Vegas Urology - Sunset, Urology Specialists of Nevada - Northwest, Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Comprehensive Cancer Centers of Nevada - Town Center, Comprehensive Cancer Centers of Nevada-Summerlin, Summerlin Hospital Medical Center, 21st Century Oncology-Fort Apache, Comprehensive Cancer Centers of Nevada, Las Vegas Cancer Center-Medical Center, OptumCare Cancer Care at Fort Apache, Urology Specialists of Nevada - Southwest,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
NevadaNV-01CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243University Medical Center of Southern Nevada,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
NevadaNV-01Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384University Medical Center of Southern Nevada,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
NevadaNV-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Wr-Crcn LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
NevadaNV-01Tocilizumab for Patients With Cancer and COVID-19 Disease217University Medical Center of Southern Nevada,National Cancer Institute (NCI)Biological: Tocilizumab
NevadaNV-01A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Optum Health Care,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
NevadaNV-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Desert West Surgery, OptumCare Cancer Care at Oakey, University Medical Center of Southern Nevada, Hope Cancer Care of Nevada, Radiation Oncology Centers of Nevada Central, Urology Specialists of Nevada - Central, 21st Century Oncology, HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Sunrise Hospital and Medical Center, Radiation Oncology Centers of Nevada Southeast, HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Comprehensive Cancer Centers of Nevada - Central Valley, University Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
NevadaNV-01Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
NevadaNV-04Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Nellis Air Force Base,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
NevadaNV-04NCI COVID-19 in Cancer Patients, NCCAPS Study200021st Century Oncology-Vegas Tenaya, Ann M Wierman MD LTD, Comprehensive Cancer Centers of Nevada - Northwest, HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas Urology - Cathedral Rock, Las Vegas Urology - Smoke Ranch, OptumCare Cancer Care at MountainView, Hope Cancer Care of Nevada-Pahrump,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New HampshireNH-02Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Dartmouth-Hitchcock Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
New HampshireNH-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Darmouth-Hitchhock Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New HampshireNH-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Darmouth-Hitchhock Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New HampshireNH-02Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300Dartmouth-Hitchcock,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
New HampshireNH-02MSCs in COVID-19 ARDS223Dartmouth-Hitchcock,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
New HampshireNH-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New HampshireNH-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Wentworth-Douglass Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New JerseyNJ-10Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Robert Wood Johnson University Hospital Somerset,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-10Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Robert Wood Johnson University Hospital Somerset,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-10Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New JerseyNJ-10Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St. Michael's Medical Center, University Hospital,Gilead SciencesDrug: Remdesivir
New JerseyNJ-10Rutgers COVID-19 Cohort Study750Clinical Research Unit Rutgers New Jersey Medical School, Rutgers School of Dental Medicine, University Hospital,Rutgers, The State University of New JerseyOther: Non-Interventional
New JerseyNJ-10Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19160University Hospital,Rutgers, The State University of New JerseyCombination Product: Hydroxychloroquine Sulfate + Azithromycin, Drug: Hydroxychloroquine Sulfate
New JerseyNJ-10Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000North Jersey Community Research Initiative,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
New JerseyNJ-10Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
New JerseyNJ-10Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Rutgers Njms Clinical Research Unit,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
New JerseyNJ-10A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270St. Michael's Medical Center,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
New JerseyNJ-10Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Rutgers University Hospital,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
New JerseyNJ-10NCI COVID-19 in Cancer Patients, NCCAPS Study2000Newark Beth Israel Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New JerseyNJ-10Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients308Beth Israel Newark,Northwell HealthDrug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin
New JerseyNJ-10Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727New Jersey Medical School Clinical Research Center CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
New JerseyNJ-10A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500St. Michael's Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
New JerseyNJ-10Aggrenox To Treat Acute Covid-19132Rutgers New Jersey Medical School University Hospital,Rutgers, The State University of New Jersey, Boehringer IngelheimDrug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Other: Standard of care
New JerseyNJ-11Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New JerseyNJ-11CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243Atlantic Health System,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
New JerseyNJ-11Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Morristown Medical Center,Gilead SciencesDrug: Remdesivir
New JerseyNJ-11Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19160Saint Barnabas Medical Center, Morristown Medical Center,Rutgers, The State University of New JerseyCombination Product: Hydroxychloroquine Sulfate + Azithromycin, Drug: Hydroxychloroquine Sulfate
New JerseyNJ-11Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986Atlantic Health System Hospital,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
New JerseyNJ-11Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Saint Barnabas Medical Center, Atlantic Health System Hospital,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
New JerseyNJ-11Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300Saint Barnabas Medical Center,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
New JerseyNJ-11Study of the Use of Favipiravir in Hospitalized Subjects With COVID-1950Atlantic Health System,Fujifilm Pharmaceuticals U.S.A., Inc.Drug: Favipiravir + Standard of Care, Drug: Standard of Care
New JerseyNJ-11A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100St Joseph's Regional Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
New JerseyNJ-11Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-1986Atlantic Health System,Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)Biological: CYNK-001
New JerseyNJ-11Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Morristown Medical Center, Atlantic Health System,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
New JerseyNJ-11NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Barnabas Medical Center, Morristown Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New JerseyNJ-11Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes80Atlantic Health System,TScan Therapeutics, Inc. 
New JerseyNJ-11PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Atlantic Melanoma Center, Chilton Medical Center, Overlook Medical Center,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
New JerseyNJ-11Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944Atlantic Health System / Morristown Medical Center,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
New JerseyNJ-12Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Capital Health,Gilead SciencesDrug: Remdesivir
New JerseyNJ-03Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000Deborah Heart and Lung Center,University of Manitoba, University Health Network, TorontoDrug: Heparin
New JerseyNJ-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Community Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New JerseyNJ-04Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New JerseyNJ-04Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0CentraState Medical Center, Robert Wood Johnson University Hospital, Jersey Shore University Medical Center, Ocean Medical Center,Gilead SciencesDrug: Remdesivir
New JerseyNJ-04A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy132Memorial Sloan Kettering Monmouth,Memorial Sloan Kettering Cancer CenterDrug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy
New JerseyNJ-01Losartan for Patients With COVID-19 Requiring Hospitalization200Cooper University Hospital,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
New JerseyNJ-01CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243Cooper University Hospital,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
New JerseyNJ-01Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Cooper University Hospital, Virtua Health Voorhees Campus,Gilead SciencesDrug: Remdesivir
New JerseyNJ-01Convalescent Plasma in Outpatients With COVID-19600Cooper University Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
New JerseyNJ-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cooper Hospital University Medical Center, Kennedy Health Systems-Cancer Center, Inspira Medical Center Woodbury,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New JerseyNJ-01Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140Cooper Research Institute,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
New JerseyNJ-05Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Institute for Pediatric Cancer and Blood Disorders,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
New JerseyNJ-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Hackensack University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Hackensack University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-05Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New JerseyNJ-05A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Hackensack University Medical Center,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
New JerseyNJ-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0The Valley Hospital, Holy Name Medical Center,Gilead SciencesDrug: Remdesivir
New JerseyNJ-05Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.16Valley Hospital,Swedish Orphan BiovitrumBiological: Emapalumab, Biological: Anakinra
New JerseyNJ-05Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
New JerseyNJ-05Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection52Hackensack University Medical Center,Hackensack Meridian HealthBiological: Convalescent Plasma
New JerseyNJ-05Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Holy Name Medical Center,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
New JerseyNJ-05A Prospective "Universal" Observational Database for COVID-195000Hackensack Meridian Health - John Theurer Cancer Center,Hackensack Meridian Health 
New JerseyNJ-05Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-1986Hackensack University Medical Center,Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)Biological: CYNK-001
New JerseyNJ-05Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Hackensack University Medical Center, Holy Name Medical Center,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
New JerseyNJ-05Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
New JerseyNJ-05A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy132Memorial Sloan Kettering Bergen,Memorial Sloan Kettering Cancer CenterDrug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy
New JerseyNJ-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Newton Medical Center, Holy Name Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New JerseyNJ-05Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140Holy Name Medical Center,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
New JerseyNJ-05Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Holy Name Hospital,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
New JerseyNJ-06Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100UMDNJ,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
New JerseyNJ-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Robert Wood Johnson University Hospital Somerset,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Robert Wood Johnson University Hospital Somerset,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-06Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New JerseyNJ-06A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Robert Wood Johnson University Hospital/Rutgers,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
New JerseyNJ-06Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Hackensack Meridian Health - JFK Medical, Monmouth Medical Center, Saint Peter's University Hospital, Bayshore Medical Center,Gilead SciencesDrug: Remdesivir
New JerseyNJ-06Rutgers COVID-19 Cohort Study750Robert Wood Johnson Medical School, Robert Wood Johnson University Hospital, Environmental and Occupational Health Sciences Institute, RUCDR Infinite Biologics,Rutgers, The State University of New JerseyOther: Non-Interventional
New JerseyNJ-06Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19160Monmouth Medical Center, Robert Wood Johnson University Hospital, Rutgers Cancer Institute of New Jersey,Rutgers, The State University of New JerseyCombination Product: Hydroxychloroquine Sulfate + Azithromycin, Drug: Hydroxychloroquine Sulfate
New JerseyNJ-06Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers44Hackensack Meridian Health,Hackensack Meridian HealthDrug: Hydroxychloroquine Sulfate (HCQ)
New JerseyNJ-06SOLIRIS® (Eculizumab) Treatment of Participants With COVID-190Robert Wood Johnson University Hospital,Alexion PharmaceuticalsBiological: eculizumab
New JerseyNJ-06Asymptomatic COVID-19 Trial0Robert Wood Johnson University Hospital,Rutgers, The State University of New JerseyDrug: Hydroxychloroquine sulfate &Azithromycin, Drug: Placebo
New JerseyNJ-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Monmouth Medical Center, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson University Hospital Somerset,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New JerseyNJ-06COVID-19 Wellness Survey593Rutgers - The State University of New Jersey,Rutgers, The State University of New JerseyOther: Survey
New JerseyNJ-06A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Rutgers University - Robert Wood Johnson Medical School,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
New JerseyNJ-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998South Jersey Infectious Disease,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
New JerseyNJ-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Inspira Medical Center Mullica Hill, Inspira Medical Center Vineland,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New JerseyNJ-02COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-11140Inspira Medical Center,Veru Inc.Drug: Veru-111
New JerseyNJ-02Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Inspira Health Center Vineland,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
New JerseyNJ-07Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Robert Wood Johnson University Hospital Somerset,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-07Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Robert Wood Johnson University Hospital Somerset,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Hunterdon Medical Center, Overlook Medical Center,Gilead SciencesDrug: Remdesivir
New JerseyNJ-07Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19160Overlook Hospital,Rutgers, The State University of New JerseyCombination Product: Hydroxychloroquine Sulfate + Azithromycin, Drug: Hydroxychloroquine Sulfate
New JerseyNJ-07Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-1986Atlantic Health System,Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)Biological: CYNK-001
New JerseyNJ-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Amici Clinical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
New JerseyNJ-07A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy132Memorial Sloan Kettering Basking Ridge,Memorial Sloan Kettering Cancer CenterDrug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy
New JerseyNJ-07Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Overlook Hospital,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
New JerseyNJ-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Hunterdon Medical Center, Overlook Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New JerseyNJ-07Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944Atlantic Health System / Overlook Medical Center,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
New JerseyNJ-09Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113St. Joseph's University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-09Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891St. Joseph's University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New JerseyNJ-09The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200Englewood Health,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
New JerseyNJ-09Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Englewood Health,Gilead SciencesDrug: Remdesivir
New JerseyNJ-09A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379St. Joseph's Regional Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
New JerseyNJ-09A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410St. Joseph's Regional Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
New JerseyNJ-08Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0CarePoint Health Bayonne Medical Center, Clara Maass Medical Center, Trinitas Regional Medical Center, Jersey City Medical Center, Christ Hospital- Carepoint Health,Gilead SciencesDrug: Remdesivir
New JerseyNJ-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus, Rutgers New Jersey Medical School,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New MexicoNM-03Convalescent Plasma to Stem Coronavirus (CSSC-001)500Center for American Indian Health, Center for American Indian Health,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
New MexicoNM-03Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Johns Hopkins Center for American Indian Health, Johns Hopkins Center for American Indian Health,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
New MexicoNM-03A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379San Juan Oncology Associates,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
New MexicoNM-03Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Center for American Indian Health, Center for American Indian Health,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
New MexicoNM-03A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410San Juan Oncology Associates,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
New MexicoNM-01Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of New Mexico Health Science Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
New MexicoNM-01Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of New Mexico Health Sciences Center,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
New MexicoNM-01Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384UNM Hospitals,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
New MexicoNM-01Plasma Adsorption in Patients With Confirmed COVID-192000UNM Health Science Center,Marker Therapeutics AG, Terumo BCTDevice: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
New MexicoNM-01Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of New Mexico Health Sciences Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
New MexicoNM-01Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of New Mexico Health Sciences Center,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
New MexicoNM-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of New Mexico Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New MexicoNM-01Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of New Mexico Clinical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
New MexicoNM-01Effects of the COVID-19 Health Emergency on Biopsychosocial Health500University of New Mexico Department of Pediatrics,University of New MexicoOther: WHOQOL-BREF survey
New YorkNY-10SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry1500Massive Bio Inc,Massive Bio, Inc.Other: Clinical Trial Matching
New YorkNY-10Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-10Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-10Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site 1, Regeneron Study Site 2,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-10Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Maimonides Medical Center, New York-Presbyterian Lower Manhattan Hospital,Gilead SciencesDrug: Remdesivir
New YorkNY-10CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)1200New York-Presbyterian Lower Manhattan Hospital,Hamilton Health Sciences Corporation, Canadian Blood Services, Héma-Québec, University of Toronto, Université de Montréal, Weill Cornell Medicine/New York-Presbyterian, New York Blood Centre, McMaster UniversityBiological: Convalescent plasma
New YorkNY-10A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Mount Sinai West,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
New YorkNY-10Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
New YorkNY-10COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-1970Maimonides Medical Center,Maimonides Medical CenterDrug: Colchicine, Drug: Usual Care
New YorkNY-10Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
New YorkNY-10Myeloproliferative Neoplasms (MPN) and COVID-1980Mount Sinai West,Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net 
New YorkNY-10Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140Maimonides Medical Center,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
New YorkNY-11Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0New York Harbor VA Medical Center, NYC Health + Hospitals/Coney Island, Staten Island University Hospital,Gilead SciencesDrug: Remdesivir
New YorkNY-11A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Staten Island University Hospital,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
New YorkNY-11Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198Brooklyn Campus of the VA,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
New YorkNY-11Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients308Staten Island University Hospital,Northwell HealthDrug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin
New YorkNY-11Study of Sargramostim in Patients With COVID-19120Richmond University Medical Center,Partner Therapeutics, Inc.Drug: Sargramostim, Drug: Standard of care
New YorkNY-12Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
New YorkNY-12A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy90Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer CenterDrug: Anakinra
New YorkNY-12Adaptive COVID-19 Treatment Trial (ACTT)1062New York University School of Medicine,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
New YorkNY-12Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Icahn School of Medicine at Mount Sinai, Weill Cornell Medical College/NYU Presbyterian Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-12Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Icahn School of Medicine at Mount Sinai, New York Presbyterian Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-12Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure165NYU Langone Medical Center,NeuroRx, Inc., Lavin Consulting, LLCDrug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care
New YorkNY-12Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site, Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-12Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000New York University School of Medicine,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
New YorkNY-12Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Mount Sinai Queens, NYU Langone Health, Hospital for Special Surgery, Memorial Sloan-Kettering Cancer Center,Gilead SciencesDrug: Remdesivir
New YorkNY-12ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection300Lenox Hill Hospital Northwell Health,Vanda PharmaceuticalsDrug: Tradipitant, Drug: Placebo
New YorkNY-12Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)829NYU Langone Medical Center,University of Washington, Bill and Melinda Gates FoundationDrug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid
New YorkNY-12Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Hospital for Special Surgery, Weill Cornell Medicine,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
New YorkNY-12A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection90NYU Langone Health,NYU Langone HealthDrug: Clazakizumab 25 mg, Drug: Clazakizumab 12.5 mg, Other: Placebo
New YorkNY-12Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-1948NYU Langone Health,NYU Langone HealthDrug: Saline oral/nasal rinse, Drug: 0.5% Povidone/Iodine oral/nasal rinse, Drug: 0.12% Chlorhexidine oral/nasal rinse
New YorkNY-12CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)1200Weill Cornell Medical Center,Hamilton Health Sciences Corporation, Canadian Blood Services, Héma-Québec, University of Toronto, Université de Montréal, Weill Cornell Medicine/New York-Presbyterian, New York Blood Centre, McMaster UniversityBiological: Convalescent plasma
New YorkNY-12Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Weill Cornell Medical Center,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
New YorkNY-12A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Mount Sinai Beth Israel,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
New YorkNY-12HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial374New York Center for Travel and Tropical Medicine,GeoSentinel FoundationDrug: Hydroxychloroquine Pre-Exposure Prophylaxis, Drug: Placebo oral tablet
New YorkNY-12COVID-19 PrEP HCW HCQ Study130NYU Langone Health,NYU Langone HealthDrug: Hydroxychloroquine (HCQ)
New YorkNY-12A Randomized Trial of Anticoagulation Strategies in COVID-1977NYU Langone Health,NYU Langone HealthDrug: Enoxaparin Higher Dose, Drug: Lower-dose prophylactic anticoagulation
New YorkNY-12Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000New York Center for Travel and Tropical Medicine,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
New YorkNY-12CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients300NYU Langone Health,NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of MiamiBiological: Convalescent Plasma, Other: Saline solution
New YorkNY-12Cardiovascular Effects of COVID-19500NYU Langone Health,NYU Langone HealthDrug: AT-001
New YorkNY-12Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998NYU Langone Medical Center,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
New YorkNY-12Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270NYU Langone Health Center,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
New YorkNY-12Treating COVID-19 With Hydroxychloroquine (TEACH)626NYU Langone Health,NYU Langone Health, State University of New York - Downstate Medical CenterDrug: Hydroxychloroquine (HCQ), Other: Pacebo: Calcium citrate
New YorkNY-12Multi-site Adaptive Trials for COVID-19233Lenox Hill Hospital,Northwell HealthDrug: SOC + Intravenous Famotidine, Drug: SOC + Placebo
New YorkNY-12MSCs in COVID-19 ARDS223NYU Langone Health, Northwell Health,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
New YorkNY-12A Study of N-acetylcysteine in Patients With COVID-19 Infection84Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer CenterDrug: N-acetylcysteine, Other: Peripheral Blood
New YorkNY-12Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection9Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer CenterDrug: Tocilizumab
New YorkNY-12A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-190Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer CenterDrug: Hydroxychloroquine, Other: Placebo
New YorkNY-12Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
New YorkNY-12A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy132Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer CenterDrug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy
New YorkNY-12Myeloproliferative Neoplasms (MPN) and COVID-1980New York-Presbyterian/Weill Cornell Medical Center, New York-Presbyterian/Weill Cornell Medical Center,Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net 
New YorkNY-12Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19360ProofPilot Online App,Research Foundation for Mental Hygiene, Inc.Behavioral: Anxiety Reduction Training, Behavioral: Kundalini Yoga and Anxiety Reduction Training, Behavioral: Meditation and Anxiety Reduction Training
New YorkNY-12NCI COVID-19 in Cancer Patients, NCCAPS Study2000Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New YorkNY-12HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists300Hospital for Special Surgery,Hospital for Special Surgery, New YorkDiagnostic Test: SARS-CoV2 serum antibody testing
New YorkNY-12Registry of CytoSorb Therapy in COVID-19 ICU Patients500New York University Medical Center,CytoSorbents, IncDevice: CytoSorb 300 mL device
New YorkNY-12At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study600ProofPilot Online App,ProofPilot, Radish Health, SanescoDevice: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette
New YorkNY-12Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198Manhattan Campus of the VA,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
New YorkNY-12Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients308Lenox Hill Hospital,Northwell HealthDrug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin
New YorkNY-12Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034New York University School of Medicine,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
New YorkNY-12Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727New York Blood Center CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
New YorkNY-12PH94B in the Treatment of Adjustment Disorder With Anxiety30Medical Research Network,VistaGen Therapeutics, Inc.Drug: PH94B
New YorkNY-12Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)186Weill Cornell Medicine,Weill Medical College of Cornell UniversityDrug: Enoxaparin sodium, Drug: Unfractionated heparin, Drug: Fondapariniux, Drug: Argatroban
New YorkNY-12A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924Alexandria Center for Life,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
New YorkNY-13Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Children's Hospital at Montefiore,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
New YorkNY-13Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Kravis Children's Hospital at Mt. Sinai,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
New YorkNY-13Adaptive COVID-19 Treatment Trial (ACTT)1062Montefiore Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
New YorkNY-13Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113James J Peters Veterans Administration Medical Center, Icahn School of Medicine at Mount Sinai, Columbia University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-13Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891James J Peters Veterans Administration Medical Center, Icahn School of Medicine at Mount Sinai, Columbia University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-13Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site, Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-13Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)1600Columbia University Irving Medical Center,Columbia UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
New YorkNY-13A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450James J Peters Veterans Administration Medical Center,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
New YorkNY-13Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Montefiore Medical Center, NYC Health + Hospitals/Metropolitan, Columbia University Irving Medical Center, New York City Hospitals - Harlem,Gilead SciencesDrug: Remdesivir
New YorkNY-13Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Montefiore Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
New YorkNY-13Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Columbia University Irving Medical Center,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
New YorkNY-13Acquiring Convalescent Specimens for COVID-19 Antibodies50Columbia University Irving Medical Center,Columbia UniversityProcedure: Blood draw
New YorkNY-13Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986Montefiore Medical Center,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
New YorkNY-13Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19138Columbia University Irving Medical Center,Matthew Dallos, Bristol-Myers Squibb, Columbia UniversityDrug: BMS-986253
New YorkNY-13Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Montefiore Medical Center,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
New YorkNY-13Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Columbia University,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
New YorkNY-13Saved From COVID-19350Columbia University Irving Medical Center,Columbia UniversityDrug: Chloroquine, Drug: Placebo oral tablet
New YorkNY-13Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore0Montefiore Medical Center,Montefiore Medical CenterDrug: Hydroxychloroquine
New YorkNY-13A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Icahn School of Medicine at Mount Sinai,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
New YorkNY-13The Covid-19 HEalth caRe wOrkErS (HEROES) Study2000Columbia University,University of ChileOther: Exposure to the SARS-CoV-2 and its consequences
New YorkNY-13SOLIRIS® (Eculizumab) Treatment of Participants With COVID-190Icahn School of Medicine at Mount Sinai,Alexion PharmaceuticalsBiological: eculizumab
New YorkNY-13Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)10000Icahn School of Medicine at Mount Sinai,Vivek Reddy, Icahn School of Medicine at Mount Sinai 
New YorkNY-13Plasma Therapy of COVID-19 in Severely Ill Patients219Columbia University Irving Medical Center,Max R. O'Donnell, New York Blood Center, Amazon.com, Inc., Columbia UniversityBiological: Convalescent Plasma (anti-SARS-CoV-2 plasma), Biological: Non-convalescent Plasma (control plasma)
New YorkNY-13CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients300Montefiore Medical Center,NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of MiamiBiological: Convalescent Plasma, Other: Saline solution
New YorkNY-13Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection0Mount Sinai Medical Center,Mesoblast International Sàrl, Mesoblast, Ltd.Drug: Remestemcel-L
New YorkNY-13Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19100Columbia University Medical Center,Columbia UniversityDrug: Enoxaparin Prophylactic Dose, Drug: Heparin Infusion, Drug: Heparin SC, Drug: Enoxaparin/Lovenox Intermediate Dose
New YorkNY-13ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers1000Columbia University Irving Medical Center,Columbia UniversityOther: COVID-19 Serology, Behavioral: Health Care Worker Survey
New YorkNY-13Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Icahn School of Medicine at Mount Sinai,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
New YorkNY-13Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Icahn School of Medicine at Mount Sinai,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
New YorkNY-13MSCs in COVID-19 ARDS223Mount Sinai Medical Center,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
New YorkNY-13A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Harlem Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
New YorkNY-13Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000Montefiore-Einstein Center for Heart and Vascular Care,University of Manitoba, University Health Network, TorontoDrug: Heparin
New YorkNY-13COVID-19: Human Epidemiology and Response to SARS-CoV-25605Columbia University Medical Center,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
New YorkNY-13Immunophenotyping Assessment in a COVID-19 Cohort2000Icahn School of Medicine at Mount Sinai,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
New YorkNY-13SUNLIGHT Study: Online Support Groups for MS to Address COVID-1932Columbia University Medical Center,Columbia UniversityBehavioral: Online support Group
New YorkNY-13Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site, Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
New YorkNY-13Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection30Columbia University Medical Center,Columbia University, NYU Langone Health, CSL BehringDrug: Clazakizumab, Other: Placebo
New YorkNY-13Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19360Columbia University Department of Psychiatry,Research Foundation for Mental Hygiene, Inc.Behavioral: Anxiety Reduction Training, Behavioral: Kundalini Yoga and Anxiety Reduction Training, Behavioral: Meditation and Anxiety Reduction Training
New YorkNY-13NCI COVID-19 in Cancer Patients, NCCAPS Study2000Montefiore Medical Center - Moses Campus, James J Peters VA Medical Center, NYP/Columbia University Medical Center/Herbert Irving Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New YorkNY-13Interferon Lambda Therapy for COVID-1966Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai, Eiger BioPharmaceuticalsDrug: Peginterferon Lambda-1A
New YorkNY-13Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140Montefiore Medical Center,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
New YorkNY-13Early CPAP in COVID-19 Confirmed or Suspected Patients200Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai, Itamar Medical LTD, Community Surgical Supply of Toms River, Inc, Philips HealthcareDevice: Continuous Positive Airway Pressure
New YorkNY-13Convalescent Plasma for COVID-19 Close Contacts200Columbia University Irving Medical Center,Columbia UniversityBiological: Convalescent Plasma (anti-SARS-CoV-2 plasma), Biological: Control (albumin 5%)
New YorkNY-13Incidence of COVID-19 Test Conversion in Post-surgical Patients500NorthShore University Hospital,Northwell HealthDiagnostic Test: COVID-19 PCR and Serology
New YorkNY-13Myocardial Injury and Major Adverse Outcomes in Patients With COVID-195000Mount Sinai Medical Center,Icahn School of Medicine at Mount Sinai 
New YorkNY-13TXA127 for the Treatment of Severe COVID-19100Columbia University Irving Medical Center,Columbia UniversityDrug: TXA127, Drug: Placebo
New YorkNY-13Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Montefiore Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
New YorkNY-13A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Columbia University,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
New YorkNY-13Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Harlem Prevention Center CRS, Columbia P&S CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
New YorkNY-13PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Mount Sinai Medical Center,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
New YorkNY-13Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure29Columbia University Medical Center,Columbia UniversityOther: Awake proning
New YorkNY-14Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Jacobi Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-14Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Jacobi Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-14Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site 1, Regeneron Study Site 2,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-14Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Montefiore Medical Center,Gilead SciencesDrug: Remdesivir
New YorkNY-14Audio Data Collection for Identification and Classification of Coughing1000Virtual Facility,HealthMode Inc. 
New YorkNY-14Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Montefiore Medical Center-Weiler,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
New YorkNY-14Dapagliflozin in Respiratory Failure in Patients With COVID-19900Jacobi Medical Center,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
New YorkNY-14Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
New YorkNY-14A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Jacobi Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
New YorkNY-15Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-15Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Lincoln Medical Center, St Barnabus Hospital,Gilead SciencesDrug: Remdesivir
New YorkNY-15Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000RH Medical Urgent Care Professional PLLC,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
New YorkNY-15A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379St. Barnabas Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
New YorkNY-15A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Lincoln Medical Mental Health Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
New YorkNY-15Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Bronx Prevention Research Center CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
New YorkNY-17Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-17Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986White Plains Hospital,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
New YorkNY-17Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Westchester Medical Center,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
New YorkNY-17Multi-site Adaptive Trials for COVID-19233Northern Westchester Hospital,Northwell HealthDrug: SOC + Intravenous Famotidine, Drug: SOC + Placebo
New YorkNY-17A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy132Memorial Sloan Kettering Westchester,Memorial Sloan Kettering Cancer CenterDrug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy
New YorkNY-17The Use of Oxygen Hoods as Compared to Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic Patients With COVID-19. A Prospective Controlled Cohort Study.136Phelps Hospital,Northwell HealthDevice: Oxygen Hood
New YorkNY-18Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Vassar Brothers Medical Center,Gilead SciencesDrug: Remdesivir
New YorkNY-18Convalescent Plasma to Stem Coronavirus (CSSC-001)500Vassar Brothers Medical Center,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
New YorkNY-18A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Vassar Brothers Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
New YorkNY-18Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Vassar Brothers Medical Center,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
New YorkNY-19Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Danbury Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-19Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Danbury Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-19COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-24000Bassett Healthcare,Bassett Healthcare, Reid Health, Goshen Health SystemDrug: lopinavir/ritonavir, Drug: Losartan, Drug: Placebos
New YorkNY-20Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St. Peter's Hospital, Ellis Hospital, Samaritan Hospital,Gilead SciencesDrug: Remdesivir
New YorkNY-20Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
New YorkNY-20A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Albany Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
New YorkNY-21Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Glens Falls Hospital,Gilead SciencesDrug: Remdesivir
New YorkNY-21A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Canton-Potsdam Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
New YorkNY-22Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Meridian Clinical Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
New YorkNY-23Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Meridian Clinical Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
New YorkNY-24Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)829SUNY - Upstate Medical University,University of Washington, Bill and Melinda Gates FoundationDrug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid
New YorkNY-24A Study of LY3127804 in Participants With COVID-1995State University of New York Hospital,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
New YorkNY-24Treatment for COVID-19 in High-Risk Adult Outpatients300SUNY - Upstate Medical University,University of Washington, Bill and Melinda Gates FoundationDrug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
New YorkNY-24Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998SUNY Upstate Medical University,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
New YorkNY-24A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270SUNY Upstate Medical University,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
New YorkNY-24NCI COVID-19 in Cancer Patients, NCCAPS Study2000Hematology Oncology Associates of Central New York-Auburn, Hematology Oncology Associates of Central New York-East Syracuse, Hematology Oncology Associates of Central New York-Onondaga Hill,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New YorkNY-25Adaptive COVID-19 Treatment Trial (ACTT)1062University of Rochester Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
New YorkNY-25Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Rochester General Hospital,Gilead SciencesDrug: Remdesivir
New YorkNY-25Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of Rochester,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
New YorkNY-25Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Rochester General Hospital,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
New YorkNY-25Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Rochester Regional Health, Rochester Regional Health,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
New YorkNY-25Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of Rochester,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
New YorkNY-25Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500University of Rochester Medical Center,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
New YorkNY-25NCI COVID-19 in Cancer Patients, NCCAPS Study2000Rochester General Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New YorkNY-25Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Rochester Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
New YorkNY-25Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727University of Rochester Vaccines to Prevent HIV Infection CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
New YorkNY-26Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-26Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Kaleida Health System,Gilead SciencesDrug: Remdesivir
New YorkNY-26Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Buffalo General Medical Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
New YorkNY-26Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
New YorkNY-26A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients400University of Buffalo,Covis Pharma S.à.r.l.Drug: Ciclesonide, Drug: Placebo
New YorkNY-26Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients44Roswell Park Cancer Institute,Roswell Park Cancer Institute, National Cancer Institute (NCI), AIM ImmunoTech Inc.Biological: Recombinant Interferon Alfa-2b, Drug: Rintatolimod
New YorkNY-26Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
New YorkNY-26A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966University of Buffalo,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
New YorkNY-26Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Sisters of Charity Hospital/ St. Joseph's Campus,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
New YorkNY-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Woodhull Medical Center, NYU Langone Hospital – Brooklyn,Gilead SciencesDrug: Remdesivir
New YorkNY-07A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Wyckoff Heights Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
New YorkNY-03Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113North Shore University Hospital, North Shore University Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-03Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891North Shore University Hospital, North Shore University Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-03Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site 1, Regeneron Study Site 2,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-03Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St. Francis Hospital,Gilead SciencesDrug: Remdesivir
New YorkNY-03COVID-19 Endoscopy Survey163Kings County Hospital Center,Al-Azhar UniversityOther: Practice details
New YorkNY-03Dapagliflozin in Respiratory Failure in Patients With COVID-19900St. Francis Hospital,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
New YorkNY-03PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine850ProHealth New York,UnitedHealth Group, ProHealth Care Associates, University of Pennsylvania Perelman School of MedicineDrug: Group A HCQ, Drug: Group B Control
New YorkNY-03Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection60Long Island Jewish Medical Center,Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical CenterDrug: Alteplase 50 MG [Activase]
New YorkNY-03Multi-site Adaptive Trials for COVID-19233North Shore University Hospital, Long Island Jewish Medical Center,Northwell HealthDrug: SOC + Intravenous Famotidine, Drug: SOC + Placebo
New YorkNY-03Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting18St. Francis Hospital,St. Francis Hospital, New YorkDrug: Hydroxychloroquine, Drug: Azithromycin, Drug: Zinc Sulfate, Drug: Doxycycline
New YorkNY-03A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy132Memorial Sloan Kettering Commack,Memorial Sloan Kettering Cancer CenterDrug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy
New YorkNY-03Advanced Endoscopy During COVID-19670Kings County Hospital Center,Al-Azhar University, Helwan University, National Liver Institute, EgyptOther: Endoscopic management according to standard of care
New YorkNY-03Dornase Alfa Administered to Patients With COVID-19 (DACOVID)5Feinstein Insitute for Medical Research at Northwell Health,Feinstein Institute for Medical Research, Cold Spring Harbor Laboratory, Northwell HealthDrug: Dornase Alfa
New YorkNY-03Famotidine Outpatient COVID-19 Treatment Study10Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory,Northwell Health, Cold Spring Harbor LaboratoryDrug: Famotidine
New YorkNY-03Incidence of COVID-19 Test Conversion in Post-surgical Patients500Long Island Jewish Medical Center,Northwell HealthDiagnostic Test: COVID-19 PCR and Serology
New YorkNY-03Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients308Huntington Hospital, Long Island Jewish Medical Center,Northwell HealthDrug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin
New YorkNY-09Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Kingsbrook Jewish Medical Center, University Hospital Brooklyn (SUNY), Kings County Hospital Center, Brookdale University Hospital, NewYork-Presbyterian Brooklyn Hospital, Mount Sinai Brooklyn,Gilead SciencesDrug: Remdesivir
New YorkNY-09Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390New York Community Hospital of Brooklyn,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
New YorkNY-09Convalescent Plasma in Outpatients With COVID-19600SUNY Downstate Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
New YorkNY-09Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Integrative Clinical Trials LLC,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
New YorkNY-09A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100SUNY Downstate Medical Center.,Hoffmann-La RocheDrug: Tociliuzumab
New YorkNY-09Treating COVID-19 With Hydroxychloroquine (TEACH)626State University of New York (SUNY) Downstate Medical Center,NYU Langone Health, State University of New York - Downstate Medical CenterDrug: Hydroxychloroquine (HCQ), Other: Pacebo: Calcium citrate
New YorkNY-09A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379SUNY Downstate Medical Center.,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
New YorkNY-02Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Good Samaritan Hospital Medical Center, Southside Hospital,Gilead SciencesDrug: Remdesivir
New YorkNY-02Multi-site Adaptive Trials for COVID-19233Southside Hospital,Northwell HealthDrug: SOC + Intravenous Famotidine, Drug: SOC + Placebo
New YorkNY-02Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients308Southside Hospital,Northwell HealthDrug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin
New YorkNY-06Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-06Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0New York Presbyterian- Queens, NYC Health + Hospitals/Queens,Gilead SciencesDrug: Remdesivir
New YorkNY-06Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.16NewYork-Presbyterian Queens,Swedish Orphan BiovitrumBiological: Emapalumab, Biological: Anakinra
New YorkNY-06A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379NYC Health + Hospitals/Elmhurst, Flushing Hospital, NYC Health + Hospitals/Queens,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
New YorkNY-08Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Brooklyn Hospital Center, Interfaith Medical Center,Gilead SciencesDrug: Remdesivir
New YorkNY-08CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)1200Brooklyn Hospital Center,Hamilton Health Sciences Corporation, Canadian Blood Services, Héma-Québec, University of Toronto, Université de Montréal, Weill Cornell Medicine/New York-Presbyterian, New York Blood Centre, McMaster UniversityBiological: Convalescent plasma
New YorkNY-04Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Nassau University Medical Center, Mount Sinai South Nassau,Gilead SciencesDrug: Remdesivir
New YorkNY-04Hyperbaric Oxygen for COVID-19 Patients20NYU Winthrop Hospital,NYU Langone HealthDevice: hyperbaric oxygen therapy (HBOT)
New YorkNY-04A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy132Memorial Sloan Kettering Nassau,Memorial Sloan Kettering Cancer CenterDrug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy
New YorkNY-04Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140Mercy Medical Center,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
New YorkNY-01Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
New YorkNY-01Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Stony Brook University Hospital,Gilead SciencesDrug: Remdesivir
New YorkNY-01Convalescent Plasma vs. Standard Plasma for COVID-19500Stony Brook University Hospital,Stony Brook UniversityBiological: Convalescent Plasma, Biological: Standard Donor Plasma
New YorkNY-01Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 190Stony Brook University Hospital,Spectral Diagnostics (US) Inc.Device: Toraymyxin PMX-20R (PMX Cartridge)
New YorkNY-01Estrogen Patch for COVID-19 Symptoms110Stony Brook University Hospital,Sharon Nachman, Stony Brook UniversityDrug: Estradiol patch
New YorkNY-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Stony Brook University Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
New YorkNY-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Jamaica Hospital Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Jamaica Hospital Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
New YorkNY-05A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Jamaica Hospital Medical Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
New YorkNY-05A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Jamaica Hospital Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
New YorkNY-05A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Jamaica Hospital Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
North CarolinaNC-10Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998PMG Research of Hickory LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
North CarolinaNC-10Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
North CarolinaNC-10NCI COVID-19 in Cancer Patients, NCCAPS Study2000CaroMont Regional Medical Center, Margaret R. Pardee Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
North CarolinaNC-12Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukapheresis Products1000Carolina BioOncology Institute,BioCytics, Inc. 
North CarolinaNC-12Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Atrium Health-Carolinas Medical Center,Gilead SciencesDrug: Remdesivir
North CarolinaNC-12Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Levine Cancer Institute-Atrium Health University City,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
North CarolinaNC-12Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300Atrium Health,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
North CarolinaNC-12Atrium COVID-19 Syndromic and Serologic Surveillance450000Atrium Health,Michael Runyon, MD, Atrium HealthOther: daily syndromic surveillance, Diagnostic Test: monthly serologic IgM/G test
North CarolinaNC-12Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998PMG Research of Charlotte LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
North CarolinaNC-12A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Novant Health Presbyterian Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
North CarolinaNC-12Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
North CarolinaNC-12An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic0Levine Cancer Institute,Genentech, Inc.Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
North CarolinaNC-12Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
North CarolinaNC-12A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Novant Health Clinical Research,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
North CarolinaNC-13Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920Greensboro CRS,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
North CarolinaNC-13Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998PharmQuest, PMG Research of Salisbury LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
North CarolinaNC-13A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Novant Health Rowan Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
North CarolinaNC-13A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Cone Health Medical Group,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
North CarolinaNC-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998PMG Research of Raleigh LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
North CarolinaNC-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Vidant Oncology-Richlands, Nash General Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
North CarolinaNC-05Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Novant Health,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
North CarolinaNC-05Mindfulness During COVID-19200Wake Forest University Health Sciences,Wake Forest University Health SciencesBehavioral: Mindfulness session(s)
North CarolinaNC-05Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Wake Forest Baptist Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
North CarolinaNC-05Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Wake Forest Baptist Health System,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
North CarolinaNC-05COVID-19 Community Research Partnership150000Wake Forest University Health Sciences,Wake Forest University Health Sciences 
North CarolinaNC-05Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986Novant Health,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
North CarolinaNC-05Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Novant Health,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
North CarolinaNC-05Convalescent Plasma in Outpatients With COVID-19600Wake Forest Baptist Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
North CarolinaNC-05A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Wake Forest University Health Sciences,Hoffmann-La RocheDrug: Tociliuzumab
North CarolinaNC-05Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998PMG Research of Winston-Salem LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
North CarolinaNC-05A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Novant Health Foryth Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
North CarolinaNC-05A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204Wake Forest Baptist Health,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
North CarolinaNC-05The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Wake Forest Baptist Health,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
North CarolinaNC-07Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000New Hanover Regional Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
North CarolinaNC-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998PMG Research of Wilmington LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
North CarolinaNC-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Vidant Oncology-Kenansville,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
North CarolinaNC-07Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Trial Management Associates,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
North CarolinaNC-01Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Duke University Medical Center Oncology, East Carolina University SC,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
North CarolinaNC-01Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Duke University,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
North CarolinaNC-01Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Duke University Health System, East Carolina University,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
North CarolinaNC-01Adaptive COVID-19 Treatment Trial (ACTT)1062Duke Human Vaccine Institute,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
North CarolinaNC-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Duke University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
North CarolinaNC-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Duke University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
North CarolinaNC-01A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Duke University Medical Center,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
North CarolinaNC-01COVID-19 Pandemic Response Network200000Duke University Medical Center,Duke University 
North CarolinaNC-01Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Duke University Medical Center,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
North CarolinaNC-01Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site, Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
North CarolinaNC-01Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection11Duke Regional Hospital, Duke University Hospital, Durham VA Medical Center,Duke UniversityOther: Standard of care, Drug: Hydroxychloroquine, Drug: Azithromycin
North CarolinaNC-01CAPTION AI to Minimize Risk of COVID Exposure0Duke Health, Duke University Medical Center,Duke University, Caption Health, Inc.Device: Caption AI
North CarolinaNC-01Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19100000Duke Clinical Research Institute,Duke University, Patient-Centered Outcomes Research Institute 
North CarolinaNC-01A Study of LY3127804 in Participants With COVID-1995East Carolina University,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
North CarolinaNC-01COPING With COVID-19( CWC-19)0Duke University,Duke UniversityBehavioral: Crisis management coaching
North CarolinaNC-01Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)120Duke University Medial Center,Duke UniversityDevice: Q-NRG Metobolic Cart Device, Device: MuscleSound Ultrasound, Device: Multifrequency Bioimpedance Spectroscopy
North CarolinaNC-01Convalescent Plasma in Outpatients With COVID-19600Duke University Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
North CarolinaNC-01Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-191000Duke Cancer Center,Duke UniversityOther: Telehealth
North CarolinaNC-01Duke COVID-19 Shared Data and Specimen Repository100000Duke University Medical Center,Duke University 
North CarolinaNC-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Duke University Medicine Circle,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
North CarolinaNC-01MSCs in COVID-19 ARDS223Duke University Medical Center,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
North CarolinaNC-01Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Duke University Medical Center, East Carolina University,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
North CarolinaNC-01A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270East Carolina University,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
North CarolinaNC-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Durham VA Medical Center, Duke University Medical Center, East Carolina University,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
North CarolinaNC-01Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-191000Duke University,Duke UniversityDietary Supplement: Lactobaciltus rhamnosus GG, Dietary Supplement: Lactobaciltus rhamnosus GG Placebo
North CarolinaNC-01hCT-MSCs for COVID19 ARDS30Duke Hospital,Joanne Kurtzberg, MD, The Marcus Foundation, Duke UniversityBiological: human cord tissue mesenchymal stromal cells
North CarolinaNC-01Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Duke Human Vaccine Institute,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
North CarolinaNC-01A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204Duke,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
North CarolinaNC-01A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924Unified Research Enterprise Brody School of Medicine at ECU,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
North CarolinaNC-08Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
North CarolinaNC-08A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Cape Fear Valley Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
North CarolinaNC-08A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Cape Fear Valley Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
North CarolinaNC-08Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Womack Army Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
North CarolinaNC-08Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Carolina Institute for Clinical Research,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
North CarolinaNC-03Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Naval Medical Center Camp Lejeune,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
North CarolinaNC-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Vidant Oncology-Kinston, CarolinaEast Medical Center, Marion L Shepard Cancer Center at Vidant Beaufort Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
North CarolinaNC-04Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of North Carolina at Chapel Hill,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
North CarolinaNC-04Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000University of North Carolina at Chapel Hill,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
North CarolinaNC-04Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0UNC Hospitals,Gilead SciencesDrug: Remdesivir
North CarolinaNC-04Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of North Carolina,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
North CarolinaNC-04Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection11Duke Regional Hospital,Duke UniversityOther: Standard of care, Drug: Hydroxychloroquine, Drug: Azithromycin
North CarolinaNC-04Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease20Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: HCQ, Drug: HCQ+AZT, Drug: Placebo
North CarolinaNC-04Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
North CarolinaNC-04ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-1910000Center for Environmental Medicine Asthma and Lung Biology,University of North Carolina, Chapel HillDiagnostic Test: To assess for development of IgG antibodies against SARS-CoV2
North CarolinaNC-04Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998PMG Research of Raleigh LLC, M3 Wake Research Inc,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
North CarolinaNC-04MSCs in COVID-19 ARDS223WakeMed,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
North CarolinaNC-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
North CarolinaNC-04Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19200NIEHS Clinical Research Unit,National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health Clinical Center (CC) 
North CarolinaNC-04Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Chapel Hill CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
North CarolinaNC-04A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204University of North Carolina School of Medicine,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
North CarolinaNC-04A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924University of North Carolina,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
North DakotaND-00Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Lillestol Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
North DakotaND-00NCI COVID-19 in Cancer Patients, NCCAPS Study2000Sanford Bismarck Medical Center, Sanford Broadway Medical Center, Sanford Roger Maris Cancer Center, Trinity Cancer Care Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
North DakotaND-00Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
OhioOH-10Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Kettering Medical Center,Gilead SciencesDrug: Remdesivir
OhioOH-10Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Wright Patterson Medical Center,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
OhioOH-10Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Dayton Clinical Research, PriMED Clinical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
OhioOH-10Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Kettering Cancer Care,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
OhioOH-10NCI COVID-19 in Cancer Patients, NCCAPS Study2000Indu and Raj Soin Medical Center, Dayton Physicians LLC-Miami Valley South, Miami Valley Hospital South, Miami Valley Hospital, Dayton Physician LLC-Miami Valley Hospital North, Greater Dayton Cancer Center, First Dayton Cancer Care, Kettering Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-11A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)242University Hospitals Seidman Cancer Center,Millennium Pharmaceuticals, Inc., TakedaDrug: TAK-981, Drug: Standard of care
OhioOH-11Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Cleveland Clinic Foundation,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
OhioOH-11Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
OhioOH-11Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113University Hospitals Cleveland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
OhioOH-11Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891University Hospitals Cleveland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
OhioOH-11CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243University Hospitals of Cleveland,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
OhioOH-11A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Cleveland Clinic Foundation,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
OhioOH-11Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Cleveland Clinic Foundation,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
OhioOH-11Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation520Cleveland Clinic,The Cleveland ClinicDietary Supplement: Ascorbic Acid, Dietary Supplement: Zinc Gluconate, Dietary Supplement: Ascorbic Acid and Zinc Gluconate, Other: Standard of Care
OhioOH-11A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227University Hospitals Cleveland Medical Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
OhioOH-11CoVID-19 Plasma in Treatment of COVID-19 Patients100University Hospitals Cleveland Medical Center,The Christ HospitalBiological: Convalescent COVID 19 Plasma
OhioOH-11Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
OhioOH-11A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100University Hospitals Cleveland Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
OhioOH-11Canakinumab in Covid-19 Cardiac Injury (The Three C Study)45Cleveland Clinic,The Cleveland Clinic, NovartisDrug: Canakinumab Injection 600mg, Drug: Canakinumab Injection 300mg, Drug: Placebos
OhioOH-11MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)400Athersys Investigational Site 101, Athersys Investigational Site 102,Athersys, IncBiological: MultiStem, Biological: Placebo
OhioOH-11Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998University Hospitals Cleveland Medical Center, VA Northeast Ohio Healthcare System, Rapid Medical Research, Senders Pediatrics,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
OhioOH-11Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant1419Rapid Medical Research Inc,Novavax, Coalition for Epidemic Preparedness Innovations (CEPI)Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2
OhioOH-11MSCs in COVID-19 ARDS223Cleveland Clinic Foundation,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
OhioOH-11Immunophenotyping Assessment in a COVID-19 Cohort2000University Hospitals Case Medical Center,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
OhioOH-11NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cleveland Clinic Akron General, Cleveland Clinic Foundation,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-11A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic1000Akron Children's Hospital, Summa Health Systems,Kent State UniversityBehavioral: Daily Coping Toolkit
OhioOH-11Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation30Cleveland Clinic Health System,The Cleveland Clinic, Kiniksa Pharmaceuticals, Ltd.Drug: Mavrilimumab, Drug: Placebos
OhioOH-11Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Case CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
OhioOH-12Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
OhioOH-12NCI COVID-19 in Cancer Patients, NCCAPS Study2000Columbus Oncology and Hematology Associates Inc, Riverside Methodist Hospital, Delaware Health Center-Grady Cancer Center, Grady Memorial Hospital, Dublin Methodist Hospital, OhioHealth Mansfield Hospital, Licking Memorial Hospital, Newark Radiation Oncology, Saint Ann's Hospital, Genesis Healthcare System Cancer Care Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-13Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Mercy Health,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
OhioOH-13MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)400Athersys Investigational Site 103,Athersys, IncBiological: MultiStem, Biological: Placebo
OhioOH-13NCI COVID-19 in Cancer Patients, NCCAPS Study2000Summa Health System - Akron Campus, Saint Elizabeth Boardman Hospital, Saint Joseph Warren Hospital, Saint Elizabeth Youngstown Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-13A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic1000Kent State University,Kent State UniversityBehavioral: Daily Coping Toolkit
OhioOH-15NCI COVID-19 in Cancer Patients, NCCAPS Study2000Adena Regional Medical Center, Mount Carmel Grove City Hospital, Fairfield Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-02Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant1419Synexus Clinical Research US,Novavax, Coalition for Epidemic Preparedness Innovations (CEPI)Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2
OhioOH-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Oncology Hematology Care Inc-Kenwood, TriHealth Cancer Institute-Anderson, Southern Ohio Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-03CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243Ohio State University Medical Center,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
OhioOH-03Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Ohio State University College of Medicine,Gilead SciencesDrug: Remdesivir
OhioOH-03Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Ohio State University Wexner Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
OhioOH-03Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Ohio State University Medical Center,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
OhioOH-03Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986OhioHealth Grant Medical Center,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
OhioOH-03Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390OhioHealth Grant Medical Center,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
OhioOH-03SOLIRIS® (Eculizumab) Treatment of Participants With COVID-190Ohio State University Wexner Medical Center,Alexion PharmaceuticalsBiological: eculizumab
OhioOH-03Convalescent Plasma in Outpatients With COVID-19600OSU Wexner Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
OhioOH-03Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Ohio State University Wexner Medical Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
OhioOH-03Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Aventiv Research Inc.,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
OhioOH-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Ohio State University Comprehensive Cancer Center, Mount Carmel East Hospital, Grant Medical Center, Mark H Zangmeister Center, Mount Carmel Health Center West, Doctors Hospital, Central Ohio Breast and Endocrine Surgery,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-03Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
OhioOH-03Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19200Mt Carmel HealthSystems,Marvin McCreary, MD, Mount Carmel Health SystemDrug: Plant Polyphenol, Dietary Supplement: Vitamin D3
OhioOH-03A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500OhioHealth Research Institute,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
OhioOH-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000OhioHealth Marion General Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000Dayton Physicians LLC-Wayne, Wayne Hospital, Springfield Regional Cancer Center, Springfield Regional Medical Center, Dayton Physicians LLC-Upper Valley, Upper Valley Medical Center, University Pointe,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-01Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Lindner Center- The Christ Hospital, Cincinnati Children's Hospital Medical Center, University of Cincinnati,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
OhioOH-01Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Cincinnati Children's Hospital Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
OhioOH-01Losartan for Patients With COVID-19 Requiring Hospitalization200University of Cincinnati Medical Center,University of Minnesota, Bill and Melinda Gates FoundationDrug: Losartan, Other: Placebo
OhioOH-01CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243Christ Hospital,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
OhioOH-01Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of Cincinnati Medical Center,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
OhioOH-01Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479University of Cincinnati Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
OhioOH-01Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia30University of Cincinnati,University of CincinnatiDrug: Sirolimus, Drug: Placebo
OhioOH-01CoVID-19 Plasma in Treatment of COVID-19 Patients100The Christ Hospital,The Christ HospitalBiological: Convalescent COVID 19 Plasma
OhioOH-01Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920Cincinnati Clinical Research Site,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
OhioOH-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Cincinnati Children's Hospital Medical Center, Sterling Research Group Ltd., Cincinnati Children's Hospital Medical Center,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
OhioOH-01Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of Cincinnati Medical Center,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
OhioOH-01COVID-19: Human Epidemiology and Response to SARS-CoV-25605Cincinnati Children's Hospital Medical Center,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
OhioOH-01Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500University of Cincinnati,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
OhioOH-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Cincinnati/Barrett Cancer Center, Good Samaritan Hospital – Cincinnati, Cincinnati Children's Hospital Medical Center, Bethesda North Hospital, TriHealth Cancer Institute-Westside, Atrium Medical Center-Middletown Regional Hospital, Dayton Physicians LLC-Atrium,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-01A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection100Good Samaritan Hospital, Bethesda North Hospital,TriHealth Inc.Drug: Convalescent Plasma
OhioOH-01Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
OhioOH-01PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Carl and Edyth Lindner Center for Research and Education at The Christ Hospital,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
OhioOH-01Viral Specific T-cells for Treatment of COVID-19100Children's Hospital Medical Center,Children's Hospital Medical Center, Cincinnati, Hoxworth Blood CenterBiological: Viral Specific T-cells (VSTs)
OhioOH-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Strecker Cancer Center-Belpre, Marietta Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-05Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
OhioOH-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Armes Family Cancer Center, Blanchard Valley Hospital, Orion Cancer Care, Toledo Clinic Cancer Centers-Toledo,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-09Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19200000OMNI Medical Services, OMNI Medical Services, OMNI Medical Services,OMNI Medical Services, LLC, OMNI Medical Services IncDrug: Cannabis, Medical
OhioOH-09Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0MetroHealth Medical Center,Gilead SciencesDrug: Remdesivir
OhioOH-09Convalescent Plasma in Outpatients With COVID-19600Mercy St. Vincent Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
OhioOH-09A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Mercy St. Vincent Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
OhioOH-09Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
OhioOH-09Fluoxetine to Reduce Intubation and Death After COVID19 Infection2000University of Toledo,University of Toledo Health Science CampusDrug: Fluoxetine
OhioOH-09Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease682Toledo Hospital and BayPark Hospital,Algernon Pharmaceuticals, Novotech (Australia)Drug: NP-120 (Ifenprodil)
OhioOH-09A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Mercy St. Vincent Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
OhioOH-09NCI COVID-19 in Cancer Patients, NCCAPS Study2000ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OhioOH-09Study of Sargramostim in Patients With COVID-19120University of Toledo Medical Center,Partner Therapeutics, Inc.Drug: Sargramostim, Drug: Standard of care
OhioOH-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Knox Community Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OklahomaOK-05Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Board of Regents of the University of Oklahoma,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
OklahomaOK-05Tocilizumab for Patients With Cancer and COVID-19 Disease217University of Oklahoma Health Sciences Center,National Cancer Institute (NCI)Biological: Tocilizumab
OklahomaOK-05Immunophenotyping Assessment in a COVID-19 Cohort2000University of Oklahoma,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
OklahomaOK-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Oklahoma Health Sciences Center, Mercy Hospital Oklahoma City,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OklahomaOK-05Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients500Stephenson Cancer Center,University of OklahomaOther: mHealth Assessments
OklahomaOK-04Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Lynn Institute of Norman,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
OklahomaOK-01The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection100Ascension St. John, Ascension St. John,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
OklahomaOK-01The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200Ascension St. John, Ascension St. John,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
OklahomaOK-01Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
OklahomaOK-01Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Saint Francis Hospital,Gilead SciencesDrug: Remdesivir
OklahomaOK-01PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364St. John Medical Center,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
OregonOR-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Sunnyside Medical Center, Providence St. Vincent Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
OregonOR-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Sunnyside Medical Center, Providence St. Vincent Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
OregonOR-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Providence Newberg Medical Center, Providence St. Vincent Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OregonOR-01A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Providence Saint Vincent's Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
OregonOR-03Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Oregon Health & Science University,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
OregonOR-03Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Oregon Health and Science University,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
OregonOR-03Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Providence Portland Medical Center, Kaiser Sunnyside Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
OregonOR-03Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Providence Portland Medical Center, Kaiser Sunnyside Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
OregonOR-03Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
OregonOR-03Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Oregon Health and Science University,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
OregonOR-03Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care13Portland Providence Medical Center,Providence Health & Services, Center for Outcomes Research and Education, Providence Cancer Center, Earle A. Chiles Research InstituteDrug: Hydroxychloroquine, Dietary Supplement: Vitamin C
OregonOR-03Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384Oregon Health and Science University,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
OregonOR-03Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986Oregon Health and Science University,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
OregonOR-03Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Oregon Health and Sciences University,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
OregonOR-03Convalescent Plasma in Outpatients With COVID-19600Oregon Health & Science University Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
OregonOR-03Plasma Adsorption in Patients With Confirmed COVID-192000Providence Portland Medical Center,Marker Therapeutics AG, Terumo BCTDevice: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
OregonOR-03Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)0Oregon Health and Science University,Oregon Health and Science University, OHSU Knight Cancer InstituteDrug: Hydroxychloroquine, Drug: Placebo
OregonOR-03Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Kaiser Permanente Northwest,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
OregonOR-03Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19600Oregon Health & Science University,Vanderbilt University Medical Center, AbbVieDrug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo
OregonOR-03Immunophenotyping Assessment in a COVID-19 Cohort2000Oregon Health and Science University,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
OregonOR-03A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Providence Portland Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
OregonOR-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Providence Portland Medical Center, Legacy Emanuel Children's Hospital, Oregon Health and Science University,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OregonOR-03Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Kaiser Permanente Northwest,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
OregonOR-02Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
OregonOR-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Alphonsus Medical Center-Baker City, Saint Charles Health System, Saint Alphonsus Medical Center-Ontario, Saint Charles Health System-Redmond,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OregonOR-04Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Good Samaritan Hospital Corvallis,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
OregonOR-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Bay Area Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
OregonOR-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Clackamas Radiation Oncology Center, Providence Cancer Institute Clackamas Clinic,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-10Adaptive COVID-19 Treatment Trial (ACTT)1062Penn State Health Milton Hershey Medical,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
PennsylvaniaPA-10Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Penn State Health Milton Hershey Medical,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
PennsylvaniaPA-10COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior18251Penn State Health Milton Hershey Medical,Milton S. Hershey Medical Center, The Huck Institutes of the Life Sciences, The Social Science Research Institute, The Department of Family and Community Medicine, Penn State College of Medicine, The College of Healthcare Information Management Executives (CHIME) 
PennsylvaniaPA-10NCI COVID-19 in Cancer Patients, NCCAPS Study2000Penn State Milton S. Hershey Medical Center, WellSpan Health-York Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-10Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Penn State Health Milton Hershey Medical,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
PennsylvaniaPA-11Dapagliflozin in Respiratory Failure in Patients With COVID-19900Lancaster General Hospital,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
PennsylvaniaPA-11NCI COVID-19 in Cancer Patients, NCCAPS Study2000Ephrata Cancer Center, Cherry Tree Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-12NCI COVID-19 in Cancer Patients, NCCAPS Study2000Lewistown Hospital, Geisinger Medical Oncology-Lewisburg, Geisinger Medical Oncology-Selinsgrove, Geisinger Medical Group,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-13NCI COVID-19 in Cancer Patients, NCCAPS Study2000Adams Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-16Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Allegheny Health Network,Gilead SciencesDrug: Remdesivir
PennsylvaniaPA-16Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic200LECOM,Lake Erie College of Osteopathic MedicineBehavioral: Meditation app usage
PennsylvaniaPA-16Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms20AHN Allegheny General Hospital, AHN West Penn Hospital,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), ElectroCore INCDevice: gammaCore® Sapphire (non-invasive vagus nerve stimulator), Other: Standard of care therapies
PennsylvaniaPA-16NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Vincent Hospital, Allegheny General Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-16A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Allegheny Health Network,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
PennsylvaniaPA-17Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Allegheny Health Network,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
PennsylvaniaPA-17NCI COVID-19 in Cancer Patients, NCCAPS Study2000Allegheny Valley Hospital, Wexford Health and Wellness Pavilion,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-18Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia7100University of Pittsburgh Medical Centre,MJM Bonten, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, UMC UtrechtDrug: Fixed-duration Hydrocortisone, Drug: Shock-dependent hydrocortisone, Drug: Ceftriaxone, Drug: Moxifloxacin or Levofloxacin, Drug: Piperacillin-tazobactam, Drug: Ceftaroline, Drug: Amoxicillin-clavulanate, Drug: Macrolide administered for 3-5 days, Drug: Macrolide administered for up to 14 days, Drug: Five-days oseltamivir, Drug: Ten-days oseltamivir, Drug: Lopinavir/ritonavir, Drug: Hydroxychloroquine, Drug: Hydroxychloroquine + lopinavir/ritonavir, Drug: Interferon-β1a, Drug: Anakinra, Drug: Fixed-duration higher dose Hydrocortisone, Drug: Tocilizumab, Drug: Sarilumab, Drug: Vitamin C, Drug: Therapeutic anticoagulation, Drug: Simvastatin, Biological: Convalescent plasma, Other: Protocolised mechanical ventilation strategy, Drug: Eritoran, Drug: Apremilast, Drug: Aspirin, Drug: Clopidogrel, Drug: Prasugrel, Drug: Ticagrelor
PennsylvaniaPA-18Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of Pittsburgh Medical Center Health System,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
PennsylvaniaPA-18Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0UPMC,Gilead SciencesDrug: Remdesivir
PennsylvaniaPA-18Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479UPMC Presbyterian/Mercy/Shadyside,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
PennsylvaniaPA-18Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Pittsburgh School of Medicine,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
PennsylvaniaPA-18SARS-COV2 Pandemic Serosurvey and Blood Sampling15000University of Pittsburgh,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
PennsylvaniaPA-18Convalescent Plasma in Outpatients With COVID-19600UPMC Presbyterian Hospital, University of Pittsburgh,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
PennsylvaniaPA-18Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920University of Pittsburgh CRS,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
PennsylvaniaPA-18Provider Burnout During COVID-19250University of Pittsburgh Medical Center,University of PittsburghBehavioral: Coping strategies video
PennsylvaniaPA-18Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500West Penn Hospital,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
PennsylvaniaPA-18Neurologic Manifestations of COVID 19 in Children500UPMC Children's Hospital of Pittsburgh,University of Pittsburgh, University of Utah, Johns Hopkins UniversityOther: Observational study only
PennsylvaniaPA-18NCI COVID-19 in Cancer Patients, NCCAPS Study2000Jefferson Hospital, Forbes Hospital, West Penn Hospital, University of Pittsburgh Cancer Institute,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St. Luke's Hospital - Bethlehem Campus,Gilead SciencesDrug: Remdesivir
PennsylvaniaPA-07Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Lehigh Valley Hospital,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
PennsylvaniaPA-07A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Lehigh Valley Hospital,Hoffmann-La RocheDrug: Tociliuzumab
PennsylvaniaPA-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Lehigh Valley Health Network,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
PennsylvaniaPA-07A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Lehigh Valley Health Network,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
PennsylvaniaPA-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Lehigh Valley Hospital-Cedar Crest, Lehigh Valley Hospital – Muhlenberg, Pocono Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Holy Redeemer Hospital and Medical Center, Pottstown Hospital, Abington Memorial Hospital-Asplundh Cancer Pavilion,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-08Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
PennsylvaniaPA-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000Northeast Radiation Oncology Center, Geisinger Medical Center-Cancer Center Hazleton, Lehigh Valley Hospital-Hazleton, Community Medical Center, Geisinger Wyoming Valley/Henry Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-02A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)242Fox Chase Cancer Center,Millennium Pharmaceuticals, Inc., TakedaDrug: TAK-981, Drug: Standard of care
PennsylvaniaPA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Temple University Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
PennsylvaniaPA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Temple University Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
PennsylvaniaPA-02Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
PennsylvaniaPA-02Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Einstein Medical Center Philadelphia,Gilead SciencesDrug: Remdesivir
PennsylvaniaPA-02Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.16Temple University Hospital,Swedish Orphan BiovitrumBiological: Emapalumab, Biological: Anakinra
PennsylvaniaPA-02Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Temple University Hospital,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
PennsylvaniaPA-02Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Temple University Hospital,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
PennsylvaniaPA-02Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
PennsylvaniaPA-02Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384Temple University Hospital,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
PennsylvaniaPA-02A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Temple University Hospital,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
PennsylvaniaPA-02Convalescent Plasma in Outpatients With COVID-19600Temple University Hospital, Einstein Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
PennsylvaniaPA-02Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
PennsylvaniaPA-02A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Temple University Hospital,Hoffmann-La RocheDrug: Tociliuzumab
PennsylvaniaPA-02A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Temple University Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
PennsylvaniaPA-02Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
PennsylvaniaPA-02Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Temple University,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
PennsylvaniaPA-02Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
PennsylvaniaPA-02Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
PennsylvaniaPA-02A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Temple University Hospital,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
PennsylvaniaPA-02Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198Philadelphia MultiService Center,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
PennsylvaniaPA-02PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Albert Einstein Medical Center,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
PennsylvaniaPA-02A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924Temple University School of Medicine,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
PennsylvaniaPA-09Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Pennsylvania State University--Hershey Children's Hospital,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
PennsylvaniaPA-09Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
PennsylvaniaPA-09Convalescent Plasma in Outpatients With COVID-19600Geisinger Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
PennsylvaniaPA-09NCI COVID-19 in Cancer Patients, NCCAPS Study2000Geisinger Medical Center, Sechler Family Cancer Center, Geisinger Cancer Services-Pottsville,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Paoli Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-03Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Childrens Hospital of Philadelphia,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
PennsylvaniaPA-03Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of Pennsylvania,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
PennsylvaniaPA-03Adaptive COVID-19 Treatment Trial (ACTT)1062Hospital of the University of Pennsylvania,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
PennsylvaniaPA-03Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Hospital of the University of Pennsylvania, Hospital of the University of Pennsylvania,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
PennsylvaniaPA-03Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Hospital of the University of Pennsylvania, Hospital of the University of Pennsylvania,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
PennsylvaniaPA-03A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Thomas Jefferson University,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
PennsylvaniaPA-03Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Philadelphia VA Medical Center,Gilead SciencesDrug: Remdesivir
PennsylvaniaPA-03The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)173University of Pennsylvania,Ravi Amaravadi, MD, University of PennsylvaniaDrug: Hydroxychloroquine Sulfate 400 mg twice a day, Drug: Hydroxychloroquine Sulfate 600 mg twice a day, Drug: Hydroxychloroquine Sulfate 600 mg once a day, Drug: Placebo oral tablet
PennsylvaniaPA-03Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers120University of Pennsylvania,Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations (CEPI)Drug: INO-4800, Device: CELLECTRA® 2000
PennsylvaniaPA-03Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019152University of Pennsylvania Health System,University of Pennsylvania, Jordana B. Cohen, MD, MSCE, Thomas C. Hanff, MD, MPH, Vicente Corrales-Medina, MD, PhD, James Brian Byrd, MD, Roberto Viau ColindresOther: Discontinuation of ARB/ACEI, Other: Continuation of ARB/ACEI
PennsylvaniaPA-03COVID-19 Plasma Collection2000Thomas Jefferson University,Thomas Jefferson UniversityOther: Plasma Donation
PennsylvaniaPA-03Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen120Thomas Jefferson University Hospital,Biohaven Pharmaceuticals, Inc.Drug: Zavegepant (BHV-3500), Drug: Placebo
PennsylvaniaPA-03MSCs in COVID-19 ARDS223University of Pennsylvania Health System,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
PennsylvaniaPA-03Sirolimus in COVID-19 Phase 10Thomas Jefferson University Hospital,Walter K. Kraft, Thomas Jefferson UniversityDrug: Sirolimus 1 MG/ML, Drug: Placebo
PennsylvaniaPA-03Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Jefferson Hospital,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
PennsylvaniaPA-03Immunophenotyping Assessment in a COVID-19 Cohort2000Drexel University College of Medicine,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
PennsylvaniaPA-03Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19105University of Pennsylvania Health System,University of PennsylvaniaOther: Observation only
PennsylvaniaPA-03COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia200University of Pennsylvania,University of PennsylvaniaDevice: Helmet Continuous Positive Airway Pressure (CPAP), Device: High Flow Nasal Oxygen (HFNO)
PennsylvaniaPA-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Thomas Jefferson University Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-03COVID-19 Convalescent Plasma for Mechanically Ventilated Population50Hospital of the University of Pennsylvania,University of PennsylvaniaBiological: COVID-19 Convalescent Plasma
PennsylvaniaPA-03Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140Thomas Jefferson University,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
PennsylvaniaPA-03Convalescent Plasma for the Treatment of COVID-19100Thomas Jefferson University,Thomas Jefferson UniversityDrug: Convalescent Plasma
PennsylvaniaPA-03COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.80Hospital of the University of Pennsylvania,University of PennsylvaniaBiological: COVID-19 Convalescent Plasma
PennsylvaniaPA-03Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Hospital of the University of Pennsylvania,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
PennsylvaniaPA-03Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Penn Prevention CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
PennsylvaniaPA-03GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel225University of Pennsylvania,GeneOne Life Science, Inc.Drug: GLS-1200, Drug: Placebo
PennsylvaniaPA-03A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Thomas Jefferson University,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
PennsylvaniaPA-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Mercy Catholic Medical Center,Gilead SciencesDrug: Remdesivir
PennsylvaniaPA-05COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers20000Villanova University,Villanova University 
PennsylvaniaPA-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Bryn Mawr Hospital, Christiana Care Health System-Concord Health Center, Riddle Memorial Hospital, Lankenau Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
PennsylvaniaPA-01Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St Mary Medical Center,Gilead SciencesDrug: Remdesivir
PennsylvaniaPA-01Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
PennsylvaniaPA-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Doylestown Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
Rhode IslandRI-02Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Kent Hospital,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
Rhode IslandRI-02Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Rhode Island Hospital,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Rhode IslandRI-02Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Roger Williams Medical Center, Kent Hospital,Gilead SciencesDrug: Remdesivir
Rhode IslandRI-02Sarilumab for Patients With Moderate COVID-19 Disease120Providence VA Medical Center,Westyn Branch-Elliman, VA Boston Healthcare SystemBiological: SARILUMAB
Rhode IslandRI-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Omega Medical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
Rhode IslandRI-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Women and Infants Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
Rhode IslandRI-02PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Rhode Island Hospital,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
Rhode IslandRI-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Miriam Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
Rhode IslandRI-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Miriam Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
Rhode IslandRI-01Convalescent Plasma to Stem Coronavirus (CSSC-001)500Lifespan/Brown University,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
Rhode IslandRI-01Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Lifespan/Brown University,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
Rhode IslandRI-01PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Miriam Hospital,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
Rhode IslandRI-01Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes36Nursing Home,Restorbio Inc.Drug: RTB101, Drug: Placebo
South CarolinaSC-06Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Medical University of South Carolina,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
South CarolinaSC-06Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Medical University of South Carolina Children's Hospital, University of South Carolina,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
South CarolinaSC-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Prisma Health Richland Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
South CarolinaSC-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Prisma Health Richland Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
South CarolinaSC-06Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Medical University of South Carolina,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
South CarolinaSC-06Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen120Roper Hospital,Biohaven Pharmaceuticals, Inc.Drug: Zavegepant (BHV-3500), Drug: Placebo
South CarolinaSC-06Convalescent Plasma in Outpatients With COVID-19600Medical University of South Carolina,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
South CarolinaSC-06A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Medical University of South Carolina,Hoffmann-La RocheDrug: Tociliuzumab
South CarolinaSC-06Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Medical University of South Carolina,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
South CarolinaSC-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Medical University of South Carolina, Prisma Health Richland Hospital, Prisma Health Baptist Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
South CarolinaSC-06Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site, Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
South CarolinaSC-06Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198Ralph H. Johnson VA Medical Center,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
South CarolinaSC-06Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
South CarolinaSC-06A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Medical University of South Carolina, Prisma Health-Midlands,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
South CarolinaSC-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000AnMed Health Cancer Center, Prisma Health Cancer Institute – Easley, Self Regional Healthcare, Prisma Health Cancer Institute – Seneca,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
South CarolinaSC-01Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
South CarolinaSC-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000South Carolina Cancer Specialists PC,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
South CarolinaSC-02Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Lexington Medical Center,Gilead SciencesDrug: Remdesivir
South CarolinaSC-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Main Street Physician's Care, Main Street Physician's Care,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
South CarolinaSC-04Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Prisma Health Richland Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
South CarolinaSC-04Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Prisma Health Richland Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
South CarolinaSC-04Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Prisma Health,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
South CarolinaSC-04Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St. Francis Hospital,Gilead SciencesDrug: Remdesivir
South CarolinaSC-04Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS20Prisma Health,Prisma Health-UpstateProcedure: Therapeutic Plasma Exchange, Drug: Ruxolitinib
South CarolinaSC-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Prisma Health Cancer Institute - Spartanburg, Saint Francis Hospital, BI-LO Charities Children's Cancer Center, Prisma Health Cancer Institute – Butternut, Prisma Health Cancer Institute – Faris, Saint Francis Cancer Center, Prisma Health Cancer Institute – Eastside, Prisma Health Cancer Institute – Greer, Gibbs Cancer Center-Pelham, Spartanberg Medical Center, Prisma Health Cancer Institute – Spartanburg,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
South CarolinaSC-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Gibbs Cancer Center-Gaffney, MGC Hematology Oncology-Union,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
South DakotaSD-00Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Meridian Clinical Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
South DakotaSD-00Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection1Sanford Health,Sanford HealthDrug: Hydroxychloroquine, Dietary Supplement: Vitamin D
South DakotaSD-00NCI COVID-19 in Cancer Patients, NCCAPS Study2000Sanford Cancer Center Oncology Clinic, Sanford USD Medical Center - Sioux Falls,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
South DakotaSD-00Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Meridian Clinical Research,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
South DakotaSD-00Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Monument Health Clinical Research,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
TennesseeTN-04Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Trinity Clinical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TennesseeTN-03Compassionate Use of Hyperbaric Oxygen Therapy100CHI,SerenaGroup, Inc., SerenaGroup Research Foundation 
TennesseeTN-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Thompson Oncology Group-Oak Ridge,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TennesseeTN-09Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100St. Jude Children's Research Hosptial,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
TennesseeTN-09St. Jude Tracking of Viral and Host Factors Associated With COVID-191517St. Jude Children's Research Hospital,St. Jude Children's Research Hospital 
TennesseeTN-09Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children400St. Jude Children's Research Hospital,St. Jude Children's Research Hospital 
TennesseeTN-09Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury46University of Tennessee Health Care System,AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company)Drug: Ibrutinib, Drug: Placebo
TennesseeTN-09Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198Memphis VA Medical Center,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
TennesseeTN-07Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Clinical Trials Center of Middle Tennessee,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
TennesseeTN-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Alliance for Multispecialty Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TennesseeTN-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000East Tennessee Childrens Hospital, Thompson Cancer Survival Center, Thompson Cancer Survival Center – West, Thompson Oncology Group-Lenoir City, Thompson Oncology Group-Maryville,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TennesseeTN-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Holston Medical Group, Holston Medical Group,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TennesseeTN-05Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)200Vanderbilt University,Vanderbilt University Medical Center, United States Department of Defense 
TennesseeTN-05Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Vanderbilt University Medical Center,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
TennesseeTN-05Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Monroe Carell Jr. Children's Hospital at Vanderbilt,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
TennesseeTN-05Adaptive COVID-19 Treatment Trial (ACTT)1062Vanderbilt University Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
TennesseeTN-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0TriStar Centennial Medical Center,Gilead SciencesDrug: Remdesivir
TennesseeTN-05Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Vanderbilt University Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
TennesseeTN-05Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Vanderbilt University Medical Center,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
TennesseeTN-05Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Vanderbilt University Medical Center,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
TennesseeTN-05Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-1990Vanderblt University Medical Center,Vanderbilt University Medical CenterOther: Saline Nasal Irrigation, Other: Saline with Baby Shampoo Nasal Irrigation
TennesseeTN-05A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Vanderbilt University Medical Cancer,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
TennesseeTN-05COVID-19 and Cancer Consortium Registry10000Vanderbilt University Medical Center,Vanderbilt-Ingram Cancer CenterOther: Web-based REDCap survey
TennesseeTN-05COVID-19 Patient Positioning Pragmatic Trial503Vanderbilt University Medical Center,Vanderbilt University Medical CenterOther: Prone, Other: Usual Care
TennesseeTN-05Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Vanderbilt University Medical Center,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
TennesseeTN-05Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Clinical Research Associates,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TennesseeTN-05Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)3000Vanderbilt University Medical Center,University of Manitoba, University Health Network, TorontoDrug: Heparin
TennesseeTN-05Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19600Vanderbilt University Medical Center,Vanderbilt University Medical Center, AbbVieDrug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo
TennesseeTN-05COVID-19: Human Epidemiology and Response to SARS-CoV-25605Vanderbilt University Medical Center,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
TennesseeTN-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Vanderbilt Breast Center at One Hundred Oaks, Vanderbilt University/Ingram Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TennesseeTN-05Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic150Vanderbilt Eye Institute,Vanderbilt University Medical CenterOther: Non invasive visual acuity testing
TennesseeTN-05Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Vanderbilt University Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
TennesseeTN-05Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Vanderbilt Vaccine CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
TennesseeTN-05The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Vanderbilt University,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
TennesseeTN-08Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Clinical Neuroscience Solutions,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TennesseeTN-08Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Baptist Memorial Hospital,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
TennesseeTN-08INB03 for the Treatment of Pulmonary Complications From COVID-19366Baptist Clinical Research Institute,Inmune Bio, Inc.Drug: INB03, Drug: Placebo
TennesseeTN-08Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
TennesseeTN-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000Baptist Memorial Hospital and Cancer Center-Collierville, Baptist Memorial Hospital and Cancer Center-Memphis, Baptist Memorial Hospital for Women,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-10Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998ARC Clinical Research at Wilson Parke, Martin Diagnostic Clinic,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-11Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Benchmark Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-11Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Benchmark Research,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
TexasTX-12Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Cook Childrens Medical Center Oncology,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
TexasTX-12Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Cook Children's,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
TexasTX-12Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Baylor University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-12Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Baylor University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-12Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Ventavia Research Group LLC, Benchmark Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-12A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Baylor All Saints Medical Center at Fort Worth,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
TexasTX-12Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite0Participating Research Facility,Hope PharmaceuticalsDrug: Sodium Nitrite, Drug: Normal Saline
TexasTX-13Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124PharmaTex Research,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
TexasTX-14Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery600MD Anderson League City,M.D. Anderson Cancer Center, National Cancer Institute (NCI)Other: Questionnaire Administration
TexasTX-14Adaptive COVID-19 Treatment Trial (ACTT)1062University of Texas Medical Branch,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
TexasTX-14Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Texas Department of Criminal Justice Hospital,Gilead SciencesDrug: Remdesivir
TexasTX-14Plasma Adsorption in Patients With Confirmed COVID-192000UTMB,Marker Therapeutics AG, Terumo BCTDevice: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
TexasTX-14Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998University of Texas Medical Branch,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-14NCI COVID-19 in Cancer Patients, NCCAPS Study2000Baptist Hospitals of Southeast Texas Cancer Center, Baptist Regional Cancer Network,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-14Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Texas Medical Branch,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
TexasTX-14Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944HCA Houston Healthcare Mainland,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
TexasTX-15Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Rio Grande Valley Clinical Research Institute,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
TexasTX-15A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379McAllen Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
TexasTX-16A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Texas Tech University Medical Center,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
TexasTX-16Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0William Beaumont Army Medical Center,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
TexasTX-17BCG Vaccine for Health Care Workers as Defense Against COVID 191800Texas A&M Family Care Clinic,Texas A&M University, Baylor College of Medicine, M.D. Anderson Cancer Center, Cedars-Sinai Medical Center, Harvard UniversityBiological: BCG Vaccine, Biological: Placebo Vaccine
TexasTX-17Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300St. David's North Austin Medical Center,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
TexasTX-17NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Joseph Regional Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-17A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Baylor Scott and White Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
TexasTX-18Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Therapeutic Concepts,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
TexasTX-18Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Spring Clinical Research,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
TexasTX-18Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19100United Memorial Medical Center,Hope Biosciences, Advanced Diagnostics Healthcare, Hope Biosciences Stem Cell Research Foundation, United Memorial Medical CenterDrug: HB-adMSC, Drug: Placebo
TexasTX-18Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Ventavia Research Group,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-18Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
TexasTX-18Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Therapeutic Concepts,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
TexasTX-18Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944HCA Houston Healthcare Medical Center,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
TexasTX-19Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Covenant Medical Center,Gilead SciencesDrug: Remdesivir
TexasTX-19Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Covenant Health System,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
TexasTX-19NCI COVID-19 in Cancer Patients, NCCAPS Study2000Covenant Children's Hospital, UMC Cancer Center / UMC Health System,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-20Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Methodist Healthcare System of San Antonio,Gilead SciencesDrug: Remdesivir
TexasTX-20Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000BFHC Research,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
TexasTX-20Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Clinical Trials of Texas Inc, Diagnostics Research Group,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-20NCI COVID-19 in Cancer Patients, NCCAPS Study2000Audie L. Murphy VA Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-21Adaptive COVID-19 Treatment Trial (ACTT)1062Brooke Army Medical Center, University of Texas Health Science Center at San Antonio,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
TexasTX-21Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St. David's South Austin Medical Center,Gilead SciencesDrug: Remdesivir
TexasTX-21Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Brooke Army Medical Center,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
TexasTX-21Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Tekton Research Inc,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-21Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500University of Texas Health Science Center,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
TexasTX-21Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin1000Dell Medical School,University of Texas at AustinOther: During COVID-19 Pandemic, Other: After COVID-19 Pandemic
TexasTX-21NCI COVID-19 in Cancer Patients, NCCAPS Study2000University Hospital, University of Texas Health Science Center at San Antonio,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-21Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Brooke Army Medical Center, University of Texas Health Science Center at San Antonio,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
TexasTX-21Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944St. David's South Austin Medical Center,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
TexasTX-22Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery600MD Anderson in Sugar Land,M.D. Anderson Cancer Center, National Cancer Institute (NCI)Other: Questionnaire Administration
TexasTX-22A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19100Hope Biosciences Stem Cell Research Foundation,Hope Biosciences, Hope Biosciences Stem Cell Research FoundationDrug: HB-adMSCs, Drug: Placebos
TexasTX-22A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-1956Hope Biosciences Stem Cell Research Foundation,Hope BiosciencesDrug: HB-adMSCs
TexasTX-22Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000LinQ Research LLC,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
TexasTX-22A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Houston Methodist Sugar Land Hospital,Hoffmann-La RocheDrug: Tociliuzumab
TexasTX-22Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998LinQ Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-24A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Baylor Scott & White All Saints Medical Center, Baylor Scott & White Medical Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
TexasTX-25Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Dell Children's Medical Center of Central Texas,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
TexasTX-25Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300St. David's Healthcare,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
TexasTX-25ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings5000St. David's Medical Center,Texas Cardiac Arrhythmia Research FoundationDiagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test
TexasTX-25Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Benchmark Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-25Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)100Texas Cardiac Arrhythmia Institute,Texas Cardiac Arrhythmia Research FoundationDiagnostic Test: diagnostic tests for COVID-19 infection
TexasTX-25Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500St David's Medical Center,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
TexasTX-25Immunophenotyping Assessment in a COVID-19 Cohort2000University of Texas at Austin,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
TexasTX-25NCI COVID-19 in Cancer Patients, NCCAPS Study2000Dell Children's Medical Center of Central Texas,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-25Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Benchmark Research,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
TexasTX-25Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944St. David's Medical Center,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
TexasTX-26Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Ventavia Research Group LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-27A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Crossroads Clinical Research,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
TexasTX-28A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204Laguna Clinical Research,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
TexasTX-30Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Texas-Southwestern Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
TexasTX-30Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113UT Southwestern Medical Center Amelia Court, Baylor University Medical Center, UT Southwestern Medical Center Amelia Court, UT Southwestern Medical Center Amelia Court,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-30Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891UT Southwestern Medical Center Amelia Court, Baylor University Medical Center, UT Southwestern Medical Center Amelia Court,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-30Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
TexasTX-30Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Baylor Scott & White Research Institute, University of Texas(UT) Southwestern Medical Center,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
TexasTX-30Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers228Baylor Research Medical Center,Baylor Research InstituteDrug: Hydroxychloroquine
TexasTX-30Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363University of Texas Southwestern Medical Center,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
TexasTX-30Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Baylor Scott & White Research Institute,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
TexasTX-30Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Baylor Scott & White Dallas,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
TexasTX-30A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Baylor Jack & Jane Hamilton Heart and Vascular Hospital, Baylor University Medical Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
TexasTX-30Convalescent Plasma in Outpatients With COVID-19600William P. Clements Jr. University Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
TexasTX-30Plasma Adsorption in Patients With Confirmed COVID-192000UT Southwestern/Clements Hospital,Marker Therapeutics AG, Terumo BCTDevice: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
TexasTX-30Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998North Texas Infectious Diseases Consultants,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-30COVID-19: Human Epidemiology and Response to SARS-CoV-25605University of Texas Southwestern Medical Center,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
TexasTX-30A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Baylor Scott & White Research Institute,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
TexasTX-30A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Parkland Health & Hospital System, University of Texas Southwestern Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
TexasTX-30NCI COVID-19 in Cancer Patients, NCCAPS Study2000Parkland Memorial Hospital, UT Southwestern/Simmons Cancer Center-Dallas,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-30Predictors of Severe COVID-19 Outcomes1500University of Texas Southwestern Medical Center,Verily Life Sciences LLC 
TexasTX-30Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198VA North Texas Health Care System,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
TexasTX-30Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Baylor Scott & White Health, University of Texas Southwestern Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
TexasTX-31Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Baylor University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-31Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Baylor University Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-31Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Baylor Scott & White Medical Center,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
TexasTX-31A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Baylor Scott & White Medical Center - Temple,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
TexasTX-31A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966Texas A&M College of Medicine,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
TexasTX-31A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Baylor Scott & White Health,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
TexasTX-32Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Texas Health Presbyterian Hospital Dallas,Gilead SciencesDrug: Remdesivir
TexasTX-32Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300Texas Health,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
TexasTX-32A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Baylor University Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
TexasTX-33Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Texas Health,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
TexasTX-33Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Liver Institute of Methodist Dallas Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-33Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Liver Institute of Methodist Dallas Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-33Convalescent Plasma to Stem Coronavirus (CSSC-001)500Methodist Dallas Medical Center,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
TexasTX-33Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
TexasTX-33A Study of Auxora in Patients With Severe COVID-19 Pneumonia400John Peter Smith Hospital,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
TexasTX-33Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection60Methodist Dallas Medical Center,Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical CenterDrug: Alteplase 50 MG [Activase]
TexasTX-33Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920Trinity Health and Wellness Center CRS,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
TexasTX-33A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)252Renibus Therapeutics,Renibus Therapeutics, Inc.Drug: RBT-9 (90 mg), Drug: 0.9% sodium chloride (normal saline)
TexasTX-33NCI COVID-19 in Cancer Patients, NCCAPS Study2000UT Southwestern/Simmons Cancer Center-Fort Worth,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-33Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure524Texas Health Harris Methodist Hospital Fort Worth,ChimerixDrug: Dociparastat sodium, Drug: Placebo
TexasTX-33A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Liver Institute at Methodist Dallas,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
TexasTX-34A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Valley Baptist Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
TexasTX-35Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin1000CommUnity Care Clinic, CommUnity Care Clinic - Rundberg,University of Texas at AustinOther: During COVID-19 Pandemic, Other: After COVID-19 Pandemic
TexasTX-35NCI COVID-19 in Cancer Patients, NCCAPS Study2000Children's Hospital of San Antonio,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-36Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)800Centex Studies Inc.,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
TexasTX-36Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Centex Studies Inc.,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
TexasTX-06Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Methodist Mansfield Medical Center,Gilead SciencesDrug: Remdesivir
TexasTX-07The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection100Next Level Urgent Care,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
TexasTX-07The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200Next Level Urgent Care,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
TexasTX-07Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19100River Oaks Hospital and Clinics,Hope Biosciences, Advanced Diagnostics Healthcare, Hope Biosciences Stem Cell Research Foundation, United Memorial Medical CenterDrug: HB-adMSC, Drug: Placebo
TexasTX-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Texas Center For Drug Development Inc,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-07COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-11140Memorial Herman Memorial City Hospital,Veru Inc.Drug: Veru-111
TexasTX-05Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000SMS Clinical Research LLC,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
TexasTX-05Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
TexasTX-05Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998SMS Clinical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
TexasTX-05Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
TexasTX-05A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204Care United Research,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
TexasTX-09A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)242M D Anderson Cancer Center,Millennium Pharmaceuticals, Inc., TakedaDrug: TAK-981, Drug: Standard of care
TexasTX-09Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250M D Anderson Cancer Center,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
TexasTX-09Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery600M D Anderson Cancer Center,M.D. Anderson Cancer Center, National Cancer Institute (NCI)Other: Questionnaire Administration
TexasTX-09DiaBetter Together for Young Adults With Type 1 Diabetes186Baylor College of Medicine,Baylor College of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Children's National Research InstituteBehavioral: DiaBetter Together, Behavioral: Peer Mentor Delivery
TexasTX-09Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Texas--Memorial Hermann Texas Medical Center,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
TexasTX-09Adaptive COVID-19 Treatment Trial (ACTT)1062Baylor College of Medicine,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
TexasTX-09Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Houston Methodist Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-09Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Houston Methodist Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
TexasTX-09Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure165Houston Methodist Hospital,NeuroRx, Inc., Lavin Consulting, LLCDrug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care
TexasTX-09The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection100M D Anderson Cancer Center,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
TexasTX-09The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200M D Anderson Cancer Center,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
TexasTX-09CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment243University of Texas at Houston,OncoImmune, Inc.Drug: CD24Fc, Drug: Placebo
TexasTX-09A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Baylor St. Luke's Medical Center, Harris Health System - Ben Taub Hospital,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
TexasTX-09Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0HCA Houston Healthcare West,Gilead SciencesDrug: Remdesivir
TexasTX-09Convalescent Plasma to Stem Coronavirus (CSSC-001)500Baylor College of Medicine, University of Texas Health Science Center,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
TexasTX-09Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479University of Texas Health Science Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
TexasTX-09Cardiovascular Manifestations of COVID-19500Memorial Hermann Hospital-Texas Medical Center,Memorial Hermann Health SystemDiagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values
TexasTX-09Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384Houston Methodist Hospital,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
TexasTX-09Awake Prone Position for Early Hypoxemia in COVID-19560Michael E. DeBakey Veteran Affairs Medical Center,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
TexasTX-09Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)30Houston Methodist Hospital,Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital SystemBiological: Mesenchymal Stromal Cells, Other: Supportive Care
TexasTX-09A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Ben Taub,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
TexasTX-09Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Baylor College of Medicine, University of Texas,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
TexasTX-09BCG Vaccine for Health Care Workers as Defense Against COVID 191800Baylor College of Medicine, Baylor St. Luke's Medical Center, Harris Health System - Ben Taub Hospital, M D Anderson Cancer Center,Texas A&M University, Baylor College of Medicine, M.D. Anderson Cancer Center, Cedars-Sinai Medical Center, Harvard UniversityBiological: BCG Vaccine, Biological: Placebo Vaccine
TexasTX-09Dapagliflozin in Respiratory Failure in Patients With COVID-19900Baylor College of Medicine,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
TexasTX-09A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227University of Texas Health Science Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
TexasTX-09Convalescent Plasma in Outpatients With COVID-19600Ben Taub General Hospital, Memorial Hermann Texas Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
TexasTX-09Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection60Ben Taub Hospital,Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical CenterDrug: Alteplase 50 MG [Activase]
TexasTX-09Study of the Use of Favipiravir in Hospitalized Subjects With COVID-1950Houston Methodist Hospital,Fujifilm Pharmaceuticals U.S.A., Inc.Drug: Favipiravir + Standard of Care, Drug: Standard of Care
TexasTX-09Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
TexasTX-09A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Houston Methodist Hospital, Michael E Debakey VA Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
TexasTX-09CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients300University of Texas Health Science Center,NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of MiamiBiological: Convalescent Plasma, Other: Saline solution
TexasTX-09A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)252Renibus Therapeutics,Renibus Therapeutics, Inc.Drug: RBT-9 (90 mg), Drug: 0.9% sodium chloride (normal saline)
TexasTX-09Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Houston Methodist Hospital,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
TexasTX-09MSCs in COVID-19 ARDS223Houston Methodist Hospital,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
TexasTX-09A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Michael E Debakey VA Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
TexasTX-09Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Baylor College of Medicine, University of Texas Health Science Center,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
TexasTX-09Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
TexasTX-09Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500University of Texas Health Science Center At Houston,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
TexasTX-09Immunophenotyping Assessment in a COVID-19 Cohort2000Baylor College of Medicine,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
TexasTX-09Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
TexasTX-09Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
TexasTX-09NCI COVID-19 in Cancer Patients, NCCAPS Study2000Baylor College of Medicine, Ben Taub General Hospital, Michael E DeBakey VA Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
TexasTX-09Predictors of Severe COVID-19 Outcomes1500Baylor College of Medicine,Verily Life Sciences LLC 
TexasTX-09Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198Michael E. DeBakey VA Medical Center,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
TexasTX-09Anti-SARS Cov-2 T Cell Infusions for COVID 1958Houston Methodist Hospital,Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital System, AlloVirBiological: Dose Finding Phase (MTD), Biological: Partially HLA-matched SARS-CoVSTs, Other: Routine care (no SARS-CoVSTs)
TexasTX-09Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Baylor College of Medicine,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
TexasTX-09The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Houston Methodist Hospital,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
TexasTX-09A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Baylor St. Luke's Medical Center, Ben Taub General Hospital, Houston Methodist Hospital,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
TexasTX-09Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124UT Health Science Center,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
TexasTX-09Study of Sargramostim in Patients With COVID-19120Memorial Hermann Hospital,Partner Therapeutics, Inc.Drug: Sargramostim, Drug: Standard of care
TexasTX-08Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery600MD Anderson in The Woodlands,M.D. Anderson Cancer Center, National Cancer Institute (NCI)Other: Questionnaire Administration
TexasTX-01CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients300University of Texas Health Science Center,NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of MiamiBiological: Convalescent Plasma, Other: Saline solution
TexasTX-01Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
TexasTX-01Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
TexasTX-01A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Baylor Scott & White Medical Center - Irving,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
TexasTX-03A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Baylor Scott & White Heart Hospital,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
TexasTX-03MSCs in COVID-19 ARDS223Baylor Smith & White,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
TexasTX-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000UT Southwestern Clinical Center at Richardson/Plano,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
UtahUT-04Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)200Intermountain Medical Center,Vanderbilt University Medical Center, United States Department of Defense 
UtahUT-04Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
UtahUT-04Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Saint Mark's Hospital,Gilead SciencesDrug: Remdesivir
UtahUT-04Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-1985Intermountain Health Care Inc.,Intermountain Health Care, Inc., University of UtahDrug: Hydroxychloroquine, Drug: Azithromycin
UtahUT-04Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Intermountain Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
UtahUT-04Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-191550Intermountain Medical Center,Intermountain Health Care, Inc., University of Utah, Utah Department of HealthDrug: Hydroxychloroquine, Drug: Azithromycin
UtahUT-04Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older600Advanced Clinical Research,ModernaTX, Inc., Biomedical Advanced Research and Development AuthorityBiological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg
UtahUT-03Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Utah Valley Hospital,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
UtahUT-03Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998J. Lewis Research Inc. / Foothill Family Clinic South,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
UtahUT-02Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)200George Wahlen Salt Lake City Veterans Administration Hospital,Vanderbilt University Medical Center, United States Department of Defense 
UtahUT-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113University of Utah Health,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
UtahUT-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891University of Utah Health,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
UtahUT-02A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure10University of Utah Health,University of UtahBiological: Human Amniotic Fluid
UtahUT-02A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Intermountain Medical Group, Intermountain LDS Hospital,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
UtahUT-02Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of Utah,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
UtahUT-02Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.16University of Utah Health,Swedish Orphan BiovitrumBiological: Emapalumab, Biological: Anakinra
UtahUT-02Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-1985University of Utah,Intermountain Health Care, Inc., University of UtahDrug: Hydroxychloroquine, Drug: Azithromycin
UtahUT-02Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479University of Utah Hospital,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
UtahUT-02Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-191550University of Utah,Intermountain Health Care, Inc., University of Utah, Utah Department of HealthDrug: Hydroxychloroquine, Drug: Azithromycin
UtahUT-02University of Utah COVID-19 Hydrochloroquine Trial400University of Utah,University of UtahDrug: Hydroxychloroquine, Drug: Placebo oral tablet
UtahUT-02Convalescent Plasma in Outpatients With COVID-19600University of Utah Healthcare,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
UtahUT-02Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Utah Health,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
UtahUT-02Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization30University of Utah Health Sciences Center,University of UtahBehavioral: Intermittent prone positioning instructions, Behavioral: Usual care positioning with no instructions
UtahUT-02Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998J. Lewis Research Inc. / Foothill Family Clinic,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
UtahUT-02Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of Utah,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
UtahUT-02Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury46Intermountain Healthcare,AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company)Drug: Ibrutinib, Drug: Placebo
UtahUT-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Farmington Health Center, University of Utah Sugarhouse Health Center, Huntsman Cancer Institute/University of Utah, George E Wahlen Department of Veterans Affairs Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
UtahUT-02Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Utah,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
UtahUT-02A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Intermountain LDS Hospital,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
UtahUT-02Study of Sargramostim in Patients With COVID-19120University of Utah Health,Partner Therapeutics, Inc.Drug: Sargramostim, Drug: Standard of care
VermontVT-00Sarilumab for Patients With Moderate COVID-19 Disease120VA Medical Center - White River Junction,Westyn Branch-Elliman, VA Boston Healthcare SystemBiological: SARILUMAB
VermontVT-00NCI COVID-19 in Cancer Patients, NCCAPS Study2000Norris Cotton Cancer Center-North,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
VermontVT-00Longitudinal COVID-19 Cohort Study225University of Vermont College of Medicine,University of VermontOther: COVID-19+ observational
VirginiaVA-10NCI COVID-19 in Cancer Patients, NCCAPS Study2000Shenandoah Oncology PC,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
VirginiaVA-11Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Inova Fairfax Medical Campus,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
VirginiaVA-11Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Inova Fairfax Medical Campus,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
VirginiaVA-11Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
VirginiaVA-11Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Inova Fairfax Medical Campus,Gilead SciencesDrug: Remdesivir
VirginiaVA-11A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Inova Fairfax Medical Campus,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
VirginiaVA-11Plasma Adsorption in Patients With Confirmed COVID-192000Inova Fairfax Medical Campus,Marker Therapeutics AG, Terumo BCTDevice: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
VirginiaVA-11Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Clinical Alliance for Research & Education,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
VirginiaVA-11NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente Tysons Corner Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
VirginiaVA-11Predictors of Severe COVID-19 Outcomes1500Inova Health Care Services,Verily Life Sciences LLC 
VirginiaVA-11Characteristics of COVID-19 Infection Among PREGnant Women100INOVA Health System,Inova Health SystemOther: COVID-19 positive via testing
VirginiaVA-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Bon Secours Memorial Regional Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
VirginiaVA-08Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Virginia Hospital Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
VirginiaVA-08Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Virginia Hospital Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
VirginiaVA-08Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Fort Belvoir Community Hospital,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
VirginiaVA-08Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)124Inova Alexandria Hospital,CSL BehringBiological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo
VirginiaVA-04Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250VCU Health System,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
VirginiaVA-04Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113VCU Health Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
VirginiaVA-04Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891VCU Health Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
VirginiaVA-04Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
VirginiaVA-04Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479VCU Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
VirginiaVA-04SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)60Hunter Holmes McGuire Veteran Affairs Medical Center, Virginia Commonwealth University,Virginia Commonwealth UniversityDrug: L-ascorbic acid, Other: Placebo
VirginiaVA-04Awake Prone Position for Early Hypoxemia in COVID-19560VCU Medical Center,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
VirginiaVA-04A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Virginia Commonwealth University,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
VirginiaVA-04Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation20Hunter Holmes Mcguire Veteran Affairs Medical Center,Hunter Holmes Mcguire Veteran Affairs Medical Center, McGuire Research InstituteDrug: L-ascorbic acid
VirginiaVA-04Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Virginia Commonwealth University,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
VirginiaVA-04Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
VirginiaVA-04Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
VirginiaVA-04A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Virginia Commonwealth University,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
VirginiaVA-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000VCU Massey Cancer Center at Stony Point, Virginia Commonwealth University/Massey Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
VirginiaVA-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Henrico Doctors Hospital,Gilead SciencesDrug: Remdesivir
VirginiaVA-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Virginia Research Center LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
VirginiaVA-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Bon Secours Saint Francis Medical Center, Bon Secours Saint Mary's Hospital, Bon Secours Cancer Institute at Reynolds Crossing, Virginia Cancer Institute,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
VirginiaVA-03Adaptive COVID-19 Treatment Trial (ACTT)1062Naval Medical Center Portsmouth,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
VirginiaVA-03Dapagliflozin in Respiratory Failure in Patients With COVID-19900Sentara Healthcare,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
VirginiaVA-03Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Naval Medical Center Portsmouth,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
VirginiaVA-03Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Sentara Norfolk General Hospital,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
VirginiaVA-03Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure524Sentara Clinical Trials,ChimerixDrug: Dociparastat sodium, Drug: Placebo
VirginiaVA-03Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Naval Medical Center Portsmouth,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
VirginiaVA-02Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Naval Surface Force Atlantic, USS Dwight D. Eisenhower CVN 69, USS Gerald R. Ford CVN 78,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
VirginiaVA-02A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Sentara Medical Group,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
VirginiaVA-06Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Carilion Medical Center,Gilead SciencesDrug: Remdesivir
VirginiaVA-06Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
VirginiaVA-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Augusta Health Center for Cancer and Blood Disorders,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
VirginiaVA-05Adaptive COVID-19 Treatment Trial (ACTT)1062University of Virginia,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
VirginiaVA-05Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic40University of Virginia,University of VirginiaDevice: Control swab, Device: Prototype swab
VirginiaVA-05MSCs in COVID-19 ARDS223University of Virginia,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
VirginiaVA-05Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia29University of Virginia,University of VirginiaDrug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
VirginiaVA-05Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Virginia,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
WashingtonWA-10Adaptive COVID-19 Treatment Trial (ACTT)1062Madigan Army Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
WashingtonWA-10Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Providence St. Peter Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-10Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Providence St. Peter Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-10Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Madigan Army Medical Center,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
WashingtonWA-10NCI COVID-19 in Cancer Patients, NCCAPS Study2000Providence Regional Cancer System-Lacey, Saint Clare Hospital, Providence Regional Cancer System-Shelton, Providence Regional Cancer System-Yelm,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WashingtonWA-10Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Madigan Army Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
WashingtonWA-08Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Wenatchee Valley Hospital,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
WashingtonWA-08Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Wenatchee Valley Hospital and Clinics,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
WashingtonWA-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000Saint Elizabeth Hospital, Swedish Cancer Institute-Issaquah,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WashingtonWA-04Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kadlec Regional Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-04Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kadlec Regional Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kadlec Clinic Hematology and Oncology,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WashingtonWA-01Adaptive COVID-19 Treatment Trial (ACTT)1062EvergreenHealth Infectious Disease Service,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
WashingtonWA-01A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Evergreen Health Infectious Disease,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
WashingtonWA-01Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034EvergreenHealth Infectious Disease Service,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
WashingtonWA-05Adaptive COVID-19 Treatment Trial (ACTT)1062Providence Sacred Heart Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
WashingtonWA-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113MultiCare Deaconess Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-05Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891MultiCare Deaconess Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-05Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
WashingtonWA-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Providence Sacred Heart Medical Center and Children's Hospital, Providence Saint Mary Regional Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WashingtonWA-05Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Providence Sacred Heart Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
WashingtonWA-07Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Seattle Children's Hospital, Fred Hutchinson Cancer Research Center,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
WashingtonWA-07Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Seattle Children's Hospital,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
WashingtonWA-07Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)120Kaiser Permanente Washington Health,National Institute of Allergy and Infectious Diseases (NIAID)Biological: mRNA-1273
WashingtonWA-07Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Virginia Mason Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-07Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Virginia Mason Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-07Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals533Everett Clinic,Dr. Deneen Vojta, Quest Diagnostics, Bill and Melinda Gates Foundation, UnitedHealth GroupDiagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals
WashingtonWA-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0University of Washington Medical Center,Gilead SciencesDrug: Remdesivir
WashingtonWA-07A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research120Everett Clinic,Dr. Deneen Vojta, PATH, Mayo Clinic, Bill and Melinda Gates Foundation, UnitedHealth GroupDiagnostic Test: Odd/Even birth year intervention groups
WashingtonWA-07Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)829University of Washington Virology Research,University of Washington, Bill and Melinda Gates FoundationDrug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid
WashingtonWA-07An Observational Study of Patients With Coronavirus Disease 20195000University of Washington,Target PharmaSolutions, Inc. 
WashingtonWA-07Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Seattle Children's Hospital,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
WashingtonWA-07Collection of Anti-SARS-CoV-2 Immune Plasma1500Bloodworks Northwest,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
WashingtonWA-07Treatment for COVID-19 in High-Risk Adult Outpatients300University of Washington Virology Research,University of Washington, Bill and Melinda Gates FoundationDrug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
WashingtonWA-07Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic10000University of Washington,University of WashingtonBehavioral: online survey
WashingtonWA-07Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Benaroya Research Institute at Virginia Mason,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
WashingtonWA-07Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270VA Puget Sound Health Care System,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
WashingtonWA-07Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19500Seattle Institute of East Asian Medicine,Center for Integrated Care, University of Utah, University of California, San FranciscoDietary Supplement: Chinese Herbal Medicine
WashingtonWA-07A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Virginia Mason Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
WashingtonWA-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Highline Medical Center-Main Campus, Swedish Cancer Institute-Edmonds, Pacific Gynecology Specialists, Swedish Medical Center-Ballard Campus, Fred Hutchinson Cancer Research Center, Seattle Cancer Carolines, University of Washington Medican Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WashingtonWA-07An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic0University of Washington Seattle Cancer Care Alliance,Genentech, Inc.Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
WashingtonWA-07Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Seattle Vaccine and Prevention CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
WashingtonWA-07A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204Fred Hutch,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
WashingtonWA-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113MultiCare Tacoma General Hospital, St Joseph Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891MultiCare Tacoma General Hospital, St Joseph Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-06Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202MultiCare Institute for Research & Innovation,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
WashingtonWA-06Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
WashingtonWA-06Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-1986Multicare Health System,Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)Biological: CYNK-001
WashingtonWA-06Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
WashingtonWA-06A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410MultiCare Institute for Research and Innovation,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
WashingtonWA-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Providence Regional Cancer System-Aberdeen, Harrison HealthPartners Hematology and Oncology-Bremerton, Harrison Medical Center, Jefferson Healthcare, Harrison HealthPartners Hematology and Oncology-Poulsbo, Franciscan Research Center-Northwest Medical Plaza,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WashingtonWA-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Providence Regional Cancer System-Centralia, PeaceHealth Saint John Medical Center, PeaceHealth Southwest Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WashingtonWA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Providence Medical Research Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Providence Regional Medical Center Everett,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-02Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
WashingtonWA-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000PeaceHealth Saint Joseph Medical Center, Providence Regional Cancer Partnership, PeaceHealth United General Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WashingtonWA-02A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Providence Regional Medical Center Everett,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
WashingtonWA-09Adaptive COVID-19 Treatment Trial (ACTT)1062University of Washington,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
WashingtonWA-09Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Swedish Center for Comprehensive Care,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-09Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Swedish Center for Comprehensive Care,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
WashingtonWA-09Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
WashingtonWA-09A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Swedish Hospital Medical Center,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
WashingtonWA-09Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Overlake Hospital Medical Center,Gilead SciencesDrug: Remdesivir
WashingtonWA-09Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)829University of Washington,University of Washington, Bill and Melinda Gates FoundationDrug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid
WashingtonWA-09Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Harborview Medical Center, Swedish Medical Center-First Hill,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
WashingtonWA-09Treatment for COVID-19 in High-Risk Adult Outpatients300University of Washington,University of Washington, Bill and Melinda Gates FoundationDrug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
WashingtonWA-09Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920University of Washington AIDS CRS,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
WashingtonWA-09Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease20Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: HCQ, Drug: HCQ+AZT, Drug: Placebo
WashingtonWA-09Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
WashingtonWA-09Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Washington,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
WashingtonWA-09Tocilizumab for Patients With Cancer and COVID-19 Disease217Valley Medical Center,National Cancer Institute (NCI)Biological: Tocilizumab
WashingtonWA-09Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
WashingtonWA-09NCI COVID-19 in Cancer Patients, NCCAPS Study2000Overlay Medical Center, Saint Francis Hospital, Valley Medical Center, Swedish Medical Center-Cherry Hill, Swedish Medical Center-First Hill,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WashingtonWA-09IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)300University of Washington, University of Washington,Implicit Bioscience, University of WashingtonBiological: IC14, Other: Placebo
WashingtonWA-09Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198VA Puget Sound Health Care System Seattle Division,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
West VirginiaWV-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Princeton Community Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
West VirginiaWV-01Convalescent Plasma Collection and Treatment in Pediatrics and Adults240West Virginia University Medicine,West Virginia UniversityBiological: Convalescent Plasma 1 Unit, Biological: Convalescent Plasma 2 Units, Other: Standard of Care
West VirginiaWV-01Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)5West Virginia University Rockefeller Neuroscience Institute,West Virginia UniversityProcedure: Stellate Ganglion Block
West VirginiaWV-01A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500West Virginia University Hospital,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
West VirginiaWV-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000West Virginia University Charleston Division,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WisconsinWI-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Aurora Cancer Care-Southern Lakes VLCC, Ascension Saint Francis - Reiman Cancer Center, Aurora Cancer Care-Kenosha South, Ascension All Saints Hospital, Aurora Cancer Care-Racine,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WisconsinWI-01Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure524Ascension All Saints Hospital,ChimerixDrug: Dociparastat sodium, Drug: Placebo
WisconsinWI-01PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Ascension All Saints,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
WisconsinWI-02Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of Wisconsin, University of Wisconsin, University of Wisconsin,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
WisconsinWI-02Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
WisconsinWI-02Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19600University of Wisconsin,Vanderbilt University Medical Center, AbbVieDrug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo
WisconsinWI-02COVID-19: Human Epidemiology and Response to SARS-CoV-25605University of Wisconsin Hospital and Clinics,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
WisconsinWI-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000William S Middleton VA Medical Center, University of Wisconsin Hospital and Clinics,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WisconsinWI-02Home Usability Study of the SARS-CoV-2 (COVID-19) Test30Exact Sciences Corporation,Exact Sciences CorporationDiagnostic Test: SARS-CoV-2
WisconsinWI-04Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
WisconsinWI-04Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Aurora Research Institute,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
WisconsinWI-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Aurora Cancer Care-Milwaukee, Ascension Columbia Saint Mary's Hospital - Milwaukee, Aurora Saint Luke's Medical Center, Aurora Sinai Medical Center, Zablocki Veterans Administration Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WisconsinWI-04Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure524Ascension St. Francis Hospital,ChimerixDrug: Dociparastat sodium, Drug: Placebo
WisconsinWI-04PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364Ascension St. Francis Hospital,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
WisconsinWI-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Aurora Cancer Care-Grafton, Ascension Columbia Saint Mary's Hospital Ozaukee, Ascension Mercy Hospital, Vince Lombardi Cancer Clinic – Oshkosh, Vince Lombardi Cancer Clinic-Sheboygan, Vince Lombardi Cancer Clinic-Two Rivers,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WisconsinWI-08NCI COVID-19 in Cancer Patients, NCCAPS Study2000ThedCare Regional Cancer Center, Ascension Saint Elizabeth Hospital, Ascension Calumet Hospital, Saint Vincent Hospital Cancer Center Green Bay, Saint Vincent Hospital Cancer Center at Saint Mary's, Aurora BayCare Medical Center, Aurora Bay Area Medical Group-Marinette, Saint Vincent Hospital Cancer Center at Oconto Falls, Saint Vincent Hospital Cancer Center at Sturgeon Bay,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WisconsinWI-03Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-190Mayo Clinic Health System - Eau Claire, Mayo Clinic Health System - Franciscan Healthercare,Mayo ClinicBiological: COVID-19 convalescent plasma
WisconsinWI-03Covid-19 Associated Coagulopathy170Gundersen Health System,University of IowaDrug: Intermediate dose thromboprophylaxis, Drug: Standard of Care thromboprophylaxis
WisconsinWI-03Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Mayo Clinic Health System in Eau Claire, Mayo Clinic Health System,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
WisconsinWI-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Marshfield Clinic-Chippewa Center, HSHS Sacred Heart Hospital, Marshfield Medical Center-EC Cancer Center, Mayo Clinic Health System-Eau Claire Clinic, Gundersen Lutheran Medical Center, Mayo Clinic Health System-Franciscan Healthcare, Ascension Saint Michael's Hospital, Marshfield Clinic Stevens Point Center, Aspirus UW Cancer Center, Marshfield Clinic - Wisconsin Rapids Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WisconsinWI-07Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Marshfield Clinic Health System,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
WisconsinWI-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Langlade Hospital and Cancer Center, Marshfield Clinic-Ladysmith Center, Marshfield Medical Center-Marshfield, Aspirus Medford Hospital, Marshfield Clinic-Minocqua Center, Cancer Center of Western Wisconsin, Marshfield Medical Center-Rice Lake, Aspirus Regional Cancer Center, Marshfield Clinic -Wausau Center, Marshfield Clinic-Weston Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WisconsinWI-05A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)242Froedtert and the Medical College of Wisconsin,Millennium Pharmaceuticals, Inc., TakedaDrug: TAK-981, Drug: Standard of care
WisconsinWI-05Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Froedtert Medical College Pulmonary Clinic, Medical College of Wisconsin,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
WisconsinWI-05Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Medical College of Wisconsin,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
WisconsinWI-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Medical College of Wisconsin,Gilead SciencesDrug: Remdesivir
WisconsinWI-05A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection131Froedtert Hospital,Medical College of Wisconsin, Froedtert HospitalBiological: anti-SARS-CoV-2 convalescent plasma
WisconsinWI-05Convalescent Plasma in Outpatients With COVID-19600Froedtert Hospital,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
WisconsinWI-05Nudges to Improve Health Behaviors That Limit COVID-19 Spread45Medical College of Wisconsin,Medical College of Wisconsin, Advancing a Healthier Wisconsin EndowmentBehavioral: Nudge
WisconsinWI-05Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Medical College of Wisconsin,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
WisconsinWI-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Ascension Southeast Wisconsin Hospital - Elmbrook Campus, Aurora Health Care Germantown Health Center, Medical College of Wisconsin, Aurora Medical Center in Summit, Ascension Medical Group Southeast Wisconsin - Mayfair Road, Aurora Cancer Care-Milwaukee West,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
WisconsinWI-05Registry of CytoSorb Therapy in COVID-19 ICU Patients500Medical College of Wisconsin,CytoSorbents, IncDevice: CytoSorb 300 mL device
WyomingWY-00NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cheyenne Regional Medical Center-West, Billings Clinic-Cody, Welch Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
Puerto RicoPR-00A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Hospital San Cristobal,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
Puerto RicoPR-00The Covid-19 HEalth caRe wOrkErS (HEROES) Study2000Ponce Health Sciences University,University of ChileOther: Exposure to the SARS-CoV-2 and its consequences
Puerto RicoPR-00NCI COVID-19 in Cancer Patients, NCCAPS Study2000Centro Comprensivo de Cancer de UPR,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-10NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Modesto,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-11Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Diablo Clinical Research Inc,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-11NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Richmond, Kaiser Permanente-Walnut Creek,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-12Adaptive COVID-19 Treatment Trial (ACTT)1062University of California San Francisco General Hospital,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
CaliforniaCA-12Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113California Pacific Medical Center, Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-12Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891California Pacific Medical Center, Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-12Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000University of California San Francisco,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
CaliforniaCA-12Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0California Pacific Medical Center, University of California Medical Center,Gilead SciencesDrug: Remdesivir
CaliforniaCA-12COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)2000University of California - San Francisco,University of California, San Francisco, University of California, Los AngelesOther: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19, Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19
CaliforniaCA-12Azithromycin for COVID-19 Treatment in Outpatients Nationwide2271University of California - San Francisco,Thomas M. Lietman, Bill and Melinda Gates Foundation, Pfizer, Stanford University, University of California, San FranciscoDrug: Azithromycin, Drug: Placebos
CaliforniaCA-12Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479UCSF Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
CaliforniaCA-12Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Kaiser Permanente San Francisco,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
CaliforniaCA-12Long-term Impact of Infection With Novel Coronavirus (COVID-19)800Zuckerberg San Francisco General Hospital,University of California, San Francisco 
CaliforniaCA-12Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site, Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
CaliforniaCA-12VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)300San Francisco VA,Salomeh Keyhani MD, San Francisco VA Health Care SystemDrug: Hydroxychloroquine, Drug: Azithromycin, Drug: Placebo oral tablet
CaliforniaCA-12Immunophenotyping Assessment in a COVID-19 Cohort2000University of California - San Francisco,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
CaliforniaCA-12Predicting Outcomes for Covid-19 Using Sonography200University of California - San Francisco,Stanford UniversityDiagnostic Test: Lung Ultrasound
CaliforniaCA-12NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-San Francisco,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-12Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic11000University of California - San Francisco,University of California, San Francisco 
CaliforniaCA-12An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic0UCSF Helen Diller Family CCC,Genentech, Inc.Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
CaliforniaCA-12Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of California San Francisco General Hospital,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
CaliforniaCA-12A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966California Pacific Medical Center,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
CaliforniaCA-12Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Bridge HIV CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
CaliforniaCA-12Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)150University of California - San Francisco,University of California, San FranciscoDrug: Oral-B Mouth Sore mouthwash, Drug: Crest Pro-Health Multi-Protection mouthwash, Drug: CloSYS mouthwash, Drug: Distilled water, Drug: Listerine Mouthwash Product
CaliforniaCA-13Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Alta Bates Summit Medical Center, Kaiser Permanente Oakland Medical Center, Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-13Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Alta Bates Summit Medical Center, Kaiser Permanente Oakland Medical Center, Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-13Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Kaiser Permanente Oakland,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
CaliforniaCA-13COVID-19 Mortality Prediction Model114Dascena,DascenaDevice: COViage
CaliforniaCA-13Classification of COVID-19 Infection in Posteroanterior Chest X-rays230Dascena,DascenaDevice: CovX
CaliforniaCA-13A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Highland Hospital Oakland, San Leandro Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
CaliforniaCA-13A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Alta Bates Summit Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
CaliforniaCA-13NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente Oakland, Kaiser Permanente Oakland-Broadway, Kaiser Permanente San Leandro,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-13Respiratory Decompensation and Model for the Triage of COVID-19 Patients197Dascena,DascenaDevice: COViage
CaliforniaCA-14Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Mills-Peninsula Medical Center, Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-14Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Mills-Peninsula Medical Center, Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-14NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Redwood City, Kaiser Permanente Cancer Treatment Center, Kaiser Permanente-South San Francisco,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-15Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Eden Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-15Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Eden Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-15NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente Dublin,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-16Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Community Regional Medical Centers,Gilead SciencesDrug: Remdesivir
CaliforniaCA-16Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479UCSF Fresno,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
CaliforniaCA-16A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270UCSF Fresno,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
CaliforniaCA-16A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-1966University of California at San Francisco - Fresno,Apellis Pharmaceuticals, Inc.Drug: APL-9, Other: Vehicle Control
CaliforniaCA-17Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-17Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-17Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Kaiser Permanente Santa Clara,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-17NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Fremont, Kaiser Permanente Medical Center - Santa Clara,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-18Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT30Stanford University,Stanford University, Pliant Therapeutics, Inc.Drug: [18F]FP-R01-MG-F2
CaliforniaCA-18Adaptive COVID-19 Treatment Trial (ACTT)1062Stanford University Hospital, VA Palo Alto Health Care System,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
CaliforniaCA-18Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113El Camino Hospital, Stanford Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-18Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891El Camino Hospital, Stanford Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-18A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Stanford University,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
CaliforniaCA-18Behavior, Environment And Treatments for Covid-19100000BEAT19.org,xCures, Genetic Alliance, LunaDNA, Cancer Commons, REDCap CloudOther: Observation of patients with known, suspected, or at risk for COVID-19 infection
CaliforniaCA-18Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0San Mateo Medical Center,Gilead SciencesDrug: Remdesivir
CaliforniaCA-18Treating COVID-19 With a Bidirectional Oxygenation Valve30Stanford University,TMC HealthCare, PEEP Medical, LLCDevice: bidirectional oxygenation mouthpiece
CaliforniaCA-18Impact of the Coronavirus (COVID-19) on Patients With Cancer50Stanford University School of Medicine,Stanford University 
CaliforniaCA-18Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19120Stanford University School of Medicine,Stanford UniversityDrug: Peginterferon Lambda-1a, Other: Placebo
CaliforniaCA-18Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Stanford University,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
CaliforniaCA-18Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
CaliforniaCA-18Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19120Stanford University,Stanford UniversityDrug: Favipiravir, Drug: Placebo, Other: Standard of care treatment
CaliforniaCA-18PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)45Stanford Health Care,Stanford UniversityDrug: Povidone-Iodine 2%, Drug: Povidone-Iodine 0.5%, Drug: Isotonic saline 0.9%
CaliforniaCA-18Convalescent Plasma in Outpatients With COVID-19600Stanford University,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
CaliforniaCA-18ACCESS A Master Digital Surveillance Protocol for COVID-191000000Medable Inc.,Medable Inc., Datavant, American Heart Association, BioIntelliSense, PWNHealth 
CaliforniaCA-18MSCs in COVID-19 ARDS223Stanford University,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
CaliforniaCA-18Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-191000Stanford University Hospital,Stanford University, National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI)Other: There is no intervention
CaliforniaCA-18Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury46Stanford University School of Medicine,AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company)Drug: Ibrutinib, Drug: Placebo
CaliforniaCA-18Immunophenotyping Assessment in a COVID-19 Cohort2000Stanford University,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
CaliforniaCA-18Emergency Ventilator Splitting Between Two or More Patients (COVID-19)4Stanford University,Stanford UniversityDevice: Emergency Ventilator Splitter
CaliforniaCA-18Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients160Stanford University,Stanford UniversityDrug: Ulinastatin, Drug: Placebo
CaliforniaCA-18An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic0Stanford University School of Medicine,Genentech, Inc.Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
CaliforniaCA-18Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Stanford University Hospital, VA Palo Alto Health Care System,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
CaliforniaCA-18A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Stanford University,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
CaliforniaCA-18Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic50Stanford University,Stanford UniversityBehavioral: Remote Cognitive Behavioral Therapy for Insomnia
CaliforniaCA-19Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-19Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Oakland Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-19Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Regional Medical Center,Gilead SciencesDrug: Remdesivir
CaliforniaCA-19NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Santa Teresa-San Jose,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-20Compassionate Use of Hyperbaric Oxygen Therapy100Community Hospital,SerenaGroup, Inc., SerenaGroup Research Foundation 
CaliforniaCA-20NCI COVID-19 in Cancer Patients, NCCAPS Study2000Salinas Valley Memorial,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-22NCI COVID-19 in Cancer Patients, NCCAPS Study2000Fresno Cancer Center, Kaiser Permanente-Fresno,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-23Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Centric Health Resources Inc.,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
CaliforniaCA-24NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mission Hope Medical Oncology - Arroyo Grande, PCR Oncology, Mission Hope Medical Oncology - Santa Maria,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-26Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Los Robles Regional Medical Center,Gilead SciencesDrug: Remdesivir
CaliforniaCA-26A Study of Quintuple Therapy to Treat COVID-19 Infection600ProgeneBiome,ProgenaBiome, DSCS CRODrug: Hydroxychloroquine, Drug: Azithromycin, Dietary Supplement: Vitamin C, Dietary Supplement: Vitamin D, Dietary Supplement: Zinc
CaliforniaCA-26A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection600ProgeneBiome,ProgenaBiome, DSCS CRODrug: Hydroxychloroquine, Dietary Supplement: Vitamin C, Dietary Supplement: Vitamin D, Dietary Supplement: Zinc
CaliforniaCA-26A Study to Explore the Role of Gut Flora in COVID-19 Infection250ProgeneBiome,ProgenaBiomeOther: There is no intervention in this study
CaliforniaCA-26A Study of ResCure™ to Treat COVID-19 Infection50ProgeneBiome,ProgenaBiome, Rinati Skin, LLCBiological: ResCure™
CaliforniaCA-26A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204FOMAT Medical Research,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
CaliforniaCA-27Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Huntington Hospital,Gilead SciencesDrug: Remdesivir
CaliforniaCA-28Adaptive COVID-19 Treatment Trial (ACTT)1062Cedars-Sinai Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
CaliforniaCA-28Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-28Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-28Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
CaliforniaCA-28CAP-1002 in Severe COVID-19 Disease0Cedars-Sinai Medical Center,Capricor Inc.Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells
CaliforniaCA-28BCG Vaccine for Health Care Workers as Defense Against COVID 191800Cedars-Sinai Medical Center,Texas A&M University, Baylor College of Medicine, M.D. Anderson Cancer Center, Cedars-Sinai Medical Center, Harvard UniversityBiological: BCG Vaccine, Biological: Placebo Vaccine
CaliforniaCA-28Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease17Cedars-Sinai Medical Center,Cedars-Sinai Medical CenterDrug: Clazakizumab
CaliforniaCA-28Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure60Cedars-Sinai Medical Center,Noah Merin, Johns Hopkins University, Cedars-Sinai Medical CenterBiological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
CaliforniaCA-28SOLIRIS® (Eculizumab) Treatment of Participants With COVID-190Cedars-Sinai Medical Center,Alexion PharmaceuticalsBiological: eculizumab
CaliforniaCA-28Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
CaliforniaCA-28Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Kaiser Permanente Los Angeles Medical Center,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-28Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
CaliforniaCA-28Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
CaliforniaCA-28NCI COVID-19 in Cancer Patients, NCCAPS Study2000Providence Saint Joseph Medical Center/Disney Family Cancer Center, Kaiser Permanente-Los Angeles Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-28Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Cedars-Sinai Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
CaliforniaCA-28A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924Cedars-Sinai Medical Center,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
CaliforniaCA-29Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-29Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-29Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)384Olive View-UCLA Medical Center,I-Mab Biopharma Co. Ltd.Drug: TJ003234, Drug: Placebo
CaliforniaCA-29Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Providence Clinical Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-29Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Olive View - UCLA Medical Center,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
CaliforniaCA-29Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
CaliforniaCA-29NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Panorama City,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-30Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-30Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-30Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Bayview Research Group,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-30NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Woodland Hills,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-30A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204Valley Clinical Trials,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
CaliforniaCA-31The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection100Premier Urgent Care of California,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
CaliforniaCA-31The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200Premier Urgent Care of California,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
CaliforniaCA-31Convalescent Plasma in Outpatients With COVID-19600Loma Linda University Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
CaliforniaCA-31Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
CaliforniaCA-31NCI COVID-19 in Cancer Patients, NCCAPS Study2000Veterans Affairs Loma Linda Healthcare System,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-31Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site, Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
CaliforniaCA-31A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19204Benchmark Research,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PBO)
CaliforniaCA-32Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250City of Hope Cancer Center,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
CaliforniaCA-32NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Baldwin Park,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-33Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000University of California,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
CaliforniaCA-33Adaptive COVID-19 Treatment Trial (ACTT)1062University of California Los Angeles Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
CaliforniaCA-33Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center, Providence St. Johns Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-33Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center, Providence St. Johns Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-33Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site, Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
CaliforniaCA-33A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450David Geffen School of Medicine UCLA,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
CaliforniaCA-33Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Westside Medical Associates of Los Angeles,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
CaliforniaCA-33Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of California - Los Angeles,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
CaliforniaCA-33Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)829University of California Los Angeles,University of Washington, Bill and Melinda Gates FoundationDrug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid
CaliforniaCA-33Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Ronald Reagan UCLA Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
CaliforniaCA-33Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986University of California - Los Angeles,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
CaliforniaCA-33Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390University of California - Los Angeles,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
CaliforniaCA-33Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202University of California - Los Angeles,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
CaliforniaCA-33The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol1800FHHI-OI-Camelot,The Camelot FoundationDrug: Hydroxychloroquine, Azithromycin, Drug: Hydroxychloroquine, Doxycycline, Drug: Hydroxychloroquine, Clindamycin, Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose., Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose., Drug: Remdesivir, Drug: Tocilizumab, Drug: Methylprednisolone, Drug: Interferon-Alpha2B, Drug: Losartan, Drug: Convalescent Serum
CaliforniaCA-33A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227UCLA Ronald Reagan Medical Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
CaliforniaCA-33Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)150UCLA Ronald Reagan Medical Center, UCLA Santa Monica Hospital,University of California, Los AngelesDrug: Colchicine Tablets, Other: Current care per UCLA treating physicians
CaliforniaCA-33Convalescent Plasma in Outpatients With COVID-19600Ronald Reagan UCLA Medical Center, Cedars-Sinai Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
CaliforniaCA-33Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease20Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: HCQ, Drug: HCQ+AZT, Drug: Placebo
CaliforniaCA-33COVID-19 Recovered Volunteer Research Participant Pool Registry10000Ronald Reagan UCLA Medical Center,University of California, Los Angeles 
CaliforniaCA-33Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-192500University of California - Los Angeles,University of California, Los AngelesBehavioral: Brief educational video
CaliforniaCA-33Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of California - Los Angeles,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
CaliforniaCA-33Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
CaliforniaCA-33NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Harbor City, UCLA / Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-33An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic0Beverly Hills Cancer Center,Genentech, Inc.Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
CaliforniaCA-33Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198VA Greater Los Angeles Healthcare System,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
CaliforniaCA-33Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of California Los Angeles Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
CaliforniaCA-33The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)80Ronald Reagan UCLA Medical Center,Ridgeback Biotherapeutics, LPDrug: EIDD-2801, Drug: Placebo (PB0)
CaliforniaCA-33Role of Children in Transmission of COVID-19 to Immunocompromised Patients300University of California - Los Angeles,Jonsson Comprehensive Cancer Center 
CaliforniaCA-33A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Providence St. John's Health Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
CaliforniaCA-34A Study of Auxora in Patients With Severe COVID-19 Pneumonia400University of Southern California,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
CaliforniaCA-34Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300University of Southern California Medical Center, USC - Los Angeles County Medical Center,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
CaliforniaCA-34A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100LAC + USC Medical Center, USC Keck Medical Center Of USC,Hoffmann-La RocheDrug: Tociliuzumab
CaliforniaCA-34Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998National Research Institute,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-34Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270LAC/USC Health Center,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
CaliforniaCA-34MSCs in COVID-19 ARDS223University of Southern California,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
CaliforniaCA-34Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19144Los Angeles County-USC Medical Center, USC / Norris Comprehensive Cancer Center,University of Southern California, National Cancer Institute (NCI)Drug: Baricitinib, Drug: Hydroxychloroquine, Drug: Placebo Administration
CaliforniaCA-34Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140University of Southern California,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
CaliforniaCA-34Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
CaliforniaCA-35Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center, Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-35Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center, Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-35NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Fontana, Kaiser Permanente-Ontario,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-36Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986Palmtree Clinical Research Inc., Eisenhower Health,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
CaliforniaCA-36Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury46Desert Regional Medical Center,AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company)Drug: Ibrutinib, Drug: Placebo
CaliforniaCA-37Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of California - Los Angeles,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
CaliforniaCA-37Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-37Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-37Progesterone for the Treatment of COVID-19 in Hospitalized Men40Cedars-Sinai Medical Center,Sara Ghandehari, IBSA Institut Biochimique SA, Cedars-Sinai Medical CenterDrug: Progesterone 100 MG
CaliforniaCA-37Immunophenotyping Assessment in a COVID-19 Cohort2000University of California - Los Angeles,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
CaliforniaCA-37NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Cadillac,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-37Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727UCLA CARE Center CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
CaliforniaCA-38Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0PIH Health Whittier Hospital,Gilead SciencesDrug: Remdesivir
CaliforniaCA-39Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0St. Jude Medical Center,Gilead SciencesDrug: Remdesivir
CaliforniaCA-39Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390St. June Medical Center,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
CaliforniaCA-39Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease20Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: HCQ, Drug: HCQ+AZT, Drug: Placebo
CaliforniaCA-39Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
CaliforniaCA-39A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100St. Jude Medical Center,Hoffmann-La RocheDrug: Tociliuzumab
CaliforniaCA-39Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
CaliforniaCA-39Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52St. Jude Medical Center,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
CaliforniaCA-39Study of Sargramostim in Patients With COVID-19120St. Jude Medical Center,Partner Therapeutics, Inc.Drug: Sargramostim, Drug: Standard of care
CaliforniaCA-40Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-40Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-40Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Rancho Research Institute,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
CaliforniaCA-40NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Bellflower,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-41Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center, Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-41Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center, Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-41NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Riverside,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-42A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379St. Joseph'S Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
CaliforniaCA-43Collection of Anti-SARS-CoV-2 Immune Plasma1500UCLA Medical Center,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
CaliforniaCA-43Convalescent Plasma in Outpatients With COVID-19600Harbor-UCLA Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
CaliforniaCA-43Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920Harbor-UCLA CRS,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
CaliforniaCA-43International Registry of Coronavirus (COVID-19) Exposure in Pregnancy25000Pregistry, Pregistry,Pregistry, Harvard School of Public HealthOther: Tested for SARS-CoV-2 (regardless of the result), Other: Clinical diagnosis of COVID-19 by a health care professional
CaliforniaCA-43Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
CaliforniaCA-43Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
CaliforniaCA-43Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic7000Pregistry,Pregistry, Harvard School of Public HealthOther: This is an online survey with no intervention.
CaliforniaCA-43A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Torrance Memorial Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
CaliforniaCA-44Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation45St. Francis Medical Center,NantKwest, Inc.Biological: BM-Allo.MSC, Biological: Placebo
CaliforniaCA-45Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Mission Hospital Regional Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-45Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Mission Hospital Regional Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-45Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure165University of California Irvine,NeuroRx, Inc., Lavin Consulting, LLCDrug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care
CaliforniaCA-45Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects120Blade Research Site,Blade Therapeutics, Clinipace WorldwideDrug: BLD-2660
CaliforniaCA-45Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19)300University of California - Irvine,University of California, IrvineBehavioral: HOPE intervention
CaliforniaCA-45Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
CaliforniaCA-45A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Hoag Hospital Irvine,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
CaliforniaCA-46Adaptive COVID-19 Treatment Trial (ACTT)1062University of California Irvine Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
CaliforniaCA-46Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center, Center for Cancer Prevention and Treatment at St. Joseph Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-46Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center, Center for Cancer Prevention and Treatment at St. Joseph Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-46The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection100University of California Irvine,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
CaliforniaCA-46The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2200University of California Irvine,Pulmotect, Inc.Drug: PUL-042 Inhalation Solution, Drug: Placebo
CaliforniaCA-46Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of California - Irvine Health,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
CaliforniaCA-46Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Anaheim Clinical Trials LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-46Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270UC Irvine Medical Center,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
CaliforniaCA-46Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of California - Irvine Health,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
CaliforniaCA-46NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Anaheim, UC Irvine Health Chao Family Comprehensive Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-46Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140University of California Irvine,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
CaliforniaCA-46Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
CaliforniaCA-46Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of California Irvine Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
CaliforniaCA-46PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer364St. Jude Hospital Yorba Linda,CTI BioPharmaDrug: Pacritinib, Drug: Placebo
CaliforniaCA-46Study of Sargramostim in Patients With COVID-19120St. Joseph Hospital of Orange,Partner Therapeutics, Inc.Drug: Sargramostim, Drug: Standard of care
CaliforniaCA-47Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Long Beach Memorial Medical Center,Gilead SciencesDrug: Remdesivir
CaliforniaCA-47Awake Prone Position for Early Hypoxemia in COVID-19560Long Beach Medical Center - MemorialCare,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
CaliforniaCA-47A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Long Beach Memorial,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
CaliforniaCA-47Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000Long Beach Clinical Trials,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
CaliforniaCA-47Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Long Beach Clinical Trials Services Inc., Collaborative Neuroscience Research,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-47A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270MemorialCare Research Miller Children's and Women's Hospital,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
CaliforniaCA-47Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198VA Long Beach Healthcare System,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
CaliforniaCA-48Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Hoag Memorial Hospital Presbyterian,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-48Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Hoag Memorial Hospital Presbyterian,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-48Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000So Cal Clinical Research,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
CaliforniaCA-48Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-1986UC Irvine,Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)Biological: CYNK-001
CaliforniaCA-48A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Harper University Hospital,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
CaliforniaCA-48Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
CaliforniaCA-48A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Hoag Memorial Hospital,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
CaliforniaCA-48NCI COVID-19 in Cancer Patients, NCCAPS Study2000UC Irvine Health Cancer Center-Newport, Kaiser Permanente-Irvine,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-48Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
CaliforniaCA-49A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)242University of California San Diego Moores Cancer Center,Millennium Pharmaceuticals, Inc., TakedaDrug: TAK-981, Drug: Standard of care
CaliforniaCA-49A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450University of California San Diego,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
CaliforniaCA-49Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of California - San Diego,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
CaliforniaCA-49Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Naval Hospital Camp Pendleton,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
CaliforniaCA-49Ramipril for the Treatment of COVID-19560University of California - San Diego,University of California, San Diego, PfizerDrug: Ramipril 2.5 MG Oral Capsule, Drug: Placebo oral capsule
CaliforniaCA-49NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of California San Diego Moores Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-49LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)60VA San Diego Healthcare System,Arch Biopartners Inc.Drug: LSALT peptide, Drug: Placebo
CaliforniaCA-49A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-1924Veterans Affairs Medical Center,Eli Lilly and Company, AbCellera Biologics Inc.Drug: LY3819253, Drug: Placebo
CaliforniaCA-50Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
CaliforniaCA-50NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-San Marcos,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-51Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0USS Abraham Lincoln CVN 72, USS Boxer LHD 4, USS Carl Vinson CVN 70, USS Essex LHD 2, USS Makin Island LHD 8, USS Nimitz CVN 68, USS Theodore Roosevelt CVN 71, USS Tripoli LHA 7,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
CaliforniaCA-51A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379El Centro Regional Medical Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
CaliforniaCA-51A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500El Centro Regional Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
CaliforniaCA-52Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of California San Diego Medical Center,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
CaliforniaCA-52Adaptive COVID-19 Treatment Trial (ACTT)1062University of California San Diego Health,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
CaliforniaCA-52Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-52Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-52Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Scripps Memorial Hospital La Jolla, Scripps Mercy Hospital,Gilead SciencesDrug: Remdesivir
CaliforniaCA-52Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection200Sharp Coronado Hospital,Sharp HealthCareDrug: Losartan
CaliforniaCA-52Convalescent Plasma in Outpatients With COVID-19600UCSD Health La Jolla,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
CaliforniaCA-52Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection60Scripps Memorial Hospital La Jolla,Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical CenterDrug: Alteplase 50 MG [Activase]
CaliforniaCA-52Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000Scripps Health,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
CaliforniaCA-52Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-1986Scripps Health,Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)Biological: CYNK-001
CaliforniaCA-52Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998California Research Foundation,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-52Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
CaliforniaCA-52Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of California San Diego Health,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
CaliforniaCA-53Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-53Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Kaiser Permanente Los Angeles Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-53A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450eStudySite,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
CaliforniaCA-53Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection200Sharp Grossmont Hospital, Sharp Chula Vista Medical Center, Sharp Memorial Hospital,Sharp HealthCareDrug: Losartan
CaliforniaCA-53Awake Prone Position for Early Hypoxemia in COVID-19560Alvarado Hospital,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
CaliforniaCA-53A Study of Auxora in Patients With Severe COVID-19 Pneumonia400Sharp Memorial San Diego,CalciMedica, Inc.Drug: Auxora, Drug: Placebo
CaliforniaCA-53Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920UCSD Antiviral Research Center CRS,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
CaliforniaCA-53Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Navy Medical Center San Diego,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
CaliforniaCA-53A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379eStudySite,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
CaliforniaCA-53Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Sharp Memorial Hospital,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
CaliforniaCA-53Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site, Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
CaliforniaCA-53A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410eStudySite - Chula Vista - PPDS, eStudySite,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
CaliforniaCA-53NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-San Diego Mission, Kaiser Permanente-San Diego Zion, Sharp Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-53IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.90Fadi A. Haddad MD Inc., Sharp Grossmont Hospital, Sharp Memorial Hosptial,Fadi Haddad, M.D., Sharp HealthCareDiagnostic Test: Clungene rapid test cassette
CaliforniaCA-53A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500eStudySite - Chula Vista - PPDS,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
CaliforniaCA-53Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-1934Sharp Grossmont Hospital, Sharp Memorial Hospital,George Sakoulas, MD, Octapharma, Sharp HealthCareDrug: Octagam
CaliforniaCA-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente Medical Center-Vacaville,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-06Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100UC Davis Medical Center,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
CaliforniaCA-06Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250University of California Davis Health System,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
CaliforniaCA-06Adaptive COVID-19 Treatment Trial (ACTT)1062University of California Davis Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
CaliforniaCA-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Sutter Medical Center Sacramento,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Sutter Medical Center Sacramento,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-06Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
CaliforniaCA-06Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of California - Davis,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
CaliforniaCA-06Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479UC Davis Medical Center,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
CaliforniaCA-06Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202UC Davis Health,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
CaliforniaCA-06Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-1986UC Davis Medical Center,Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)Biological: CYNK-001
CaliforniaCA-06Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998UC Davis Medical Center,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-06Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of California - Davis,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
CaliforniaCA-06PET/CT Imaging in COVID-19 Patients10University of California - Davis,University of California, DavisDrug: 18F-αvβ6-BP
CaliforniaCA-06Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
CaliforniaCA-06A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Sutter Medical Foundation,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
CaliforniaCA-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente Downtown Commons, University of California Davis Comprehensive Cancer Center, Kaiser Permanente-South Sacramento, South Sacramento Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-06Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19140University of California Davis,Pluristem Ltd.Biological: PLX-PAD, Biological: Placebo
CaliforniaCA-06Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
CaliforniaCA-06Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of California Davis Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
CaliforniaCA-08Adaptive COVID-19 Treatment Trial (ACTT)1062Naval Medical Center San Diego,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
CaliforniaCA-08Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Naval Medical Center San Diego,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
CaliforniaCA-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Paradigm Clinical Research Center,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
CaliforniaCA-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Enloe Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-09NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Deer Valley Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-04Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Sutter Medical Center Sacramento,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-04Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Sutter Medical Center Sacramento,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-04A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19270Sutter Institute for Medical Research,Janssen Pharmaceutica N.V., BelgiumDrug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC)
CaliforniaCA-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Roseville, Permanente Medical Group-Roseville Radiation Oncology, Kaiser Permanente-Stockton, Gene Upshaw Memorial Tahoe Forest Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113St Joseph Hospital Eureka, Sutter Santa Rose Regional Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891St Joseph Hospital Eureka, Sutter Santa Rosa Regional Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
CaliforniaCA-02Predicting Outcomes for Covid-19 Using Sonography200Stanford University,Stanford UniversityDiagnostic Test: Lung Ultrasound
CaliforniaCA-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser San Rafael-Gallinas,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-07Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection202Kaiser Permanente Sacramento,Karyopharm Therapeutics IncDrug: Selinexor, Other: Placebo
CaliforniaCA-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kaiser Permanente-Rancho Cordova Cancer Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
CaliforniaCA-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Santa Rosa Memorial Hospital,Gilead SciencesDrug: Remdesivir
CaliforniaCA-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Rohnert Park Cancer Center, Kaiser Permanente-Santa Rosa, Kaiser Permanente-Vallejo,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
AlabamaAL-07Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100University of Alabama,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
AlabamaAL-07Adaptive COVID-19 Treatment Trial (ACTT)1062University of Alabama at Birmingham,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
AlabamaAL-07Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19200University of Alabama,Massachusetts General Hospital, Xijing Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda HospitalDrug: Nitric Oxide Gas
AlabamaAL-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0University of Alabama - Birmingham,Gilead SciencesDrug: Remdesivir
AlabamaAL-07Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of Alabama at Birmingham,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
AlabamaAL-07SARS-COV2 Pandemic Serosurvey and Blood Sampling15000University of Alabama,National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) 
AlabamaAL-07TXA and Corona Virus 2019 (COVID19) in Outpatients100University of Alabama at Birmingham,University of Alabama at BirminghamDrug: Tranexamic acid tablets, Drug: Placebo oral tablet
AlabamaAL-07Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients60University of Alabama at Birmingham,University of Alabama at BirminghamDrug: Tranexamic acid, Drug: Placebo oral tablet
AlabamaAL-07Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-1920Alabama CRS,National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTDDrug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin
AlabamaAL-07Early Treatment of Cytokine Storm Syndrome in Covid-1930University of Alabama at Birmingham,University of Alabama at BirminghamDrug: Anakinra, Drug: Normal saline
AlabamaAL-07Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia451Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: Canakinumab, Drug: Placebo
AlabamaAL-07Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of Alabama at Birmingham,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
AlabamaAL-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Alabama at Birmingham Cancer Center, Veterans Administration Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
AlabamaAL-07Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure524University of Alabama at Birmingham,ChimerixDrug: Dociparastat sodium, Drug: Placebo
AlabamaAL-07Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034University of Alabama at Birmingham,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
AlabamaAL-07Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19727Alabama Vaccine CRS,HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials NetworkOther: Sample collection
AlabamaAL-04Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression208Octapharma Research Site,OctapharmaBiological: Octagam 10%, Other: Placebo
AlabamaAL-01Dapagliflozin in Respiratory Failure in Patients With COVID-19900Heart Group of the Eastern Shore,Saint Luke's Health System, AstraZeneca, George Clinical Pty LtdDrug: Dapagliflozin 10 MG, Drug: Placebo
AlabamaAL-01Trial of Hydroxychloroquine In Covid-19 Kinetics58University of South Alabama,University of South AlabamaDrug: Hydroxychloroquine, Other: Placebo
AlabamaAL-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Alliance for Multispecialty Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
AlabamaAL-01Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
AlabamaAL-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000USA Health Strada Patient Care Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
AlabamaAL-06Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Birmingham Clinical Research Unit,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
AlabamaAL-03Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)390Advanced Cardiovascular LLC,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
AlabamaAL-03Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.62Research Site,AstraZeneca, Acerta Pharma B.V.Drug: Acalabrutinib
AlabamaAL-05Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998North Alabama Research Center, LLC, Medical Affiliated Research Center, Optimal Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
ColoradoCO-05Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)0Evans Army Community Hospital,U.S. Army Medical Research and Development CommandBiological: Anti-Sars-CoV-2 Convalescent Plasma
ColoradoCO-05Convalescent Plasma for the Treatment of Patients With COVID-190UCHealth Memorial Hospital North,University of Colorado, DenverBiological: COVID-19 Convalescent Plasma
ColoradoCO-05NCI COVID-19 in Cancer Patients, NCCAPS Study2000Penrose-Saint Francis Healthcare, Rocky Mountain Cancer Centers-Penrose,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ColoradoCO-06Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study250Children's Hospital Colorado,Ansun Biopharma, Inc.Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL
ColoradoCO-06Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Colorado University Denver,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
ColoradoCO-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113University of Colorado Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
ColoradoCO-06Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891University of Colorado Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
ColoradoCO-06Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
ColoradoCO-06Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0The Medical Center Of Aurora,Gilead SciencesDrug: Remdesivir
ColoradoCO-06Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Medical Center of Aurora, University of Colorado Hospital,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
ColoradoCO-06Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine1363Children's Hospital Colorado/University of Colorado Denver,Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke UniversityDrug: Hydroxychloroquine, Drug: Placebo oral tablet
ColoradoCO-06Safety and Efficacy of Baricitinib for COVID-1980University of Colorado - Denver,University of Colorado, DenverDrug: Baricitinib
ColoradoCO-06The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation20Children's Hospital Colorado,University of Colorado, DenverDiagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation
ColoradoCO-06Convalescent Plasma in Outpatients With COVID-19600University of Colorado,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
ColoradoCO-06Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection60University of Colorado - Denver,Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical CenterDrug: Alteplase 50 MG [Activase]
ColoradoCO-06Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
ColoradoCO-06Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Colorado Denver,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
ColoradoCO-06Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Lynn Institute of Denver,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
ColoradoCO-06Convalescent Plasma for the Treatment of Patients With COVID-190Children's Hospital Colorado, University of Colorado Hospital, UCHealth Highlands Ranch Hospital,University of Colorado, DenverBiological: COVID-19 Convalescent Plasma
ColoradoCO-06Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19600University of Colorado School of Medicine,Vanderbilt University Medical Center, AbbVieDrug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo
ColoradoCO-06COVID-19: Human Epidemiology and Response to SARS-CoV-25605Children's Hospital Colorado,National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho)Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys
ColoradoCO-06Surgical Telemedicine in the COVID-19 Pandemic Era180Children's Hospital Colorado,University of Colorado, DenverOther: Completion of pre-pandemic survey, Other: Completion of survey after peak of pandemic, Other: Completion of post telemedicine encounter survey
ColoradoCO-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Medical Center of Aurora, Rocky Mountain Cancer Centers-Aurora, Rocky Mountain Regional VA Medical Center, Rocky Mountain Cancer Centers-Centennial, Rocky Mountain Cancer Centers-Littleton, Littleton Adventist Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ColoradoCO-06Registry of CytoSorb Therapy in COVID-19 ICU Patients500Medical Center of Aurora,CytoSorbents, IncDevice: CytoSorb 300 mL device
ColoradoCO-06An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic0University Of Colorado,Genentech, Inc.Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)
ColoradoCO-06Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Rocky Mountain Regional Veteran Affairs Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
ColoradoCO-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000North Colorado Medical Center, Kaiser Permanente-Lone Tree, Rocky Mountain Cancer Centers-Sky Ridge, Sky Ridge Medical Center, Longmont United Hospital, Rocky Mountain Cancer Centers-Longmont, Parker Adventist Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ColoradoCO-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113SCL Health St. Joseph Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
ColoradoCO-02Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891SCL Health St. Joseph Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
ColoradoCO-02Convalescent Plasma for the Treatment of Patients With COVID-190UCHealth Poudre Valley Hospital,University of Colorado, DenverBiological: COVID-19 Convalescent Plasma
ColoradoCO-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000Boulder Community Hospital, Rocky Mountain Cancer Centers-Boulder, Good Samaritan Medical Center, Kaiser Permanente-Rock Creek, McKee Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ColoradoCO-01Adaptive COVID-19 Treatment Trial (ACTT)1062Denver Health Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir
ColoradoCO-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113SCL Health St. Joseph Hospital, SCL Health St. Joseph Hospital, Rose Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
ColoradoCO-01Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891SCL Health St. Joseph Hospital, SCL Health St. Joseph Hospital, Rose Medical Center,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
ColoradoCO-01Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
ColoradoCO-01A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia450Denver Health Medical Center,Hoffmann-La RocheDrug: Tocilizumab (TCZ), Drug: Placebo
ColoradoCO-01Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Rose Medical Center, Swedish Medical Center,Gilead SciencesDrug: Remdesivir
ColoradoCO-01Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479Denver Health Medical Center, St. Joseph Hospital,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
ColoradoCO-01A Study of LY3127804 in Participants With COVID-1995National Jewish Medical and Research Center,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
ColoradoCO-01Awake Prone Position for Early Hypoxemia in COVID-19560St. Joseph's Hospital National Jewish Health,Boston UniversityOther: Self-prone position recommendation, Other: Usual care
ColoradoCO-01Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection60Denver Health Medical Center, National Jewish Health,Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical CenterDrug: Alteplase 50 MG [Activase]
ColoradoCO-01Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)432Novartis Investigative Site,Novartis Pharmaceuticals, Incyte Corporation, NovartisDrug: Ruxolitinib, Drug: Placebo
ColoradoCO-01Convalescent Plasma for the Treatment of Patients With COVID-190Denver Health Medical Center,University of Colorado, DenverBiological: COVID-19 Convalescent Plasma
ColoradoCO-01Study of Efficacy and Safety of MAS825 in Patients With COVID-19140Novartis Investigative Site,Novartis Pharmaceuticals, NovartisDrug: MAS825, Drug: Matching placebo
ColoradoCO-01International SARS-CoV-2 (COVID-19) Infection Observational Study10000Denver Public Health,University of Minnesota, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)Other: Data Collection
ColoradoCO-01A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410Denver Health Medical Center,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
ColoradoCO-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cancer Center of Colorado at Sloan's Lake, Kaiser Permanente-Franklin, National Jewish Health-Main Campus, The Women's Imaging Center, Porter Adventist Hospital, Colorado Blood Cancer Institute, Presbyterian - Saint Lukes Medical Center - Health One, Rocky Mountain Cancer Centers-Midtown, SCL Health Saint Joseph Hospital, Rocky Mountain Cancer Centers-Rose, Rose Medical Center, Western Surgical Care, Mountain Blue Cancer Care Center – Swedish, Swedish Medical Center, Saint Anthony Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ColoradoCO-01Adaptive COVID-19 Treatment Trial 2 (ACTT-2)1034Denver Health Medical Center,National Institute of Allergy and Infectious Diseases (NIAID)Other: Placebo, Drug: Remdesivir, Drug: Baricitinib
ColoradoCO-07COVID-19 Diagnostic Self-testing Using Virtual Point-of-care200Neuroganics,Neuroganics LLC, Neuroganics Diagnostics LLCDiagnostic Test: COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support, Other: Telemedicine
ColoradoCO-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000National Jewish Health-Western Hematology Oncology, National Jewish Health-Northern Hematology Oncology, SCL Health Lutheran Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ColoradoCO-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mercy Medical Center, Southwest Oncology PC, Saint Mary's Hospital and Regional Medical Center, Saint Mary Corwin Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
AlaskaAK-00Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-1970Providence Health Network,Massachusetts General Hospital, University of Alabama at BirminghamDrug: Nitric Oxide
AlaskaAK-00NCI COVID-19 in Cancer Patients, NCCAPS Study2000Anchorage Associates in Radiation Medicine, Anchorage Radiation Therapy Center, Alaska Breast Care and Surgery LLC, Alaska Oncology and Hematology LLC, Alaska Women's Cancer Care, Anchorage Oncology Centre, Katmai Oncology Group, Providence Alaska Medical Center, Fairbanks Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ArizonaAZ-09A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227HonorHealth John C. Lincoln Medical Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
ArizonaAZ-09Convalescent Plasma in Outpatients With COVID-19600Chandler Regional Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
ArizonaAZ-09Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Alliance for Multispecialty Research LLC,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
ArizonaAZ-09NCI COVID-19 in Cancer Patients, NCCAPS Study2000Banner Children's at Desert,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ArizonaAZ-09Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198Phoenix VA Health Care System,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
ArizonaAZ-09Vitamin D Testing and Treatment for COVID 1941Arizona State University,Arizona State University, Southwest College of Naturopathic MedicineDietary Supplement: Vitamin D3
ArizonaAZ-01Convalescent Plasma to Stem Coronavirus (CSSC-001)500Center for American Indian Health, Center for American Indian Health,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
ArizonaAZ-01Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Chinle Comprehensive Health Care Facility, Johns Hopkins Center for American Indian Health, Whiteriver Indian Hospital,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
ArizonaAZ-01Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Center for American Indian Health, Center for American Indian Health,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
ArizonaAZ-02Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of Arizona - Phoenix,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
ArizonaAZ-02Treating COVID-19 With a Bidirectional Oxygenation Valve30TMC HealthCare,TMC HealthCare, PEEP Medical, LLCDevice: bidirectional oxygenation mouthpiece
ArizonaAZ-02A Study of LY3127804 in Participants With COVID-1995Banner University Medica Center,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
ArizonaAZ-02A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Banner University Medical Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
ArizonaAZ-02Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of Arizona,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
ArizonaAZ-06Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Mayo Clinic - Arizona,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
ArizonaAZ-06Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry50000Mayo Clinic in Arizona,Mayo Clinic, Society of Critical Care Medicine, Boston UniversityOther: observational
ArizonaAZ-06Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-190Mayo Clinic in Arizona,Mayo ClinicBiological: COVID-19 convalescent plasma
ArizonaAZ-06Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection25HonorHealth,HonorHealth Research InstituteDrug: Atovaquone/Azithromycin
ArizonaAZ-06Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-1980Perseverance Research Center, Perseverance Research Center,Perseverance Research Center, LLC, Athena Medical GroupDrug: Hydroxychloroquine, Drug: Indomethacin, Drug: Zithromax Oral Product
ArizonaAZ-06Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19300Mayo Clinic,Humanigen, Inc.Biological: Lenzilumab, Drug: Standard of Care
ArizonaAZ-06A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227HonorHealth Scottsdale Osborn Medical Center, HonorHealth, HonorHealth Scottsdale Shea Medical Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
ArizonaAZ-06Study of the Use of Favipiravir in Hospitalized Subjects With COVID-1950HonorHealth,Fujifilm Pharmaceuticals U.S.A., Inc.Drug: Favipiravir + Standard of Care, Drug: Standard of Care
ArizonaAZ-06A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Mayo Clinic - Arizona,Hoffmann-La RocheDrug: Tociliuzumab
ArizonaAZ-06Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998HOPE Research institute, Pain Center of Arizona,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
ArizonaAZ-06Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Mayo Clinic,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
ArizonaAZ-06Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)500Honor Health Research Institute,Incyte CorporationDrug: Placebo, Drug: Ruxolitinib
ArizonaAZ-06Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants52Honor Health,BeiGeneDrug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo
ArizonaAZ-06NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mayo Clinic Hospital in Arizona, Mayo Clinic in Arizona,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ArizonaAZ-06COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-11140HonorHealth,Veru Inc.Drug: Veru-111
ArizonaAZ-06Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)190Atea Study Site,Atea Pharmaceuticals, Inc.Drug: AT-527, Other: Placebo
ArizonaAZ-06A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Valleywise Health Medical Center,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
ArizonaAZ-06Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-1944Mayo Clinic in Arizona,ViralClear Pharmaceuticals, Inc.Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir
ArizonaAZ-05MSCs in COVID-19 ARDS223Dignity Health,Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI)Biological: Remestemcel-L, Drug: Placebo
ArizonaAZ-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000Kingman Regional Medical Center,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ArizonaAZ-03Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000Yuma Regional Medical Center Cancer Center,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
ArizonaAZ-03Convalescent Plasma to Stem Coronavirus (CSSC-001)500University of Arizona - Tucson,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
ArizonaAZ-03Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease479University of Arizona,Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)Drug: Hydroxychloroquine, Drug: Placebo
ArizonaAZ-03A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Univ of AZ Coll of Med,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
ArizonaAZ-03Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344University of Arizona,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
ArizonaAZ-03Immunophenotyping Assessment in a COVID-19 Cohort2000University of Arizona College of Medicine,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
ArizonaAZ-07Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients100Phoenix Childrens Hospital,Novartis Pharmaceuticals, NovartisDrug: Crizanlizumab
ArizonaAZ-07Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Phoenix Children's Hospital,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
ArizonaAZ-07Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Banner-University Medical Center,Gilead SciencesDrug: Remdesivir
ArizonaAZ-07Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic101Banner University Medicine Women's Institute,University of ArizonaOther: "Calm" is a mindfulness meditation mobile app
ArizonaAZ-07A Study of LY3127804 in Participants With COVID-1995Banner University Medica Center,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
ArizonaAZ-07A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)227Banner University Medical Center,Kinevant Sciences GmbH, Roivant Sciences, Inc.Drug: Gimsilumab, Drug: Placebo
ArizonaAZ-07Convalescent Plasma in Outpatients With COVID-19600Valleywise Health Medical Center,Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - NetworkBiological: Convalescent Plasma, Biological: Saline
ArizonaAZ-07Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Arizona,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
ArizonaAZ-07Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-1986Banner University Medical Center,Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)Biological: CYNK-001
ArizonaAZ-07A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia379Banner University Medica Center,Genentech, Inc.Drug: Placebo, Drug: Tocilizumab
ArizonaAZ-07Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic328Banner University Medica Center,University of ArizonaDevice: Calm Meditation App
ArizonaAZ-07NCI COVID-19 in Cancer Patients, NCCAPS Study2000Cancer Center at Saint Joseph's,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ArkansasAR-03Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-1986University of Arkansas,Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)Biological: CYNK-001
ArkansasAR-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Mercy Hospital Fort Smith,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ArkansasAR-02Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)5000Arkansas Children's Hospital Research Institute,Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
ArkansasAR-02Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)6000University of Arkansas for Medical Sciences,Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA SoftwareDrug: Colchicine, Drug: Placebo oral tablet
ArkansasAR-02Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults1000University of Arkansas for Medical Sciences,Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS)Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
ArkansasAR-02Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia270Central Arkansas Veterans Healthcare System,Alexion PharmaceuticalsBiological: Ravulizumab, Other: Best Supportive Care
ArkansasAR-02Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease800GSK Investigational Site,GlaxoSmithKlineBiological: Otilimab, Biological: Placebo, Drug: Standard of care
ArkansasAR-02A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia410University of Arkansas For Medical Sciences,Genentech, Inc.Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo
ArkansasAR-02NCI COVID-19 in Cancer Patients, NCCAPS Study2000University of Arkansas for Medical Sciences,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ArkansasAR-02Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)20Baptist Health Center for Clinical Research,Beyond Air Inc.Device: Nitric Oxide delivered via LungFit™ system
ArkansasAR-02Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization198Central Arkansas VHS John L. McClellan Memorial Veterans Hospital,VA Office of Research and DevelopmentDrug: Degarelix, Other: Saline
ArkansasAR-04Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection4000HealthStar Research LLC,Romark Laboratories L.C.Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex
ArkansasAR-04NCI COVID-19 in Cancer Patients, NCCAPS Study2000CHI Saint Vincent Cancer Center Hot Springs,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ArkansasAR-01INB03 for the Treatment of Pulmonary Complications From COVID-19366NEA Baptist,Inmune Bio, Inc.Drug: INB03, Drug: Placebo
ArkansasAR-01Compassionate Use of Hyperbaric Oxygen Therapy100White River Wound Healing Center,SerenaGroup, Inc., SerenaGroup Research Foundation 
ArkansasAR-01NCI COVID-19 in Cancer Patients, NCCAPS Study2000Baptist Memorial Hospital and Fowler Family Cancer Center – Jonesboro, NEA Baptist Memorial Hospital,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ConnecticutCT-01Convalescent Plasma in the Treatment of COVID 1948Trinity Health Of New England,Saint Francis CareBiological: Convalescent Plasma
ConnecticutCT-05Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0The Hospital of Central Connecticut,Gilead SciencesDrug: Remdesivir
ConnecticutCT-05Convalescent Plasma to Stem Coronavirus (CSSC-001)500Danbury Hospital,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
ConnecticutCT-05A Study of LY3127804 in Participants With COVID-1995Nuvance Danbury Hospital,Eli Lilly and CompanyDrug: LY3127804, Drug: Placebo
ConnecticutCT-05Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 190University of Connecticut Health Center,Spectral Diagnostics (US) Inc.Device: Toraymyxin PMX-20R (PMX Cartridge)
ConnecticutCT-05Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Danbury Hospital,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
ConnecticutCT-03Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment1113Yale-New Haven Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
ConnecticutCT-03Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)4891Yale-New Haven Hospital,Gilead SciencesDrug: Remdesivir, Drug: Standard of Care
ConnecticutCT-03Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-191912Regeneron Study Site,Regeneron Pharmaceuticals, SanofiDrug: Sarilumab, Drug: Placebo
ConnecticutCT-03Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Middlesex Health,Gilead SciencesDrug: Remdesivir
ConnecticutCT-03The Role of Resistant Starch in COVID-19 Infection1500Yale University,Yale University, University of Michigan, University of MinnesotaDrug: Dietary Supplement containing resistant starch, Dietary Supplement: Placebo Starch
ConnecticutCT-03Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-1986Yale University,CytoDyn, Inc.Drug: Placebos, Drug: Leronlimab (700mg)
ConnecticutCT-03Camostat Mesylate in COVID-19 Outpatients114Yale University,Yale UniversityDrug: Camostat Mesilate, Other: Placebo
ConnecticutCT-03Sarilumab for Patients With Moderate COVID-19 Disease120VA Connecticut Health System,Westyn Branch-Elliman, VA Boston Healthcare SystemBiological: SARILUMAB
ConnecticutCT-03CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients300Yale University,NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of MiamiBiological: Convalescent Plasma, Other: Saline solution
ConnecticutCT-03Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals43998Clinical Research Consulting, Yale-New Haven Hospital,BioNTech SE, PfizerBiological: BNT162b1, Biological: BNT162b2, Other: Placebo
ConnecticutCT-03Immunophenotyping Assessment in a COVID-19 Cohort2000Yale School of Medicine,National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's HospitalProcedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments
ConnecticutCT-03NCI COVID-19 in Cancer Patients, NCCAPS Study2000Veterans Affairs Connecticut Healthcare System-West Haven Campus,National Cancer Institute (NCI)Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
ConnecticutCT-03A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia500Yale University School of Medicine,Hoffmann-La Roche, Gilead SciencesDrug: Remdesivir, Drug: Tocilizumab, Drug: Placebo
ConnecticutCT-04Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)0Greenwich Hospital, The Stamford Health Medical Group,Gilead SciencesDrug: Remdesivir
ConnecticutCT-04Convalescent Plasma to Stem Coronavirus (CSSC-001)500Norwalk Hospital,Johns Hopkins UniversityBiological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
ConnecticutCT-04A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia100Norwalk Hospital,Hoffmann-La RocheDrug: Tociliuzumab
ConnecticutCT-04Convalescent Plasma to Limit SARS-CoV-2 Associated Complications1344Norwalk Hospital,Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID)Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor

You can also download the data.

 

Sign up to receive COVID-19 clinical trial updates and other resources.

 

An All-Of Nation Effort

You may be surprised to learn the search for safe and effective treatments and cures for COVID is very much a local story. All across the country, America’s innovation community has mobilized like never before to fight the coronavirus pandemic. 

The scope is as impressive as the speed. To date, scientists have conducted clinical trials of potential coronavirus solutions in all 50 states, across approximately 96 percent of congressional districts. 

American innovators are doing their part to fight the pandemic. But they can’t do it alone. 

They’re relying on legislators to support smart innovation policy – that means maintaining strong intellectual property protections; removing trade barriers, like unnecessary regulations, tariffs, and export bans; and encouraging strategic collaboration through public-private partnership. 

With the right innovation policy agenda in place, we’ll help ensure that the medical discoveries happening today can be delivered to patients tomorrow. 

 

Volunteer for a Clinical Trial 

Healthy people can help in the fight against the pandemic by volunteering for a clinical trial to find safe and effective new vaccines. 

Even though the FDA has authorized some vaccines to prevent COVID-19, we still need volunteers for vaccine clinical trials. If we have several vaccines that work, we can end the pandemic sooner. We also need vaccines that can work for many different people. 

Learn More

 

Additional Resources

Discover the latest resources and insights to help American businesses, workers, and families.

START HERE    NEW RELIEF PACKAGE    VACCINE FAQS